Development of Immunotherapy for Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Using CSF1R Re-targeted Human T-lymphocytes. by Achkova, Daniela Yordanova
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








Development of Immunotherapy for Classical Hodgkin Lymphoma and Anaplastic











DEVELOPMENT OF IMMUNOTHERAPY FOR 
CLASSICAL HODGKIN’S LYMPHOMA AND 
ANAPLASTIC LARGE CELL LYMPHOMA USING 




Daniela Yordanova Achkova (1261437) 
 
 
Submitted to King’s College London for the award of 




CAR Mechanics Group, Research Oncology,  






















Classical Hodgkin’s lymphoma (cHL) represents the most common subtype of 
malignant lymphoma in young people in the Western world. Despite modern treatment 
strategies, about 20% of patients still die due to relapse or progressive disease. 
Anaplastic large cell lymphoma (ALCL) is a type of T/null-cell lymphoma that 
represents about 20-30% of paediatric lymphomas and has an aggressive clinical 
course with frequent relapse. Recently, high-level expression of CSF-1R on malignant 
cells in cHL and ALCL has been linked to shorter progression free survival, providing a 
rationale to test adoptive CSF-1R-targeting chimeric antigen receptor (CAR) T-cell 
therapy. This approach encompasses the genetic modification of T-cells to express a 
CAR, a fusion receptor coupling the recognition of CSF-1R on the tumour cell surface 
to the delivery of tailored T-cell activation signal. To optimize this approach for human 
translation, a panel of CSF-1R-targeting CARs were designed and co-expressed with 
the chimeric cytokine receptor 4αβ, which allows for selective expansion and 
enrichment of CAR-transduced T-cells using IL-4.  
 
Successful re-direction of CAR-grafted T-cells against a panel of cHL and ALCL tumour 
cell lines was confirmed by monitoring target cell destruction, cytokine release and T-
cell proliferation. An innovative approach was developed and optimised in which target 
engagement results in provision of CAR-derived dual co-stimulation in trans (“double 
targeting”). Data outlined in this thesis suggest that the “double targeting” approach 
elicits more robust and sustained anti-tumour activity both in vitro and in vivo in 
comparison to second and third generation CARs. This is accompanied by superior 
antigen-specific proliferation, cytokine secretion (IL-2 and IFN-γ) and cytotoxicity upon 
consecutive rounds of antigen stimulation. These results warrant further investigation 
into the translational potential of “the double targeting” approach. Furthermore, the data 
detailed in this thesis provide for the first time the basis for successful application of 
CAR-based immunotherapy against CSF-1R-expressing malignancies. 
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FIRE FMS intronic regulatory element 
FR- Folate receptor- 
g Gram 
GaLV Gibbon Ape Leukaemia Virus 
gamma c Common amma 
GC Germinal centres 
GC Gluccorticoids  
GD2 Ganglioside D2 
GM-CSF Granulocyte-macrophage colony-stimulating factor  
GR Glucocorticoid receptors  
GR1 Protein Gamma Response 1 
GRE Glucocorticoid response elements 
20 
 
GvHD Graft versus host disease 
HEK 293 Human Embryonic Kidney 293 
HL Hodgkin’s lymphoma 
HLA Human leukocyte antigen  
HRP Horseradish peroxidase 
HRS cells Hodgkin and Reed-Sternberg cells 
HZ-5 Hardy-Zuckerman five strain 
IFN- Interferon-gamma 
IFRT Involved field radiotherapy 
Ig Immunoglobulin 
IL Interleukin 
IL-2Rβ Interleukin-2 receptor beta subunit 
IL-4R Interleukin-4 receptor alpha subunit 
IN Viral integrase 
IκBα Inhibitor of -κB  
JAK-STAT Janus kinase/ signal transducers and activators of transcription 
kb kilobase 
L&H cells Lymphocytic and histocytic cells 
LAG3 Lymphocyte-activation gene 3 
LB Luria Broth 
LD Lymphodepletion 
LDHL Lymphocyte-depleted Hodgkin’s lymphoma 
LeY Lewis Y antigen 
LGNHL Low grade NHL 
LRHL Lymphocyte-rich Hodgkin’s lymphoma 
LTR Long Terminal Repeat 
M-CSF Macrophage colony-stimulating factor 
M-CSFR Macrophage colony-stimulating factor receptor  
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MA Matrix (virus protein) 
mA Miliamper 
Mab Monoclonal antibody 
MCHL Mixed cellularity Hodgkin’s lymphoma 
MCL Mantle cell lymphoma 
MEK Mitogen-activated protein kinase kinase 
mL Mililiter 
mM Milimolar 
MMPs Matrix metalloproteases 
MoMLV Moloney murine leukaemia virus 
Mona Monocyte adaptor 
MOPS 3-(N-Morpholino)-propanesulfonic acid 
MPM Malignant pleural mesothelioma 
MR Minor responses 
mRNA Messenger RNA 
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide 
NC Nucleocapsid (virus protein) 
NE Not evaluable for disease status 
NEB New England Biolabs 
NHL Non-Hodgkin’s lymphoma  
NK Natural killer cells 
NLPHL Nodular lymphocyte-predominant Hodgkin’s lymphoma  
nm Nanometer 
NOD Non-obese Diabetic 
NPM Nucleophosmin  
NSCLC Non-small cell lung carcinoma  
NSHL Nodular sclerosis Hodgkin’s lymphoma  
OS Overall survival  
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PAI-1 Plasminogen activator inhibitor-1 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate Buffered Saline 
PCR Polymerase Chain Reaction 
PD1 Programmed cell Death protein 1 
PDAC Pancreatic ductal adenocarcinoma 
PDGFR Platelet-derived growth factor receptor 
PE Phycoerythrin 




Peridinin-chlorophyll-protein complex-Cyianine 5.5 
Positron-emission tomography/computerized tomography  
PI3K Phosphatidylinositol 3-kinase 
PIPE Polymerase Incomplete Primer Extension 
Poly(A) site Polyadenilaton site 
PPT Polypurine tract 
PR Partial response 
PR Protease (viral) 
PTPζ Protein Tyrosine Phosphatase Zeta 
REAL Revised European-American Lymphoma  
rhIL Recombinant Human Interleukin 
RIPA Radioimmunoprecipitation Assay 
RNA Ribonucleic Acid 
rpm Rotations per minute 
RPMI Roswell Park Memorial Institute 
RT Reverse transcriptase 




scFv Single chain antibody fragment 
SCID Severe Combined Immunodeficiency 
SD Stable disease 
SDS Sodium dodecyl sulphate 
SHM Somatic hypermutation 
siRNA Small interfering RNA 
SLL Small lymphocytic lymphoma 
SM Susan McDonough strain  
SMZL Splenic marginal zone lymphoma 
SOC Super Optimal Broth 
SOCS1 Suppressor of cytokine signalling 1 
SP Surface proteins 
SUSAR Suspected unexpected severe adverse reaction 
T2A Thosea asigna derived sequence 
TAG-72 Tumour-associated glycoprotein 72 
TAM Tumour-associated macrophages 
TBE Tris/Borate/EDTA 
TBM Tetramethylbenzadine 
TBST Tris Buffered Saline and Tween 20 
TCR T cell receptor 
TE Tris/EDTA 
TFG TRK-fused gene 
TIM3 T-cell immunoglobulin and mucin-domain containing-3 
TKI Tyrosine kinase inhibitor 
TM Transmembrane 
TNFR Tumor necrosis family receptor 
TP63 Tumour protein p63  
Treg Regulatory T-cells  
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tRNA Transfer RNA 
TSCM Memory stem T-cells  
tTa Transactivator 
uPA Urokinase plasminogen activator 
URD Unrelated donor 
UV Ultraviolet 
V/cm Volt/centimeter 
VEGF Vascular endothelial growth factor 
VH Variable heavy chain 
VL Variable light chain 
VSV-G Vesicular stomatitis virus - G 
WHO World Health Organization  
βC Common beta subunit 






Chapter 1 Introduction 
The adoptive transfer of chimeric antigen receptor (CAR)-expressing T-cells is a 
relatively new but promising approach in the field of cancer immunotherapy. It relies on 
genetic reprogramming of T-cells with an artificial immune receptor that redirects their 
specificity against a target of choice expressed by cancer cells. The goal of this PhD 
was to develop a CAR based immunotherapeutic approach for classical Hodgkin’s 
lymphoma (cHL) and anaplastic large cell lymphoma (ALCL). To achieve this goal, I set 
out to engineer an optimised CAR directed against the colony-stimulating factor-1 
receptor (CSF-1R), a molecule that is aberrantly up-regulated in these malignant 
disorders.  
 
1.1 Hodgkin’s Lymphoma 
Hodgkin’s lymphoma (HL) is a B-cell derived haematological malignancy that was first 
described in 1832 by Thomas Hodgkin, working at Guy’s hospital [1]. It usually 
presents with lymphadenopathy, typically affecting the supraclavicular or lower cervical 
region, often coupled with symptoms that include fever (>38oC), night sweats, fatigue 
and/or weight loss (systemic B symptoms).  
 
Hodgkin’s lymphoma is one of the most common lymphoid malignancies in the 
Western world, occurring at an annual frequency of 3 new cases per 100 000 people 
[2]. Each year roughly 2000 new cases are diagnosed in the UK [3]. The disease 
presents with two age-related peaks of incidence – the first peak occurs in young 
adults (20-30 years old) while the second smaller peak affects adults aged over 65 
years. Despite the introduction of multi-agent chemotherapy and improved radiation 
techniques in recent years, 20-30% of patients experience relapse or progressive 
disease after initial treatment [4]. In 2012, over 25,000 people died of this cancer 
worldwide (http://www.cancerresearchuk.org/health-professional/hodgkin-lymphoma-
mortality-statistics#heading-Three; accessed February 15th, 2016). Therefore, a more 
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effective targeted therapy is urgently needed for those patients in whom standard 
management approaches fail.  
 
1.1.1 Classification of Hodgkin’s Lymphoma 
Hodgkin’s lymphoma is a germinal centre B-cell derived lymphoma. According to the 
World Health Organization (WHO)/Revised European-American Lymphoma (REAL) 
classification [5], Hodgkin’s lymphoma is divided into two clinico-pathologically 
distinctive disease entities, based on biology, clinical features, morphology, 
immunophenotype and composition of associated leukocytic infiltrate. Classical 
Hodgkin’s lymphoma (cHL) accounts for approximately 95% of cases while nodular 
lymphocyte-predominant Hodgkin’s lymphoma (NLPHL) comprises the remaining 5% 
[6]. 
 
1.1.1.1 Nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL)  
In nodular lymphocyte-predominant HL, the malignant cell population consists of 
lymphocytic and histocytic (L&H) cells. These abnormal cells have a different origin and 
immunophenotype to those found in cHL, which are termed Hodgkin and Reed-
Sternberg cells (HRS) [7]. In cHL, HRS cells have the following phenotype: 
CD30+CD15+CD20-CD45- while L&H cells in NLPHL display the phenotype: CD30-
CD15-CD20+CD45+. The NLPHL sub-type of Hodgkin’s lymphoma will not be discussed 
any further in this thesis since the focus of my study has been cHL and anaplastic large 
cell lymphoma (ALCL).  
 
Classical Hodgkin’s lymphoma is further subdivided into 4 groups:  
 Nodular sclerosis Hodgkin’s lymphoma (NSHL) 
 Mixed cellularity Hodgkin’s lymphoma (MCHL) 
 Lymphocyte-depleted Hodgkin’s lymphoma (LDHL) 




1.1.1.2 Nodular sclerosis Hodgkin’s lymphoma (NSHL) 
Nodular sclerosis HL is the most frequent type of cHL, accounting for about 70% of 
cases [6]. This disease subtype is characterized by the presence of collagen bands 
that divide the node into nodular clusters and by the presence of HRS variants called 
Lacunar cells. In general, nodular sclerosis HL has a good prognosis. This variant can 
be subdivided into nodular sclerosis grade 1 (NS1) and nodular sclerosis grade 2 
(NS2) depending on the number of RS cells and the degree of fibrosis. These sub-
types have relatively better and poorer prognosis respectively.  
 
1.1.1.3 Mixed cellularity Hodgkin’s lymphoma (MCHL) 
Mixed cellularity HL accounts for about 20% of cHL cases [6]. This variant is 
characterized by scattered HRS cells in a diffuse inflammatory background. Prognosis 
of MCHL is not as good as in NSHL. 
 
1.1.1.4 Lymphocyte-depleted Hodgkin’s lymphoma (LDHL) 
Lymphocyte-depleted HL is very rare, accounting for less than 1% of cHL cases. 
However, it is the most aggressive subtype of this disease. Patients often present with 
advanced stage disease (eg stage III-IV; see Table 1.1) and have the poorest 
prognosis. Lymphocyte-depleted HL is characterized by high number of malignant 
(HRS) cells and relatively few non-neoplastic lymphocytes.  
 
1.1.1.5 Lymphocyte-rich Hodgkin’s lymphoma (LRHL) 
Lymphocyte-rich HL accounts for about 3% of cases [6]. It is characterized by small 
numbers of HRS cells associated with an immune infiltrate similar to that observed in 




1.1.2 Clinical presentation, diagnosis and stages 
Most patients with cHL present with enlarged lymph nodes in one or more supra-
diaphragmatic areas, mainly in the neck. Diagnosis and disease staging is based upon 
physical examination, tumour biopsy, positron-emission tomography/computerized 
tomography (PET/CT) from the neck to the pelvis and bone marrow biopsy [8]. The 
disease is staged according to the Ann Arbor staging system (Table 1.1), which was 
developed in 1971 [9] and later modified in 1989 (Cotswold modification) [10]. This 
staging system defines the extent of disease progression, which facilitates the selection 
of initial treatment options. Patients are classified into four stages followed by a letter A 
or B indicating respectively the lack or presence of B symptoms (fatigue, weight loss, 
fever, night sweats, itchy skin etc.)  
 
 
Table 1.1 Staging of Hodgkin’s Lymphoma according to the Ann Arbor system. 
 
STAGE SYMPTOMS 
I Involvement of one lymph node or lymphoid structure 
II Involvement of two or more lymph nodes on the same side of 
the diaphragm  
III Involvement of lymph nodes on both sides of the diaphragm 





1.1.3 Origin of Hodgkin and Reed-Sternberg (HRS) cells 
The malignant cells in cHL, referred to as Hodgkin and Reed-Sternberg cells (HRS), 
account for only about 2% of the tumour mass, whereas the majority of the malignancy 
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is composed of a mixed inflammatory infiltrate comprised of T-cells, neutrophils, 
eosinophils, mast cells, plasma cells, fibroblasts and macrophages. The vast variety of 
cell types surrounding HRS cells underlines the importance of the tumour micro-milieu 
in cHL [11]. Hodgkin and Reed-Sternberg cells are large (20-60m in diameter) and are 
either mono-nucleated (Hodgkin cells) or bi- and multinucleated cells (Reed-Sternberg 
cells) [12]. 
 
1.1.3.1 Phenotype of HRS cells 
Hodgkin and Reed-Sternberg cells have largely down-regulated their B-cell specific 
gene expression program and have gained expression of markers associated with 
other haematopoietic lineages [13]. They lack several classical B-cell markers, 
including B-cell receptor, CD79A, CD79B, CD19, CD20, PU.1, OCT2 and BOB1 
expression [14]. By contrast, those cells typically demonstrate constitutive activation of 
NF-κB and JAK-STAT pathways and aberrantly express T-cell markers (CD3, 
NOTCH1, GATA3), cytotoxic cell markers (granzyme B, perforin), dendritic cell markers 
(CCL17), NK cell markers (ID2), granulocyte markers (CD15) and myeloid cell markers 
(CSF-1R) [2, 15].  
 
1.1.3.2 Anti-apoptotic evasion strategies employed by HRS cells 
Classical HL is considered to have a germinal centre B-cell origin since 
immunoglobulin (Ig) gene rearrangements have been identified in HRS cells, excised 
by micro-manipulation from cHL cases [16, 17]. Germinal centres (GC) are micro-
anatomical structures arising within lymphoid follicles, which develop as a result of the 
clonal expansion of antigen-specific B-cells. During germinal centre development, 
antigen-stimulated B-cells undergo several rounds of proliferation and somatic 
hypermutation (SHM) of Ig V genes. Only those cells with a B-cell receptor (BCR) that 
displays high affinity for antigen and is non self-reactive are rescued from apoptosis. 
Hodgkin and RS cells exhibit evidence of SHM and lack of BCR expression, which 
suggests that they are pre-apoptotic B-cells that have escaped antigen selection by 
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acquiring transforming mutations [17]. In the sections that follow, three of the anti-
apoptotic evasion strategies implicated in HRS survival within the GC are described 
briefly. 
 
1.1.3.2.1 NF-B signalling pathway 
The NF-B signalling pathway plays a key role in the regulation of cell proliferation and 
apoptosis. This pathway has repeatedly been shown to be constitutively activated in 
cHL [18, 19]. Subsequently, this phenomenon was explained by the presence of 
mutations that render IB defective [18]. Those observations suggest that the NF-B 
signalling pathway contributes to the survival of malignant B-cells in cHL.   
 
1.1.3.2.2 JAK-STAT signalling 
Signalling by the Janus kinase/ signal transducers and activators of transcription (JAK-
STAT) system has also been implicated in proliferation and apoptosis resistance in 
HRS cells. Cytokine-mediated activation of the JAK-STAT pathway in response to 
interleukin (IL)-6, IL-9 and IL-13 is well documented in cHL and involves downstream 
activation of STAT3, STAT5 and STAT6 [20, 21]. Additionally, frequent genomic gains 
of JAK2 [22] and inactivating mutations of suppressor of cytokine signalling 1 (SOCS1 - 
a negative regulator of JAK-STAT signalling) [23], have been described.  
 
1.1.3.2.3 Fas death receptor pathway escape 
The Fas receptor is a member of the tumor necrosis family receptor superfamily 
(TNFR). Fas is a death receptor and is directly involved in B-cell apoptosis during 
antigen selection in the GC. Several studies have reported that HRS cells are resistant 
to Fas-mediated apoptosis due to high levels of expression of the inhibitory molecule c-




1.1.4 Role of Epstein-Barr virus in Hodgkin’s lymphoma pathogenesis 
Epstein-Barr virus (EBV) is a ubiquitous human gamma-herpesvirus that has infected 
over 90% of adults infected worldwide, leading to life-long latent infection [25]. Although 
EBV is found in about 40% of cHL cases [26], its contribution to the pathogenesis of 
the disease is unknown. In EBV+ tumours, all of the HRS cells are infected [27]. This is 
extremely unlikely to happen by chance bearing in mind that infected cells form a tiny 
fraction (1-100 cells per million) of the B-cell population. Furthermore, the 
monoclonality of EBV DNA in HRS cells has been demonstrated which indicates that 
the EBV infection precedes the clonal expansion of tumour cells [28].  
 
Although the role of EBV infection in the pathogenesis of cHL is unclear, it has been 
established that two EBV proteins (LMP1 and LMP2A) provide signals that mimic those 
derived from CD40 and BCR. By this means, EBV infection could theoretically provide 
an apoptotic escape mechanism for HRS cells within the GC [29]. 
 
1.1.5 Signalling by Receptor Tyrosine Kinases (RTK) in cHL 
Receptor tyrosine kinases (RTK) are commonly involved in cancer pathogenesis and 
usually signal through the phosphatidylinositol 3’kinase (PI3K)/AKT, mitogen-activated 
protein kinase (MEK1/2/ERK1/2) and JAK-STAT pathways [30, 31]. Several RTKs 
showing autocrine activation in HRS cells have been implicated in the pathogenesis of 
cHL, including platelet-derived growth factor receptor A (PDGFRA), DDR2, 
tropomyosine related kinase A (TRKA), tropomyosine related kinase B (TRKB), 
tyrosine kinase with Ig and EGF homology domain (TIE1), ephrin type B receptor 1 
(EPHB1) and RON [32, 33]. These findings indicate that aberrant RTK signalling is an 
important factor in cHL pathogenesis and that it may be a novel therapeutic target. 
 
Recently, Lamprecht et al. have reported that CSF-1R is constitutively activated in 
most cHL-derived cell lines and that primary cHL cells are characterized by aberrant 
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CSF-1 and CSF-1R co-expression [34, 35]. Additionally, a separate study has outlined 
a correlation between CSF-1R expression on HRS cells and first line treatment failure 
in a cohort of 29 cHL patients [4]. It has been demonstrated that the number of tumour-
associated macrophages (TAM) and CSF-1R expression on HRS cells, taken as 
individual markers, are both linked with inferior treatment outcome. The combined use 
of those 2 gene expression features has been suggested as a prognostic factor for 
identification of high-risk patients for primary treatment failure and death after ABVD-
type combination chemotherapy (see Table 1.2 for acronym). Although the nature of 
interactions between HRS cells and TAMs is not clear, it is possible that tumour cell 
growth is supported by autocrine (HRS cells) or paracrine (TAM) CSF-1 secretion, 
acting to stimulate CSF-1R on HRS cells. In the light of these findings, CSF-1R 
emerges as a promising target for at-risk and refractory cHL patients.    
 
1.1.6 Management of cHL: from standard care to novel agents 
Treatment recommendations for cHL vary in different countries but, in general, patients 
with early stage disease (e.g. stage I and II) receive a combination of 2-4 cycles of 
chemotherapy (ABVD or BEACOPP) (Table 1.2) and radiotherapy (20 Gy involved field 
radiotherapy (IFRT)) [36, 37]. Patients with advanced stage disease (e.g. stage III and 
IV) are treated with 6-8 cycles of chemotherapy [36, 37].  
 
1.1.6.1 Radiotherapy 
Radiotherapy was the first curative treatment for cHL, as described by Peters in 1958 
and Kaplan in 1966 [38, 39]. Owing to the contiguous manner by which cHL usually 
spreads, radiation therapy was initially administered to large fields (e.g. mantle fields, 
“inverted Y fields” or both). This approach provides effective treatment both to tumours 
and to clinically unaffected neighbouring tissues, but resulted in significant toxicity in 
some cases. Owing to the effectiveness of modern chemotherapy, wide field 





In the mid 1960s the treatment of cHL was revolutionized by the introduction of the first 
multidrug chemotherapy regimen, MOPP, which consisted of mechlorethamine, 
vincristine, procarbazine and prednisone [40]. Next, the ABVD regimen was developed 
(Table 1.2) and owing to its superior efficacy and lower toxicity, it replaced MOPP as a 
standard treatment [41]. More recently, the “escalated BEACOPP” regimen (Table 1.2) 
was developed and has achieved improved complete remission rates compared to 
ABVD in a number of clinical trials, although toxicity appears to be increased [42]. 
Alternatively, patients who fail to achieve complete response to ABVD may be treated 
with more intensive regimens such as escalated BEACOPP followed by autologous 
stem cell transplantation (ASCT). 
 
Table 1.2 Chemotherapy regimens 
 






Doxorubicin (Adriamycin) (A)* Anthracycline 
Bleomycin (B) Glycopeptide antibiotic complex 
Vinblastine (V) Vinca-alkaloid 









Bleomycin (B) Glycopeptide antibiotic complex 
Etoposide (E) Topoisomerase II inhibitor 
Doxorubicin (Adriamycin) (A) Anthracycline 
Cyclophosphamide (C) Alkylating 
Vincristine (Oncovin) (O) Vinca-alkaloid 
Procarbazine (P) Alkylating 





1.1.6.3  Targeted therapies 
Classical HL is largely associated with good prognosis and is characterized by 70-80% 
overall survival (OS) of advanced stage patients treated with standard chemotherapy 
regimens [43]. The main risk of death in those patients comes from the development of 
late complications including secondary malignancies (leukaemia and solid tumours) 
and cardiac disease, such that 15 years after the end of treatment, mortality related to 
late effects exceeds that of the original disease [44]. Furthermore 20-30% of patients 
present with relapse or progressing disease after initial treatment [4]. Those patients 
receive salvage chemotherapy plus potentially further treatment including ASCT with or 
without involved field radiotherapy. Each of those additional treatments entails 
significant risk for the patient, with ASCT having a non-relapse mortality rate of 2-3% 
[45-47]. In order to improve disease outcome further, there has been considerable 
interest in the development of targeted therapies. So far, the anti-CD20 monoclonal 
antibody rituximab has been the only targeted therapy introduced into primary 
treatment for NLPHL and is now under investigation for cHL (e.g. HD18 study, 
exploring the combination of this agent with escalated BEACOPP) [48-50]. A blocking 
anti-CD40 antibody (lucatumumab) and a chimeric anti-CD80 antibody (galixumab) 
have also been tested in early phase clinical trials but have shown limited efficacy 
(13.5% and 10.3% overall response rate, respectively) [51, 52]. Similarly, early phase 
studies with anti-CD25 antibodies, either conjugated with recombinant diphtheria toxin 
or with 131Iodine, showed discouraging results [53, 54]. Monoclonal antibodies against 
CD30 are also under investigation. Despite initial low response rate with the anti-CD30 
monoclonal antibodies SGN-30 [55] and MDX-060 [56], antibody engineering has 
allowed for enhanced antibody-directed cell mediated cytotoxicity (ADCC) bringing a 
second line of CD30-targeting antibodies in early phase clinical trials (MDX-1401 (trial 
reference: NCT00634452) and XmAb2513 (NCT00606645) (clinicatrials.gov website, 




By far the most exciting advancement in the therapy of cHL has been brentuximab 
vedotin, a CD30-specific antibody-drug conjugate. In 2011, the U.S. Food and Drug 
Administration (FDA) approved brentuximab vedotin for the treatment of cHL after 
failure of ASCT or after failure of at least two prior multi-agent chemotherapy regimens 
in patients who are not ASCT candidates. In a phase II clinical trial of patients with 
relapsed/refractory Hodgkin’s lymphoma, treatment with single-agent brentuximab 
vedotin resulted in overall response rates of 75% with 34% complete remissions [58]. 
Median duration of response was 20.5 months for those in complete remission and 6.7 
months for all responding patients. More recently, brentuximab has been evaluated in 
combination with a number of chemotherapy regimens including DHAP 
(dexamethasone, cytarabine, cisplatin – NCT02280993), ICE (ifosfamide, carboplatin, 
etoposide – NCT02227199), gemcitabine (NCT01780662) and ABVD, the latter 
resulting in unacceptable lung toxicity [59]. Consequently, the ABVD chemotherapy 
regimen was modified to omit bleomycin and include brentuximab, resulting in 96% 
complete response with no significant pulmonary toxicities registered [59]. Following 
these encouraging results a phase 3 clinical trail comparing standard ABVD treatment 
to AVD plus brentuximab vedotin is currently underway (NCT01712490).  
 
Recently, combination therapy with brentuximab and checkpoint inhibition has become 
an area of extensive interest. The combination of brentuximab and ipilimumab (CTLA-4 
checkpoint inhibitor) is already under investigation (NCT01896999). Furthermore, a 
striking response to PD1 blockade as a single agent has been reported in two clinical 
trials using nivolumab (74% overall response and 17% complete response) [60] and 
pembrolizumab (66% overall response and 21% complete response) [61]. Given these 
promising results, a combination therapy of PD1 checkpoint blockade with brentuximab 
can be envisaged in the near future [57]. 
 
Other targeted therapies, currently in early phase clinical trials, include novel agents 
like the mTOR inhibitor everolimus, the histone deacetylase inhibitor panobinostat, 
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JAK/STAT (INCB039110) and PI3 kinase (INCB040093) inhibitors [42]. High response 
rates have been seen with the use of everolimus (47% overall response, 1 complete 
response) [62] and panobinostat (27% overall response) [63] as single agents. 
Additionally, in a phase 1 study patients who received a combination of the JAK1 
inhibitor and the PI3 kinase inhibitor had an overall response rate of 67% [64]. Further 
studies will be needed to confirm these results, but combined modulation of several 
pathways may be a promising approach in this disease. 
 
1.1.6.4 Clinical evaluation of CAR T-cell immunotherapy for cHL 
Currently, there are several ongoing early phase clinical trials using CD30-targeting 
CAR T-cells in cHL. Baylor College has 2 open clinical trials using a CAR targeting 
CD30 in cHL (NCT01192464 and NCT01316146) while the University of Cologne has 
one (NCT01645293) and the Chinese PLA General Hospital has one such trial 
(NCT02259556) [65]. Reported preliminary results from Baylor College are 
encouraging in that no treatment attributable adverse events have been observed in 
the 9 enrolled patients (7 cHL and 2 ALCL). However, one patient has achieved 
complete response with 1 partial response and 4 patients with stable diseases at 6 
weeks post treatment [66].  
 
Classical Hodgkin’s lymphoma has become a highly curable disease over the last few 
decades due to the introduction of multidrug chemotherapy. However late 
complications (including secondary malignancies) and long term toxic effects are still a 
major concern in cured patients. Furthermore novel more effective targeted therapies 
are needed for cHL patients who have relapsed after ASCT and patients who have 




1.2 Anaplastic Large Cell Lymphoma 
Anaplastic large cell lymphoma (ALCL) is a type of Non-Hodgkin’s lymphoma (NHL) 
first described by Stein et al. in 1985 [67]. It represents a diverse group of tumours with 
common morphological and immunophenotypic characteristics, but with varying clinical 
and genetic features. Anaplastic large cell lymphoma is a T-cell or null-cell lymphoma, 
named after the frequent anaplastic features evident in histological analysis [67].  
 
1.2.1 Classification of anaplastic large cell lymphoma 
Anaplastic large cell lymphoma can present in two forms: cutaneous (c-ALCL) and 
systemic. Cutaneous ALCL is limited to the skin whereas systemic ALCL can involve 
lymph nodes, bone, soft tissue, liver and lung. Distinction between cutaneous ALCL 
and systemic ALCL with cutaneous involvement is clinically important, as these 
disorders require different forms of treatment. Cutaneous ALCL generally has a less 
aggressive disease course than systemic ALCL. The following paragraphs refer to 
systemic ALCL unless mentioned otherwise.  
 
According to the World Health Organization (WHO) tumour classification, ALCL is sub-
divided into two types depending on the anaplastic lymphoma kinase expression (ALK), 
giving ALK positive (ALK+) and ALK negative (ALK-) ALCL [68]. Both types of ALCL are 
characterized by uniform expression of the CD30 antigen on the cell surface. 
 
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase, whose expression is 
generally limited to perinatal neural tissue. The ALK gene has a recognized pathogenic 
role as it is frequently involved in chromosomal translocations, mutations and 




1.2.2 Clinical presentation, epidemiology and diagnosis 
Anaplastic large cell lymphoma represents about 5% of NHL cases in adults and 20-
30% of all paediatric lymphomas [70, 71]. Expression of ALK is typically found in about 
60-80% of cases of ALCL. The ALK+ subtype of ALCL is mainly observed in children 
and young adults with a male predominance (6.5:1 male to female ratio). By contrast, 
ALK- ALCL primarily occurs in older individuals and presents with no gender 
predominance [5].   
 
Anaplastic lymphoma kinase positive ALCL often presents as an aggressive disease 
with systemic symptoms. By contrast, a less aggressive presentation is typical for ALK 
negative ALCL cases, although these lymphomas are associated with worse prognosis. 
Diagnosis is based upon physical examination and tumour biopsy. The disease is then 
staged according to the Ann Arbor staging system (Table 1.1), which was developed in 
1971 [9] and later modified in 1989 [10]. About 70% of patients present with advanced 
(stage III or IV) disease with abdominal and/or peripheral lymphadenopathy, often 
associated with extra-nodal infiltrates and involvement of the bone marrow [72]. In 
adults, breast involvement most frequently associated with breast implants has also 
been described [73-75].  
 
Anaplastic lymphoma kinase expression is an important prognostic factor in ALCL. The 
overall 5-year survival rate is approximately 70-80% for ALK+ ALCL and substantially 
less (30-40%) for ALK- ALCL. [76]  
 
1.2.3 Chromosomal translocations 
The expression of ALK in ALCL is a consequence of chromosomal translocations 
involving the ALK gene locus. In 80% of ALK+ ALCL cases, translocation occurs 
between the ALK gene on chromosome 2 and the nucleophosmin (NPM) gene on 
chromosome 5, giving rise to the fusion protein, NPM-ALK [77]. Since the initial 
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discovery of NPM-ALK, numerous other fusion partners of ALK have been discovered, 
including tropomyosin 3 and 4, clathrin heavy chain-like 1 (CLTC1), TRK-fused gene 
(TFG) and many more [78, 79]. Fusion proteins derived from translocations involving 
the ALK gene have oncogenic potential due to aberrant constitutive tyrosine kinase 
activation, resulting in the continuous transmission of growth-promoting cellular signals 
[80]. The ALK kinase activates different downstream signalling cascades. In particular, 
Ras-ERK activation is essential for ALCL cell proliferation while the JAK3-STAT3 and 
PI3K-AKT pathways are central for cell survival [81].  
 
Despite ALK- ALCL being characterized by the absence of chromosomal translocations 
involving the ALK gene, two different translocations have recently been reported. 
These involve dual specificity phosphatase 22 (DUSP22), located on chromosome 
6p25.3 and tumour protein p63 (TP63), found on chromosome 3q28. Importantly, 
chromosomal rearrangements involving these loci have been implicated in the further 
stratification of disease prognosis [82]. While DUSP22 rearranged ALK- disease has 
similar overall survival rates compared to ALK+ disease (5-year overall survival (OS) of 
70-80%), TP63 rearrangements convey a worsened prognosis (5-year OS of 15%) and 
poor response to initial treatment [82]. The mechanistic implications of these 
rearrangements for disease pathogenesis are currently unknown and remain under 
investigation.  
 
1.2.4 Morphologic features and subtypes 
Systemic ALCL can be subdivided morphologically into 3 types – common variant, 
lymphohistiocytic variant and the small cell variant [83].  
 In the common variant, large lymphoid cells are found in which nuclei have 
been described as horseshoe shaped and chromatin poor [84], with multiple 
nucleoli. These cells, called “hallmark” cells, form large sheet-like structures 
within the tumour. Multinucleated cells with Reed-Sternberg–like appearance 
may also occur. 
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 The lymphohistiocytic variant is characterized by a large number of histiocytes, 
which may mask the anaplastic tumour cell population. The neoplastic cells are 
CD30+ and often cluster around blood vessels [85]. 
 The small cell variant is characterized by a mixture of small, medium-sized and 
large lymphoid cells with irregular shaped nuclei. A typical feature of this variant 
is large cells surrounding small vessels [86]. 
 
1.2.5 Immunophenotype 
Anaplastic large cell lymphoma is a T-cell derived malignancy but in some cases it may 
have an apparent “null cell” phenotype due to loss of several pan T-cell antigens. 
Regardless, all ALCL cases show evidence for a T-cell lineage of origin at the genetic 
level. In more than 75% of cases, tumour cells are CD3 negative. They are mostly CD4 
positive, variably positive for CD45 and strongly positive for CD25. Most typically, all 
tumour cells are CD30 positive [87]. Some cases express markers typically associated 
with other lineages including CD15, PAX5, CD13, CD33 and CSF-1R [34, 88-90]. 
 
1.2.6 Management of ALCL: from standard care to novel agents 
Currently first line of treatment for ALCL consists of chemotherapy regimens such as 
CHOP (cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (oncovin), 
and predniso(lo)ne) but long-term disease outcome varies depending on the subtype 
[79]. While about 80% of patients respond to treatment, 40-65% of patients develop 
recurrent disease [91]. The overall 5-year survival rate is approximately 70-80% for 
ALK+ ALCL and 30-40% for ALK- ALCL [76]. The standard management of patients 
who fail a multidrug chemotherapy regimen includes the use of salvage chemotherapy 
such as romidepsin (Istodax) [92] and pralatrexate (Folotyn) [93], followed by ASCT 
[94, 95]. For patients who are not suitable or who fail ASCT, the prognosis is extremely 




1.2.6.1 Targeted therapies 
Targeted therapies for ALCL largely overlap with those for cHL because of the 
ubiquitous expression of CD30 in both malignancies. In a phase I study by Younes et 
al., 2 patients with refractory ALCL (unknown ALK status) were enrolled and treated 
with brentuximab, leading to complete response in both cases [96]. In a similar phase I 
study involving 5 patients with refractory/relapsed ALCL (also unknown ALK status), 
80% achieved a complete response following treatment with this agent [97]. Notably, 
the first study to show no difference in outcomes between brentuximab-treated ALK- 
and ALK+ subgroups was a phase II clinical trial, which enrolled 53 patients with 
refractory/relapsed ALCL (72% of which were ALK-). In that study, 52% of patients 
achieved a complete response regardless of the ALK status, thereby eliminating the 
historical survival difference observed between the two subtypes of ALCL. Based on 
that pivotal trial in 2011, FDA approved brentuximab vedotin for the treatment of ALCL 
in the second line setting, after failure of at least one prior multi-agent chemotherapy 
regimen. Currently, patients with CD30+ newly diagnosed mature T-cell lymphomas are 
being enrolled in a phase III clinical trial (ECHELON-2, NCT01777152), which aims at 
comparing brentuximab vedotin in combination with CHP with the standard-of-care 
CHOP in first-line setting [98]. 
 
Another approach to the treatment of ALK+ ALCL involves the use of ALK inhibitors. 
The current leading compound is crizotinib. This agent has shown clinical success and 
is currently FDA approved for the treatment of non-small cell lung carcinoma (NSCLC) 
harbouring ALK translocations [99]. While initial treatment with crizotinib is frequently 
successful against ALCL, tumours acquire resistance to this therapy. Initial response to 
therapy lasts on average 10.5 months [100]. 
 
The limited successes of current therapeutic approaches for advanced-stage risk group 
patients who have failed several multidrug regimens and have relapsed after ASCT or 
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are not eligible for ASCT underlines the need for the development of more effective 
targeted therapy that will improve the success of sustained remission of this disease. 
 
1.3  Colony-Stimulating Factor-1 Receptor and its Ligands  
Historically, members of the receptor tyrosine kinase (RTK) family have been the 
subject of intense investigation owing to their fundamental role in signal transduction 
and cellular communication. Several RTKs are central players in determining whether 
cells proliferate, differentiate, migrate or die. In addition to their role in normal cellular 
processes, RTKs are also widely known for their role in the initiation and progression of 
a number of cancer types.  
 
The colony-stimulating factor-1 receptor (CSF-1R) is also known as macrophage 
colony-stimulating factor receptor (M-CSFR) or CD115. This integral transmembrane 
glycoprotein exerts its biological functions in response to two competing ligands, 
namely colony-stimulating factor-1 (CSF-1) or interleukin (IL)-34. Binding of either 
ligand promotes oligomerisation and transphosphorylation of the receptor, leading to 
the activation of signal transduction [101, 102].  
 
1.3.1 Structure and function of CSF-1R 
Colony-stimulating factor-1 receptor is a member of the type III RTK family, which also 
includes c-kit [103], Flt-3 [104], platelet-derived growth factor receptor (PDGFR)α [105] 
and PDGFRβ [106]. Similar to the other members of its family, CSF-1R is composed of 
an extracellular glycosylated ligand-binding segment with 5 immunoglobulin (Ig)-like 
domains, a transmembrane domain and a kinase insert, dividing the intracellular kinase 
domain into 2 lobes [107]. Within the cytoplasmic kinase domain, 8 tyrosine 
phosphorylation sites have been described, distributed between the juxtamembrane 
section (Y546 and Y561), the kinase insert (Y699, Y708 and Y723) and the distal 




Signalling through CSF-1R has been primarily studied in macrophages [112]. In the 
inactive form of CSF-1R, the juxtamembrane domain mediates a critical auto-inhibitory 
role by preventing the activation loop from adopting an active conformation [113]. 
Ligand binding induces non-covalent dimerization of the receptor chains, thus relieving 
inhibition by phosphorylation of Y561 (Y559 in mouse) [114]. This tyrosine is the first 
residue to be phosphorylated in response to ligand binding and is crucial for full 
receptor activation and subsequent tyrosine phosphorylation [112, 114, 115]. The 
phosphorylated sites function as docking sites for a variety of proteins that include 
several Src family kinases, the p85 subunit of PI3K, phospholipase C2, suppressor of 
cytokine signalling-1, Grb2, and c-Cbl [110, 116]. In turn, this leads to signalling waves 
involving ERK1/2, PI3K, Raf and MAP kinase and Akt (Figure 1.1) [117]. The resultant 
gene expression program promotes proliferation, differentiation and survival of the cell.  
 
Binding of IL-34 to CSF-1R triggers phosphorylation of ERK1/2, indicating that CSF-1 
and IL-34 generate signals that at least in part overlap [102]. However, the kinetics of 
CSF-1R signalling in response to IL-34 as well as the rate of receptor internalization, 






Figure 1.1 CSF-1R signalling in myeloid cells. 
Binding of CSF-1 or IL-34 induces CSF-1R chain dimerization, leading to cross-tyrosine 
phosphorylation, and the direct association of signalling molecules with the receptor through 
their phosphotyrosine-binding domains. The resultant gene expression program promotes 
proliferation, differentiation and survival of the cell. Abbreviations: Cbl, Casitas B lineage; MEK, 




1.3.2 CSF-1R and its ligands 
Colony-stimulating factor-1 receptor is encoded by the c-fms proto-oncogene. This was 
first discovered as the cellular homologue of the active viral oncogene v-fms, encoded 
by the Susan McDonough (SM) and Hardy-Zuckerman five (HZ-5) strains of the feline 
sarcoma virus [101]. The human c-fms gene, located on chromosome 5q33.3, is 75 kb 
in length and is under the tight regulation of a promoter and an intronic enhancer 
element (FMS intronic regulatory element or FIRE), both of which are evolutionarily 
highly conserved [118]. Two naturally occurring isoforms of CSF-1R have been 
reported, as a result of different processing pathways, but no significant ligand affinity 
differences have been established between both CSF-1R isoforms. [119]. 
 
Colony-stimulating factor-1 receptor has two known ligands – it is the unique receptor 
for CSF-1 and recently it has been shown to also bind IL-34 [102].  
 
1.3.2.1 Colony-stimulating factor-1 
Colony-stimulating factor-1, also known as macrophage colony stimulating factor (M-
CSF), is a homodimeric glycoprotein. Owing to alternative mRNA splicing and post-
translational modification, CSF-1 exists in three isoforms: secreted glycoprotein, 
secreted proteoglycan and cell surface glycoprotein [120]. Under physiological 
conditions, CSF-1 is produced by fibroblasts, endothelial cells, monocytes, 
macrophages, osteoblasts, microglia, keratinocytes, bone marrow stromal cells, natural 
killer cells, B-cells and T-cells [118, 121-124]. The main physiological role of CSF-1 is 
as a haematopoietic growth factor responsible for the survival, proliferation, 
differentiation and motility of cells of the monocyte lineage [125]. In addition, CSF-1 
plays a major role in bone remodelling by osteoclasts. [120].  
 
Inactivating mutation of the Csf1 locus in the op/op mouse (Csf1op/ Csf1op) leads to a 
decrease in tissue macrophages and severe deficiency in osteoclasts [126]. Gene 
targeting of the c-fms locus essentially results in the same phenotype, the most striking 
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manifestation of which is osteopetrosis. Notably, osteopetrotic mice exhibit CSF-1-
independent recovery of macrophages and osteoclasts, reaching normal numbers by 
7-9 months of age [127]. The mechanism of this process is yet not clear, but most 
probably it is mediated by vascular endothelial growth factor (VEGF) [128] and/or IL-3 
and granulocyte-macrophage colony-stimulating factor (GM-CSF) [129], although the 
contribution of other growth factors cannot be ruled out.  
 
1.3.2.2 Interleukin 34 
The existence of an additional CSF-1R ligand was suspected for a long time due to the 
greater severity of the osteopetrotic phenotype of CSF-1R-/- mice compared to the 
op/op mice, but the actual ligand, termed IL-34, was discovered only recently [102]. 
Interleukin 34 binds CSF-1R in a specific and CSF-1-independent manner and 
surprisingly shows no sequence similarity to CSF-1 or to any other known protein [102]. 
Interleukin 34 overlaps functionally with CSF-1 by promoting survival, proliferation and 
macrophage colony formation. Yet, these two cytokines exhibit significant tissue-
specific and developmental differences in their expression patterns. For example, both 
IL-34 and CSF-1 are indispensable for brain development but are expressed within 
different regions [130]. This implies that IL-34 is functionally redundant with CSF-1 but 
their differential spatial expression points towards complementary functioning. 
 
Despite the functional similarities between IL-34 and CSF-1, they exhibit several 
significant differences: 
 IL-34 and CSF-1 have overlapping, but yet distinct binding sites on CSF-1R 
[102]. 
 IL-34 binds with considerably higher affinity to CSF-1R than does CSF-1 (Kd of 
1pM versus 34 pM respectively) [102]. 
 
Recently, a novel IL-34 receptor was identified termed PTP-ζ [131]. It is primarily 
expressed on neural progenitors and glial cells and is highly expressed in human 
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glioblastomas [132]. Unsurprisingly, IL-34 is highly expressed in the brain and has an 
important role in microglial development. In agreement with this, IL-34-deficient (IL-
34−/−) mice exhibit severe deficits in microglia formation [133].  
 
1.3.3 CSF-1R in normal physiology and pathology 
In normal physiology, CSF-1R expression is limited to the mononuclear phagocyte 
lineage. It is primarily expressed on macrophages, non-classical monocytes 
(CD14+CD16+) and osteoclasts. During inflammation, signalling through CSF-1R 
promotes cytotoxicity, phagocytosis, chemotaxis and cytokine production by these cell 
types and furthermore modulates the development and function of dendritic and 
Langerhans cells [134]. In addition, the CSF-1/CSF-1R axis plays a key role in bone 
metabolism [135], brain inflammation mediated by microglia [136] and in female 
reproduction [137]. Abnormal signalling through CSF-1R has been reported to be 
implicated in a number of inflammatory disorders such as arthritis [138], atherosclerosis 
[139], obesity, tumour growth and metastasis [140]. 
 
Expression of CSF-1R has been reported in diverse cancer types. Lamprecht et al. 
have demonstrated that CSF-1R is constitutively activated in most cHL-derived cell 
lines and that primary cHL cells express both CSF-1 and CSF-1R [141, 142]. In cHL 
and ALCL, CSF-1R expression has been shown to originate from an aberrantly 
activated endogenous long terminal repeat (LTR), suggesting that the origin of the 
unnatural CSF-1R expression found on HRS and ALCL cells is loss of epigenetic 
control. Aberrant CSF-1R expression is also commonly documented in tumours of 
epithelial origin such as breast [143, 144] and ovarian cancer [145]. Furthermore CSF-
1R expression has been strongly associated with poor prognosis in those cancers, 
which makes it an attractive target for drug discovery [146-148]. A more detailed 





1.4  Chimeric Antigen Receptors 
Chimeric antigen receptors are also known as “T-bodies” or chimeric immune 
receptors. These molecules were first developed by Eshhar et al. [149, 150] and are 
engineered as bespoke cDNA fusions. Efficient host cell delivery may be achieved 
using viral or non-viral expression systems, leading to transient or stable transgene 
expression. In general, CARs are expressed within host cells as membrane-spanning 
homodimers at the cell surface. Most commonly, T-cells are used as host cells 
although other populations such as natural killer (NK) cells may also be used. Upon 
target engagement, CARs undergo cross-linking at a synaptic interface formed with the 
target cell [151], leading in turn to activation of one or more immune effector functions. 
 
1.4.1 Structure and evolution of chimeric antigen receptors 
Structurally, CARs consist of an extracellular targeting domain and variable spacer 
domain (hinge), followed by a transmembrane region and an endodomain with 
signalling function (please refer to Figure 4.1, A on page 150). 
 
1.4.1.1 Targeting domain 
The targeting or antigen-recognition domain most commonly consists of a single-chain 
antibody fragment (scFv) that has been assembled from an antibody variable heavy 
(VH) and light (VL) chain, joined by a flexible linker. Alternatively, natural [152-155] or 
chimeric ligands [156] may serve in this role. A recent innovation entails the design of 
universal CARs that may be used in a “plug and play” manner with biotinylated [157] or 
fluorescein-conjugated monoclonal antibodies [158]. Similarly, FcγRIIIa (CD16)-based 
CARs have been developed in which the high affinity V158 Fc receptor variant is 
employed as a targeting adaptor. These CARs harness the ability to mediate antibody-
directed cytotoxicity and other lymphocyte effector functions when engineered cells are 




Chimeric antigen receptors bind directly to native cell surface polypeptides, 
glycoproteins, glycans or glycolipids. This means that the need for antigen processing 
or human leukocyte antigen (HLA)-restricted presentation is bypassed, in contrast to 
αβ T-cell receptors (TCRs). This is an important advantage since down-regulation of 
HLA antigen expression is a widespread immune escape mechanism employed by 
transformed cells [160]. Furthermore, this attribute eliminates the need for matching to 
the patient’s HLA haplotype.  
 
1.4.1.2 Hinge/ spacer domain 
The targeting domain is generally separated from the T-cell membrane by a hinge/ 
spacer, which facilitates binding of the target epitope. Consequently, optimization of 
length [161] or flexibility [162] of this element may prove crucial to the attainment of 
enhanced function. Most commonly, hinge/spacers are derived from immunoglobulin 
Fc/ hinge regions or lymphocyte transmembrane receptors, such as CD8+. The choice 
is important since immunoglobulin-derived modules may interact with Fc-receptor 
bearing myeloid cells, leading to off-target effects [163] or in vivo exhaustion and 
activation-induced T-cell death [164]. 
 
1.4.1.3 Transmembrane domain 
The transmembrane domain also primarily serves a structural role and is commonly 
derived from membrane-spanning lymphocyte molecules such as CD28, CD4 or CD8 
[165, 166]. In some cases, sequence selection may also influence CAR function. One 
such example is the ability of CARs containing the CD3ζ transmembrane domain to 





1.4.1.4 Signalling domain – defining the generations of chimeric antigen 
receptors 
Refinement of the signalling domain has engendered the greatest interest in the 
optimization of CAR-mediated anti-tumour activity. Indeed, endodomain composition 
has given rise to the classification system used most commonly to describe these 
molecules. First generation CARs contain a single module that delivers a TCR-like 
“signal 1”, most commonly the endodomain of CD3ζ or the closely related γ subunit of 
the high affinity receptor for IgE, FcεR1 (for a schematic please refer to Figure 4.1, A) 
[168]. Disappointingly however, clinical studies using T-cells that express first 
generation CARs have yielded unsatisfactory results (Tables 1.3 and 1.4) [169-171]. 
While safety was acceptable, sub-optimal anti-tumour responses associated with a lack 
of in vivo expansion and persistence of CAR T-cells were observed. These clinical 
observations provided a strong rationale for the development of systems whereby 
“signal 2” or co-stimulation could also be provided to CAR-engineered T-cells. This 
may be achieved by expression of the CAR in T-cells that undergo periodic stimulation 
by antigen-presenting T-cells (e.g. T-cells with specificity for latent viruses) [172] or 
alternatively through further CAR engineering. 
 
The latter approach is best illustrated by the development of second generation CARs, 
in which a co-stimulatory signalling motif is also incorporated within the CAR 
endodomain (for a schematic please refer to Figure 4.1, A). [173] Several groups have 
demonstrated in both pre-clinical and clinical studies that CARs in which CD3ζ and a 
co-stimulatory motif are aligned in-cis are functionally superior to those containing 
CD3ζ alone. Commonly used co-stimulatory domains include those derived from CD28 
[173, 174], 4-1BB [175, 176], OX40 [176, 177], ICOS [176, 178], CD27 [179], DAP10 
[180], or 2B4(CD244) [181]. Importantly however, the order of these signalling motifs 
appears to be paramount for delivery of optimal co-stimulation [173, 174]. Furthermore, 
uncertainty persists as to what constitutes the optimal configuration of the CAR co-
stimulatory domain(s). In general, IL-2 release is greatest using the CD28-CD3ζ 
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configuration [180]. However, the combination of ICOS-CD3ζ has been reported to 
elicit enhanced cytotoxicity [176], accompanied by Th17 differentiation [178]. Adding to 
complexity, contrasting results have also been obtained in distinct models. For 
example, in one model, the inclusion of CD28 sequences protected CAR-engineered 
cells from the inhibitory effects of regulatory T-cells (Treg) and cytokines such as IL-10 
and transforming growth factor- [182]. By contrast, the ability of CD28-containing 
CARs to mediate enhanced IL-2 production has also been reported to enhance Treg 
infiltration, ultimately compromising anti-tumour activity [183]. Chimeric antigen 
receptors containing 4-1BB have been reported in some [184] but not all studies [180] 
to promote multi-functionality of cytokine production, which is generally considered 
desirable. However, 4-1BB containing CARs may deliver constitutive signalling in the 
absence of target engagement, a property that may be advantageous or 
disadvantageous depending upon clinical indication [185]. 
 
More recently, third generation CARs have been described in which two or more co-
stimulatory signalling domains are placed in-cis within the CAR endodomain (for a 
schematic please refer to Figure 4.1, A). Examples include CARs in which CD3ζ and 
CD28 have been co-expressed with p56lck [186] OX-40 [162, 177, 187] or 4-1BB [162, 
184, 188, 189]. Simultaneous provision of co-stimulation through complementary 
signalling pathways may further improve in vivo survival and function of CAR T-cells. 
Nonetheless, careful comparison with appropriate matched second generation CARs is 
warranted to provide clear evidence of the superiority of these more complex 
endodomain configurations. 
 
1.4.2 Toxicity induced by CAR T-cell immunotherapy 
Whilst CAR T-cell immunotherapy has shown unprecedented success against 
otherwise untreatable haematological malignancies, it also holds the capacity to elicit a 
number of toxicities including cytokine release syndrome (CRS), tumour lysis syndrome 




1.4.2.1 Tumour lysis syndrome 
Tumour lysis syndrome refers to a group of metabolic abnormalities caused by the 
rapid lysis of malignant cells and the subsequent release of intracellular metabolites. It 
is most commonly associated with haematological malignancies after the 
administration of cytotoxic therapy [190]. Tumour lysis syndrome is characterised by 
elevated serum levels of uric acid, potassium and phosphate, accompanied by 
hypocalcaemia and sometimes progressing to renal failure. It has been successfully 
managed with aggressive hydration and diuresis, allopurinol and rasburicase treatment 
[191] . 
 
1.4.2.2 Cytokine release syndrome 
Cytokine release syndrome is a potentially life-threatening toxicity that has been 
observed after administration of IL-2 [192], some monoclonal antibodies [193, 194] as 
well as following CAR T-cell administration [195-198]. Severe CRS is described as 
cytokine storm and can be fatal [195]. It usually occurs up to 20 days post CAR T-cell 
infusion and is currently managed with corticosteroids, cytokine antagonists and 
supportive therapy [199]. Cytokine storm is characterized by high fever, hypotension, 
tachycardia and seizures. Those symptoms are correlated with rise in serum IL-6 and 
C-reactive protein (CRP). The severity of CRS has been associated with disease 
burden, which implies that it is most probably caused by T-cell and macrophage 
activation. Cytokines most commonly up-regulated include IFN, TNF, IL-6 and IL-10. 
To date, there has been no reported implication of IL-4 in a cytokine storm event 
induced by CAR T-cell administration.   
 
1.4.2.3 Neurologic toxicity 
Neurotoxicity is another serious toxicity observed in several patients treated with CD19-
targeting CAR T-cells [200-202]. Symptoms of neurologic toxicity include visual 
hallucination, delirium, dysphasia and epilepsy or seizures. Whilst to date neurotoxicity 
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has been fully reversible, the underling mechanism as to how CAR T-cells induce 
neurotoxicity is unclear, particularly as it does not correlate with the severity of CRS. 
However, it is plausible that elevated cytokine levels are partially responsible for the 
neurological symptoms, since similar events have been reported with blinatumomab (a 
bispecific T-cell engager antibody against CD19/CD3) administration [203, 204].  
 
1.4.2.4 Anaphylaxis 
In addition to those toxicities, anaphylactic shock following CAR T-cell infusion has also 
been observed [205]. One patient developed anaphylaxis and cardiac arrest within 
minutes of completing a third infusion of CAR T-cells. The patient was treated with 
mRNA electroporated murine anti-human mesothelin CAR T-cells and the adverse 
effect was most probably due to the induction of IgE antibodies specific for the murine-
based antibody sequences present in the CAR. Ultimately the IgE-mediated event 
developed as a result of the intermittent dosing schedule spanning over 49 days and 
allowing enough time for immunoglobulin class switching from IgG to IgE. Shortening 
the infusion scheduale to 20 days would greatly improve the safety of the therapy and 
switching in the future to fully humized antibodies will eliminate their antigenic potential 
as allergens.   
 
1.4.2.5 “On-target/off-tumour” toxicity 
Most CAR T-cell targets are not tumour restricted but have shared expression on 
normal tissue thereby causing some degree of “on-target/off-tumour” toxicity upon 
target engagement on nonpathogenic tissues. A typical example of “on-target/off-
tumour” toxicity is B-cell aplasia with resultant hypogammaglobulinaemia caused by 
CD19-targeting CAR T-cells. Another example of “on-target/off-tumour” toxicity has 
been reported in patients with metastatic renal cell carcinoma following treatment with 
first generation CAR T-cells targeted against carbonic anhydrase-IX (CAIX) [206-208]. 
A number of the patients developed hepatotoxicity owing to recognition of target on 
biliary epithelium and which could be mitigated by prior treatment with a CAIX-specific 
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blocking antibody. Finally, in a fatal example of “on-target/off-tumor” toxicity, a patient 
treated with HER2-targeting CAR T-cells developed respiratory failure followed by 
multi-organ failure, associated with severe CRS [195]. This was believed to be due to 
on-target toxicity following recognition of HER2 in pulmonary parenchyma [195] or 
microvasculature [209]. 
 
Safety of CAR T-cell immunotherapy remains problematic. On-target toxicity has been 
linked to frequent occurrence of CRS (which has been lethal on occasions), in addition 
to other organ-based toxicities (e.g. B-cell aplasia with CD19-targeted CAR T-cells). 
These findings emphasize the need for identification of new and safer targets. In 
parallel, management of CRS is becoming more streamlined with recent descriptions of 
grading systems [201] and recommended management protocols for this adverse 
reaction [200]. In particular, the usefulness of the IL-6 receptor-α antagonist antibody 
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ALL x 4 
CLL – 
Richter x 2 
CLL x 2 
2 (CD28-
CD3) 
Nil Well tolerated 
No GvHD 
Patients had relapsed following allo SCT 
Donor-derived virus-specific T-cells (reactive against EBV, 
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Adult ALL.  
Four patients then proceeded to allo SCT 



























B-cell aplasia (all 
responders) 
 
25/30 patients aged <22 years 
Overall survival of 78% at 6 months 
Relapse with CD19+ disease in 4 cases and CD19 null 
disease in 3 cases 
Tocilizumab ameliorated CRS 
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Adult ALL – median age 50 years 
Defined clinical criteria for severe (s)CRS and identified C-












1-3 x 106 
cells/kg 
 
ALL x 20 







Grade 4 CRS in 3 patients 
at higher dose level 
Reversible neurotoxicity in 
6 patients 
 
Children and young adults 
Dose escalation phase I trial with intention to treat analysis 
Maximum tolerated dose 1 x 106 cells/kg 
Two patients relapsed with CD19 null disease 














1-5 x 106 
cells/kg 
 
DLBCL x 9 
CLL x 4 
SMZL x 1 








One unexplained death 16 
















0.4 – 8.2 x 
106 cells 
 
ALL Ph- x 4 
ALL Ph+ x 1 







Fever, Tachycardia, and 
Hypotension 
 
Lack of new-onset of aGvHD post CAR T-cell infusion 
CAR T-cell persistence less than 4 weeks 




12PD DLBCL x 4 
FL x 1 
MCL x 5 
transplants and recipients of sibling transplants 
.  
 








4.4 x 109 




F-NHL x 8 
MCL x 1 
1 (CD3) CTX No grade 3-4 toxicity T-cell cultures/ CD8+ clones electroporated to co-express 
CAR and G418 resistance gene, allowing selection.  
IL-2 in n=4, which prolonged T-cell survival. 
No anti-CAR inhibitory factor induced, perhaps owing to 






2 NE 1.2 - 2.1 x 
109/m2 in 3 
doses 
DLBCL 1 (CD3) 28 days 
post auto 
HSCT 
No T-cell related toxicity 
noted. 
CD8+ T-cell clones electroporated to co-express CAR and 
G418 resistance gene, allowing selection. Responses 
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Fever and hypotension 
post two infusions 
 
T-cell bulk cultures electroporated to co-express CAR and 
G418 resistance gene, allowing selection.  
Low dose IL-2 administered for 14 days. 
Two patients with NE disease remained free of progression 
for 12 and 24 months. 
The duration of cell culture before infusion was >69 days. 











18-55 x 108 
cells, infused 
































Neutropenia x 1 
Fever, rigors. skin “flare” 
reaction x 1 
No grade 3-4 toxicity 
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Abbreviations: aGvHD – acute graft versus host disease; ALL – acute lymphoblastic leukaemia; ALL Ph+ - Philadelphia chromosome positive acute lymphoblastic leukaemia; ALL Ph- - 
Philadelphia chromosome negative acute lymphoblastic leukemia; allo SCT – allogeneic stem cell transplant; AML – acute myeloid leukaemia; auto HCT – autologous stem cell 
transplant; B – bendamustine; B-NHL – B-cell non-Hodgkin’s lymphoma; BR – bendamustine + rituximab; C – cyclophosphamide; CF – cyclophosphamide and fludarabine-based 
lymphodepletion; CMV – cytomegalovirus; CLL – chronic lymphocytic leukaemia; Cond – conditioning therapy prior to T-cell infusion; CP – cyclophosphamide and pentostatin; CR – 
complete remission; CRS – cytokine release syndrome; CTX – cytoreductive chemotherapy; DLBCL – diffuse large B-cell lymphoma; DLI – donor leukocyte infusion; EBV-CTL – 
Epstein Barr virus specific cytotoxic T-lymphocytes; EC – etoposide + cyclophosphamide; F – fludarabine; F-NHL – follicular NHL; gen - generation; GvHD – graft versus host disease; 
LD – lymphodepletion; LGNHL – low grade NHL; LeY – Lewis Y antigen; MCL – mantle cell lymphoma; NE – non evaluable disease; PR – partial remission; SC – subcutaneous; scFv 
– single chain antibody fragment used to target CD19; SD – stable disease; SLL – small lymphocytic lymphoma; SMZL – splenic marginal zone lymphoma; SUSAR – suspected 
unexpected severe adverse reaction; URD – unrelated donor.  §dose of CAR T-cells 
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1.4.3 Clinical evaluation of CAR T-cells 
Over the past decade, there has been an exponential increase in the number of clinical 
studies undertaken to evaluate the safety and efficacy of CAR T-cell based 
immunotherapy in patients with diverse malignant disorders.  
 
1.4.3.1 Clinical experience in patients with solid tumours 
Solid tumours account overwhelmingly for the greatest unmet need in the modern 
management of cancer. It is unsurprising therefore that initial clinical trials of CAR T-
cell immunotherapy were undertaken in this setting (Table 1.3). Although ultimately 
disappointing to date, this initial clinical experience provides a highly valuable insight 
into the challenges posed by the development of effective CAR T-cell immunotherapy 
for common cancer types.  
 
The first study to be published in full was undertaken in patients with metastatic 
epithelial ovarian cancer [169]. T-cells were targeted against folate receptor- using an 
scFv-based first generation CAR and were administered intravenously (IV), without 
prior lymphodepletion. Although no substantial toxicity was observed, an efficacy signal 
was not demonstrated in this study. Lack of anti-tumour activity was linked to failure of 
T-cell persistence and poor homing to the tumour.  
 
In the context of solid tumour immunotherapy, greatest success has been achieved 
when CARs have been delivered to virus-specific T-cells. This approach has been 
pioneered by the group at Baylor College of Medicine who demonstrated moderate 
efficacy in children with neuroblastoma, treated with GD2 re-targeted first generation 
CAR T-cells [172, 213]. Efficacy was most apparent in patients in whom CAR T-cells 
persisted, justifying the move towards evaluation of second generation CARs. 
Nonetheless, a key challenge is presented by the frequency with which CAR T-cell 
targets are expressed in vital healthy organs, imposing a clear risk of induction of 
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unacceptable toxicity. Illustrating this, one patient with HER2+ metastatic colon cancer 
unfortunately succumbed to a suspected unexpected serious adverse reaction 
(SUSAR) that occurred soon after the IV infusion of HER2 re-targeted T-cells [195]. 
The CAR contained an scFv derived from the trastuzumab (Herceptin) antibody which 
was coupled to a fused CD28 + 4-1BB + CD3ζ “third generation” endodomain. A total 
of 1 x 1010 cells (79% transduced) were infused, following conditioning with 
lymphodepleting chemotherapy. However, respiratory distress occurred rapidly and 
progressed to multi-organ failure, CRS and death. This SUSAR was believed to have 
resulted from recognition of low levels of HER2, which is present in both the pulmonary 
parenchyma [195] and microvasculature [209]. Imaging studies highlight the challenge 
imposed by IV delivery of CAR T-cells, which persist in the pulmonary circulation for 
several hours after administration [234]. Earlier imaging studies in man using indium-
labelled CAR T-cells suggests that sustained pulmonary retention of these cells may 
not be target-dependent and is more prolonged and accompanied by dyspnea when 
highly activated T-cells are infused [169]. 
 
A second example of on-target toxicity has been reported in patients with metastatic 
renal cell carcinoma following treatment with first generation CAR T-cells targeted 
against carbonic anhydrase-IX (CAIX) [206-208]. A number of the patients developed 
hepatotoxicity owing to recognition of target on biliary epithelium and which could be 
mitigated by prior treatment with a CAIX-specific blocking antibody. 
 
In summary, solid tumours have largely proven refractory to treatment with CAR T-cells 
to date. Nonetheless, several studies are currently ongoing involving second 
generation CAR T-cells in several solid tumour types (Table 1.5). There is a clear need 
to refine systems to achieve delivery, persistence, intra-tumoural penetration and 
sustained effector function of these cells within the often hostile tumor 
microenvironment. Solutions may require even greater levels of innovative CAR 
engineering and/ or the combined use of these cells with traditional and emerging 
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cancer therapeutic agents, including chemotherapy [235], radiotherapy [236] and/ or 
immune checkpoint blockers [237] respectively. Use of regional delivery systems in 
selected tumor types such as mesothelioma [238] and head and neck cancer [156, 
239, 240] are also under evaluation. A further recently developed technology that may 
potentiate such loco-regional delivery systems entails the use of biodegradable 
implants to enhance the dispersal and persistence of CAR T-cells [241]. 
 
1.4.3.2 Clinical experience in patients with haematological malignancies 
B-cell malignancy has been the focus of greatest interest and success in the clinical 
evaluation of CAR T-cell immunotherapy [242]. The approach builds upon the efficacy 
of monoclonal antibodies targeted against B-cell lineage antigens, notably the anti-
CD20 antibody, rituximab. However, greatest impact has been achieved using CAR T-
cells directed against CD19 rather than CD20 (Table 1.4) [242]. CD19 is a particularly 
attractive target since it is expressed by virtually all B-cell malignancies and throughout 
all stages of B-lineage differentiation but it is not found on haematopoietic stem cells or 
other tissues [243]. Consequently, it is predicted that effective targeting of CD19-
expressing cells would be accompanied by B-cell depletion and impaired antibody-
forming capacity, consequences that can be managed effectively by immunoglobulin 
replacement therapy.  
 
The first study in which CAR+ T-cells were redirected against a haematological 
malignancy yielded disappointing results [229]. In that study, T-cells were re-targeted 
against CD20 using an scFv-based first generation CAR and were administered to 
patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). While no 
substantial toxicity was observed, no CAR-attributed clinical responses occurred.  
 
Since this report, several other clinical trials have targeted B-cell malignancies using a 
diversity of CARs directed most commonly against CD19 or CD20 (Table 1.4). With the 
introduction of second generation CARs, dramatic responses have regularly been 
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observed in trials conducted at a number of independent centres. In a proof of principle 
study, the group at Baylor College of Medicine simultaneously infused T-cells 
transduced with either a first-generation (CD3ζ) or a 2nd generation (CD28-CD3ζ) 
CD19-targeted CAR to patients with relapsed or refractory NHL [222] The study 
conclusively demonstrated that T-cells modified with the 2nd generation CAR exhibited 
enhanced expansion and persistence in vivo, accompanied by an improved capacity to 
penetrate CD19+ malignant lesions. However, the overall efficacy of the CAR T-cells in 
this study was limited, perhaps in part since preparatory lymphodepletion was not 
employed [222]. 
 
Strikingly compelling efficacy has been achieved when second generation CD19-
targeted CAR T-cells have been administered after cytotoxic or lymphodepleting 
chemotherapy. Studies conducted at the University of Pennsylvania indicate that 
engraftment of engineered cells occurs optimally when they are infused 2 days after 
such conditioning therapy [244]. Arguably, results have been most impressive in 
patients with adult and childhood ALL, in whom complete remission (CR) rates of over 
66% have been consistently achieved [197, 200-202, 210]. The data are all the more 
impressive given the fact that they have been attained in multiple centres using distinct 
CD19-targeted CAR formats and following conditioning using a variety of regimens 
(Table 1.4). 
 
The University of Pennsylvania group has pioneered the clinical development of the 
FMC63/CD8/4-1BB/CD3ζ CAR, described originally by Campana [245]. In ALL 
patients, they have reported a 90% CR rate (27/30 patients). Sustained remission of up 
to 2 years was achieved in 19 patients [202]. The success of this study is perhaps best 
exemplified by the 50% rate of sustained long-term remission that is attributable to 
CAR T-cell immunotherapy in the absence of subsequent allogeneic stem cell 
transplantation. This finding has been linked to the long-term persistence of CAR-




The Memorial Sloan Kettering Group reported an 88% CR rate with their CD19 CAR, 
which is configured as an SJ25C1/CD28/CD3ζ fusion [200]. The National Cancer 
Institute are employing a CAR in which the FMC63 scFv is coupled to CD28/CD3 and 
which has achieved a highly impressive 67% CR rate when analyzed on an intention to 
treat basis [201]. In both of the latter cases, T-cells appear to persist for a considerably 
shorter period (approximately 30 days) when compared to the 4-1BB-based CAR, 
meaning that the therapy is of particular utility as a device to attain molecular CR as a 
bridge to allogeneic stem cell transplantation.  
 
CD19-targeted CAR T-cells have also resulted in an impressive CR rate in patients 
with diffuse large B-cell lymphoma, indolent lymphomas and chronic lymphocytic 
leukaemia (CLL) [227]. Of 15 patients treated, there were eight CRs (including four 
patients with DLBCL), four partial remissions, one patient with stable disease and two 
who were not evaluable [227]. Encouraging data have also been generated when 
donor-derived anti-CD19 CAR T-cells have been used to treat B-cell malignancies that 
have relapsed after allogeneic hematopoietic stem cell transplantation (Table 1.4). A 
small number of studies have been reported in patients with myeloid malignancies, 
although success has been much more limited to date. Several trials are ongoing at the 
time of writing in patients with B-cell and other haematological malignancies (Table 
1.5). 
 
While data generated using CD19 CAR T-cells are extremely impressive, several 
points warrant further exploration. Direct comparison of data generated by different 
centres is highly challenging since patients differ with respect to several key 
parameters, including disease nature and burden, prior treatment history and 
conditioning regimen employed (including the use of some agents with direct anti-
tumour activity). Furthermore, studies have employed CARs that differ in scFv targeting 
moiety, hinge/ spacer, co-stimulatory module, T-cell activating stimulus used during 
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manufacture, gene transfer vector, T-cell expansion protocols and final composition of 
cell products used [242]. Nonetheless, these data collectively provide a great impetus 
to the field and encourage the development of analogous approaches for other 
lymphomas, including cHL and ALCL. 
 
This thesis details the work that I have undertaken to investigate the feasibility of using 
CAR-grafted T-cells for the treatment of cHL and ALCL. To the best of my knowledge, 
this is the first time that CAR+ T-cells have been used to target CSF-1R. The data 
contained within this thesis suggest that such a targeting strategy is justified and that 
the use of CSF-1R-targeted CAR+ T-cells could represent a possible future treatment 
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*www.clinicaltrials.gov Search terms: chimeric antigen receptor, chimeric T-cell. Accessed 14/02/2016 
 
ALL - acute lymphoblastic leukaemia; AML - acute myeloid leukaemia; B-ALL - B cell acute lymphocytic leukaemia; CAR, chimeric antigen receptor; CEA - carcinoembryonic antigen; 
CLL - chronic lymphocytic leukaemia; CR - complete response; DLBCL - Diffuse Large B-Cell Lymphoma; EGFR – epidermal growth factor receptor; FAP – fibroblast activation 
protein; GD2 – ganglioside D2; GPC3 - glypican-3; HCC - hepatocellular carcinoma; MM – multiple myeloma; MS - Myelodysplastic Syndrome; MPM - Malignant Pleural 
Mesothelioma; MSKCC – Memorial Sloan Kettering Cancer Center; NHL - non-Hodgkin’s lymphoma; NI – no information; SCCHN - Squamous Cell Cancer of the Head and Neck; 
GBM - Glioblastoma multiforme. 
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Chapter 2 Materials and Methods 





Figure 2.1 A schematic representation of the various chimeric antigen receptor constructs 
used in this thesis. 
CSF-1 = colony-stimulating factor-1, IL-34 = interleukin 34, IL-4R = Interleukin-4 receptor alpha 
subunit, IL-2Rβ = Interleukin-2 receptor beta subunit, CD3ζ = CD3 zeta chain, CD8α = CD8 alpha 







2.1.1 Generation of CAR Constructs 
The constructs SFG C28ζ and SFG CTr were produced by Dr. Scott Wilkie prior to the 
commencement of this PhD. All other constructs were designed and cloned over the 
course of the project using the Polymerase Incomplete Primer Extension (PIPE) cloning 
method (please refer to section 2.1.2). All retroviral constructs are shown schematically in 
Figure 2.2 (page 80). Successful cloning was confirmed by restriction pattern agarose gel 
analysis and sequencing identified no mutations within the coding sequences (Source 
Bioscience, UK).  
 
C28ζ and CTr were cloned in the SFG retroviral vector as NcoI/XhoI fragments, ensuring 
that their start codons are in the precise place (the naturally occurring NcoI site) 
previously occupied by the deleted env gene. Gene expression is achieved from the 
Moloney murine leukaemia virus (MoMLV) long terminal repeat (LTR), which has 
promoter activity and virus packaging of the RNA is ensured by the MoMLV ψ packaging 
signal, which is flanked by splice donor and acceptor sites.  
 
2.1.1.1 SFG C28ζ construct  
SFG C28ζ comprises of a human fusion gene encoding the CD8 chain leader sequence 
(amino acids (AA) 1 to 18), CSF-1 (AA 19 to 178), the partial extracellular, 
transmembrane and intracellular domain of CD28 (AA 179 to 285) and the intracellular 
domain of the CD3 zeta (CD3ζ) chain (AA 286 to 397). 
 
2.1.1.2 SFG CTr construct 
SFG CTr is designed as a matched truncated control for SFG C28ζ. The endodomain in 
CTr has been truncated to remove the entire CD3ζ sequence and all but the three most N-





2.1.1.3 SFG C4 construct 
The SFG C4 (4αβ + C28ζ) construct (Figure 2.1 and Figure 2.2) is defined by the co-
expression of the C28ζ CAR with the chimeric cytokine receptor 4αβ [246]. The chimeric 
cytokine receptor 4αβ is a fusion molecule comprising of IL-4Rα ectodomain (AA 1 to 233) 
and the shared IL-2/15R endodomain (AA 241 to 551). It was designed to achieve 
selective IL-4-driven proliferation of CAR+ T-cells in which 4αβ is co-expressed. Dual 
expression of both constructs using the same promoter was achieved by the introduction 
of a self-cleaving 2A peptide sequence between the 4αβ and C28ζ coding regions. This 
peptide was derived from the insect virus Thosea asigna and is therefore referred as a 
T2A sequence [247]. The T2A sequence permits dual polypeptide expression from the 
same mRNA molecule by inducing a ribosomal ‘skip’, in which a peptide bond between 
the two encoded polypeptides is ‘missed’ [248]. The stop codon at the 3’ end of the 4αβ 
sequence has been removed to ensure full expression. Since the T2A peptide leaves a 
short peptide overhang on the C-terminus of the upstream encoded polypeptide (in this 
case 4αβ), a furin cleavage site was introduced upstream of the T2A sequence to remove 
this sequence (Figure 2.2). Construction of C4 was achieved by means of the PIPE 
cloning method (please refer to section 2.1.2). Briefly, 40 bp C28ζ-specific primers (all 
listed in Table 2.1) were used for PCR SFG C28ζ vector linearization and generation of 
single-stranded 5′-ends by PIPE. Simultaneously, the 4αβ sequence was PCR amplified 
using a pair of 40 bp primers with 5′-C28ζ-end overlapping sequences, thereby generating 
single-stranded C28ζ-end homologous products by PIPE. In a following step, the PIPE 
products were mixed and the single-stranded overlapping sequences annealed and 
assembled as a complete SFG C4 construct. 
 
2.1.1.4 SFG C4B construct 
The SFG C4B (4αβ + C28Bζ) construct (Figure 2.1 and 2.2) is defined by the co-
expression of the C28Bζ CAR with the chimeric cytokine receptor 4αβ. The new CAR 
C28Bζ is a 3rd generation CAR comprising of a human fusion gene encoding the CD8 
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alpha chain leader sequence (AA 1 to 18), the CSF-1 peptide (AA 19 to 178), the partial 
extracellular, transmembrane and intracellular domains of CD28 (AA 179 to 285), followed 
by the CD137 (4-1BB) endodomain (AA 286 to 327) and the intracellular domain of the 
CD3 zeta (CD3ζ) chain (328 to 439 bases). Construction was achieved by means of PIPE 
cloning (please refer to section 2.1.2). In short, 40 bp C4-specific primers (Table 2.1) were 
used for PCR SFG C4 linearization at the site of fusion between the intracellular domains 
of CD28 and CD3ζ within the C28ζ construct, thereby generating single-stranded 5′-ends. 
Simultaneously, the 4-1BB sequence was PCR amplified using a pair of 40 bp primers 
with 5′-end overlapping sequences, thereby generating single-stranded C4-end 
homologous products, which were then used in a enzyme-free ligation to generate the 
SFG C4B construct.  
 
2.1.1.5 SFG CT4 construct 
The SFG CT4 (4αβ + CTr) construct (Figure 2.1 and 2.2) was designed as a matched 
truncated control of C4 and C4B. The chimeric cytokine receptor 4αβ was cloned 
upstream of the CTr construct, providing means of selective expansion of CAR-
transduced T-cells. Construction of SFG CT4 was achieved using the same PIPE cloning 
strategy used for the generation of SFG C4 (see 2.1.1.3). 
 
2.1.1.6 SFG C34B construct  
The SFG C34B (4αβ + C28ζ + 34B) construct was designed to explore the possibility of 
dual CAR-based targeting of CSF-1R (Figure 2.1 and 2.2). To test this, a fusion molecule 
termed 34B was designed. It was engineered as a fusion between the human IL-34 
signalling peptide (AA 1 to 20), human IL-34 peptide (AA 21 to 245), the extracellular and 
transmembrane domains of CD8 (AA 246 to 312) and the 4-1BB signalling endodomain 
(AA 313 to 355). Expression of all three elements was achieved with the insertion of a 
second T2A peptide and furin cleavage site, separating C28ζ from 34B. To avoid the 
introduction of a large direct repeat which would induce proviral instability, the second T2A 
DNA sequence was codon “wobbled” to be as different as possible from the first T2A 
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sequence, while maintaining the encoded protein sequence. The 34B construct, along 
with the second T2A DNA sequence, upstream of it, were designed and codon optimised 
as a cDNA cassette, which was synthesised by GenScript. Construction of SFG C34B 
was achieved using the PIPE cloning method. As described previously (see section 2.1.2 
and 2.1.1.3) 40 bp self-complementary primers (Table 2.1) were used to linearize SFG C4 
and PCR amplify the cDNA cassette. The PCR products were then mixed to assemble the 
complete SFG C34B construct. 
 
2.1.1.7 SFG 43428ζ construct 
The SFG 43428ζ (4αβ + 3428z) construct (Figure 2.1 and 2.2) is defined by the co-
expression of a new 2nd generation CAR termed 3428z with the chimeric cytokine receptor 
4αβ. The 3428ζ construct differs from C28ζ in only the targeting moiety, in which the CSF-
1 peptide has been replaced with full length human IL-34, and in the signal peptide, in 
which the IL-34 leader sequence (bases 1-60) has been used. Construction of this new 
second generation CAR was achieved by means of the PIPE cloning (please refer to 
section 2.1.2). This time the PIPE method was utilized for swapping the CSF-1 targeting 
moiety in C28ζ with IL-34. To achieve this, three primer pairs were designed (Table 2.1). 
The first two vector-specific primer pairs, flanking the existing CSF-1, were used for 
amplification of two vector fragments, subsequently treated by DpnI to destroy the 
Escherichia (E.) coli-derived PCR template. The last primer pair, with 5′-vector-fragment-
end overlapping sequences, was used for amplification of the incoming IL-34 sequence. 
The three PCR products were mixed together and transformed into chemically competent 
E. coli cells. 
 
2.1.1.8 SFG 43428Bζ construct 
The SFG 43428Bζ (4αβ + 3428Bζ) construct (Figure 2.1 and 2.2) is defined by the co-
expression of a new 3rd generation CAR termed 3428Bζ with the chimeric cytokine 
receptor 4αβ. The 3428Bζ construct differs from C4B in only the targeting moiety, in which 
the CSF-1 peptide has been replaced with full length human IL-34, and in the signal 
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peptide, in which the IL-34 leader sequence (bases 1-60) has been used. The same PIPE 
technique was employed for its construction as is described in section 2.1.1.7.  
 
2.1.1.9 SFG 434Tr construct 
The SFG 434Tr (4αβ + 34Tr) construct (Figure 2.1 and 2.2) is defined by the co-
expression of the non-signalling 34Tr construct and the chimeric cytokine receptor 4αβ. It 
is designed as a matched truncated control for SFG 43428ζ and SFG 43428Bζ. A similar 
PIPE-based cloning strategy as the one described in section 2.1.1.7, involving swapping 
of the targeting moiety CSF1 in CTr with the IL-34 peptide, was used for the construction 
of 34Tr. 
 
2.1.1.10 SFG 34CB construct 
The SFG 34CB (4αβ + 3428ζ + CB) construct is a second dual CAR directed against 
CSF-1R. In the closely related SFG C34B (described previously in section 2.1.1.6), signal 
1 and 2 (CD28) are provided upon binding of CSF-1 to the target and an additional signal 
2 (4-1BB) comes from IL-34 binding to CSF-1R. By contrast, in SFG 34CB these two 
targeting moieties have been exchanged. In the first fusion, CD28 and CD3ζ have been 
joined to IL-34. This molecule has been co-expressed with a second fusion in which CSF-
1 has been joined to the CD8 hinge and transmembrane domain followed by the 
intracellular domain of 4-1BB (Figure 2.1 and 2.2). To generate the SFG 34CB construct, 
four primer pairs were designed (Table 2.1). The first two vector-specific primer pairs, 
flanking the existing CSF-1 and IL-34 sequences, were used for amplification of 2 vector 
fragments. The second two primer pairs, with 5′-vector-fragment-end overlapping 
sequences, were used for amplification of the incoming IL-34 and CSF-1 sequences with 
swapped places. The four PCR products were used in an enzyme-free ligation to generate 











Figure 2.2 A schematic of the SFG retroviral vector containing the 4 chimeric cytokine 
receptor and the various CAR constructs used in this thesis.  
Individual coding sequences are separated using T2A peptides derived from the Thosea asigna 
insect virus, which induces a ribosomal ‘skip’ and therefore misses a peptide bond between the C-
terminal glycine and proline. Attachment of the T2A peptide sequence at the C-terminus of the 
upstream construct is prevented by the presence of a furin cleavage site, which is linked to the T2A 





2.1.2 Polymerase Incomplete Primer Extension (PIPE) Cloning 
The PIPE cloning method is a PCR-based alternative to the conventional restriction 
enzyme- and ligation-dependent cloning methods [249]. It eliminates the use of restriction 
enzymes and ligation, and thus the incorporation of restriction sites, which could encode 
extra, unwanted residues into expressed proteins [250]. The PIPE method relies on the 
inefficiency of the amplification process in the final cycles of a PCR reaction, possibly due 
to the decreasing availability of deoxynucleotide triphosphates (dNTPs), which results in 
the generation of partially single-stranded (PIPE) PCR products with overhanging 5`ends 
[251]. Using appropriate primer design these 5` overhanging ends can be used as “sticky 
ends”. To achieve this a set of vector-specific primers were used for PCR vector 
linearization and another set of primers with 5’-vector-end overlapping sequences were 
used for insert amplification, generating incomplete extension products by PIPE (Figure 
2.3). The PIPE products were subsequently treated by Dpn I (NEB) digestion according to 
the manufacturer’s instructions in order to destroy E. coli-derived vector template, thus 
reducing background contamination. The unpurified PIPE products were mixed at a 1:1 
molar ratio, followed by a 30 minute incubation at 60°C. Finally, 2μl from the mixture was 









Figure 2.3 Schematic representation of PIPE cloning. 
A set of vector-specific primers were designed for SFG linearization. In parallel, the desired insert 
was amplified with another set of 5’ SFG-end homologous primers. The PIPE products were mixed 





2.1.2.1 Materials, Reagents and Equipment 
 Primers (please refer to Table 2.1) 
 Template 
 Nuclease-free water 
 Phusion High-Fidelity DNA Mastermix (Thermo Scientific, UK) 
 Eppendorf Mastercycler Gradient PCR Machine 
 
2.1.2.2 Protocol 












2.1.3  Restriction Enzyme Digestion 
DNA digestion and restriction patterns were used to accurately verify successful cloning 
and presence of inserts.  
 
2.1.3.1 Materials, Reagents and Equipment 
 Restriction enzymes (NEB, UK) 
 10x Restriction enzyme buffers (NEB, UK) 
 100x Bovine Serum Albumin (BSA) (NEB, UK) 
Nuclease-free water XL 
2x Phusion PCR MasterMix 25L 
Forward primer 2.5L (10M) 
Reverse primer 2.5L (10M) 
Template DNA XL (10ng) 








 Denaturation 98oC 10 sec 
Annealing 60oC 30 sec 
Extension 72oC 15-30 sec/kb 
Store 4oC hold  
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 Nuclease-free water 
 DNA template 
 Eppendorf Mastercycler Gradient PCR machine 
 Ice 
 
2.1.3.2  Protocol 
1. A 20μL reaction mixture was produced for a double digest. All components were 
kept on ice while the reaction was set up. 
XμL (1μg) DNA 
XμL Nuclease free water 
2μL 10x NEB Buffer 
0.5μL Enzyme 1 (1U) 
0.5μL Enzyme 2 (1U) 
1μL 1 in 10 diluted BSA 
2. Reaction mixtures were incubated for one hour in a PCR machine at 37oC. 
3. To each reaction mixture was added 4μL of 6x DNA loading buffer.  






















































































































2.1.4 Separation of DNA Fragments by Agarose Gel Electrophoresis 
Agarose gel electrophoresis was used for separation of DNA fragments by size. Migration 
rates are dependent on the pore size of the gel, which is determined by the agarose 
concentration. Optimal resolution of the fragments of interest was achieved by using 1% 
agarose, which ensures 0.25 – 12kb range of separation. 
 
2.1.4.1  Materials, Reagents and Equipment 
 Electrophoresis grade Agarose (MP Biomedicals, UK) 
 10x TBE buffer (please see below) 
 6x DNA loading buffer (please see below) 
 Ethidium Bromide (Sigma-Aldrich, UK) 
 1 kb DNA ladder (NEB, UK) 
 Gel Mould (Biorad, UK) 
 Gel Comb (Biorad, UK) 
 Gel Tank (Biorad, UK) 
 Microwave 
 UV Transilluminator (UVI Tech, UK) 
 
Buffers and solutions: 
10x TBE: 108g Tris-base, 55g boric acid, 9.3g EDTA in 1L deionised water 
6x DNA Loading Buffer: Distilled water, 40% (w/v) sucrose, 0.25% (w/v) bromophenol 
blue, 0.25% (w/v) xylene cyanol 
 
2.1.4.2  Protocol 
1. One gramme of agarose was mixed with 100mL 1xTBE and heated in a microwave 
until completely dissolved. 
2. After cooling under cold running water, 0.30μg/mL ethidium bromide was added 
and the mixture swirled vigorously to ensure even distribution. 
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3. The gel was poured into a pre-cast mould, a comb inserted and the mixture was left 
to set at room temperature. 
4. Prior to loading, samples were mixed 5:1 with 6x DNA loading buffer. In addition to 
the samples, a 1kb DNA ladder was loaded to allow the size of migrating DNA 
fragments to be estimated. 
5. The gel was run at 5-8 V/cm until sufficient migration (as visualised by the loading 
dye) had occurred. 
6. The DNA was visualised with UV light at 254 nm using a UV transilluminator. 
 
2.1.5  Transformation of Escherichia coli TOP10F’ Strain 
Replenishment of plasmid stocks and selection of newly produced vectors was achieved 
by introducing the plasmid into chemically competent E. coli. All steps followed common 
microbiological practice, using a Bunsen burner to provide sterile conditions. 
 
2.1.5.1  Materials, Reagents and Equipment 
 TOP10F’ E. coli (Invitrogen, UK) 
 Plasmid DNA 
 Agar plates 
 Super Optimal broth with Catabolite repression (SOC) (Sigma-Aldrich, UK) 
 Water bath set at 42oC  
 Ice 
 Oven set at 37oC  
 Bunsen burner 
 Excella E-25 incubator shaker 
 Glass spreaders 





Buffers and solutions: 
SOC Media = 20g bacto tryptone, 5g bacto yeast extract, 10mM Sodium Chloride (NaCl), 
2.5mM Potassium Chloride (KCl), 10mM Magnesium Chloride (MgCl2), 10mM Magnesium 
Sulphate (MgSO4), 20mM Glucose. 
 
2.1.5.2  Protocol 
1. One vial of TOP10F’ E. coli was thawed on ice. 
2. 1μg Plasmid DNA was added to the E. coli and incubated for 30 minutes on ice. 
3. Bacteria were heat shocked at 42°C for 90 seconds and subsequently incubated 
on ice for 5 minutes. 
4. Following addition of 300μL SOC media, samples were shaken at 220rpm for one 
hour at 37°C.  
5. Simultaneously, agar plates containing ampicillin were dried in an oven at 37°C.  
6. The E. coli were spread onto the pre-dried plate and incubated at 37°C overnight. 
 
2.1.6  Production of Agar Plates 
2.1.6.1  Materials, Reagents and Equipment 
 LB agar (Novagen, UK) 
 Ampicillin (Sigma-Aldrich, UK) 
 Microwave oven 
 Non-tissue culture treated 10cm Petri-dishes (Fisher Scientific, UK) 
 Bunsen burner 
 
Buffers and solutions: 




2.1.6.2  Protocol 
1. 500mL agar was melted in a microwave oven for 20min at 40% maximum power to 
obtain a molten solution. 
2. After cooling down, a selective antibiotic (100mg ampicillin) was added and mixed 
thoroughly. 
3. The solution was distributed evenly over 20 Petri dishes and left to solidify at room 
temperature. 
4. Petri dishes were stored at 4°C. 
 
2.1.7  Selection of Bacterial Clones 
2.1.7.1  Materials, Reagents and Equipment 
 Luria-broth (L-broth) 
 Ampicillin (Sigma Aldrich, UK)) 
 50mL Conical Centrifuge Tubes (Fisher Scientific, UK) 
 20μL pipette tips 
 Excella E-25 incubator shaker 
 
Buffers and solutions: 
L-broth: 10g tryptone, 5g yeast extract, 0.5g NaCl 
 
2.1.7.2  Protocol 
1. 5mL of L-broth, containing 100μg of Ampicillin was aliquotted into 50mL Falcon 
tubes. 
2. Single bacterial colonies were picked using a pipette tip and submerged in the L-
broth. 
3. The tubes were shaken at 220rpm for 16 hours at 37°C prior to being centrifuged 
at 3000g for 10 minutes to pellet the bacteria. The supernatant was discarded and 




2.1.8  Storage of Bacterial Clones 
2.1.8.1  Materials, Reagents and Equipment 
 100% glycerol (Sigma-Aldrich, UK) 
 850μL bacterial culture 
 cryo-vials 
 
2.1.8.2  Protocol 
1. 150μl sterile 100% glycerol and 850μl of the bacterial culture (frozen stock is 15% 
glycerol) were added to a sterile, labelled cryo-vial and mixed well. 
2. Frozen stock of bacterial clones was stored at -80°C. 
 
2.1.9  Isolation of Plasmid DNA from E. coli – MiniPrep 
Plasmid DNA was extracted from the bacterial cultures using a QIAprep Spin Miniprep kit. 
The procedure is based on Birnboim and Doly’s rapid alkaline lysis protocol [252], in 
which bacterial lysis is achieved using sodium dodecyl sulphate (SDS) in the presence of 
200mM sodium hydroxide (NaOH). The strong alkaline environment resulted in 
denaturation of proteins and chromosomal DNA and ensured their co-precipitation with 
SDS upon neutralization of the solution and conversion to high salt environment by the 
addition of potassium acetate. The supercoiled conformation of the plasmid DNA 
prevented separation of the DNA strands, thereby ensuring that it remained in solution. 
Contaminating RNA was eliminated by both the addition of RNAse A to the initial re-
suspension buffer and precipitation in the high salt environment of the neutralization 
buffer. Any remaining impurities were removed by running the aqueous phase through a 
column containing a silica membrane. The neutralization buffer contained the chaotropic 
salt, guanidine hydrochloride, which induced dehydration of the plasmid DNA, allowing it 
to bind strongly to the silica membrane, whilst other contaminating factors were removed 
in the flow-through. Following two further wash steps with chaotropic salt and ethanol 
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containing buffers, the purified plasmid DNA was eluted from the column using a low salt 
buffer. 
 
2.1.9.1 Materials, Reagents and Equipment 
 QIAprep spin Miniprep kit (Qiagen, UK) 
 Pelleted TOP10F’ E. coli 
 1.5mL Eppendorf tubes 
 Eppendorf 5415R refrigerated Micro-centrifuge 
 
Buffers and solutions: 
Buffer P1 = 50mM Tris-HCl (pH 8), 10mM EDTA, added 100μg/mL RNAse A 
Buffer P2 = 200mM NaOH, 1% (w/v) SDS 
Buffer EB = 10mM Tris-HCl (pH 8.5) 
 
NOTE: Qiagen does not publish the full composition of the neutralizing N3 buffer, buffer 
PB or buffer PE. Buffer N3 is known to contain guanidine hydrochloride (as the source of 
chaotropic salt) and acetic acid (probably in the form of potassium acetate) to neutralize 
the alkaline environment caused by the NaOH in buffer P2. Buffer PB also contains 
guanidine hydrochloride, along with isopropanol. No details regarding the composition of 
buffer PE have been released. 
 
2.1.9.2  Protocol 
1. Pelleted bacteria were re-suspended in 250μL buffer P1. 
2. An equal volume of buffer P2 was added and the sample was gently inverted 
approximately 10 times to ensure complete mixing. 
3. 350μL buffer N3 was added to each sample and complete mixing was achieved 
through gentle inversion. 
4. Centrifugation at 15,700g pelleted the white precipitate in each sample. 
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5. The aqueous phase was carefully transferred to a QIAprep spin column and the 
white precipitate discarded. 
6. Following centrifugation at 15,700g, each column was washed with 500μL buffer 
PB and centrifuged at 15,700g, before discarding the eluate. 
7. Each column was washed with 750μL buffer PE and centrifuged at 15,700g and 
the eluate was again discarded. 
8. After an additional centrifugation at 15,700g to remove any residual ethanol, the 
DNA was eluted in 50μL buffer EB through centrifugation at 15,700g. 
9. The concentration of the isolated DNA was determined and stored at -20°C. 
 
2.1.10 Isolation of Plasmid DNA – Maxi-Prep 
Maxi-preps were used for the isolation of highly concentrated plasmid DNA. As with mini-
preps, the process relies on bacterial lysis under strong alkaline conditions, with proteins 
and chromosomal DNA removed by precipitation upon neutralisation and conversion to a 
high salt environment. RNA impurities were removed through the addition of RNase A in 
the initial re-suspension buffer. Once insoluble contaminants had been removed via 
centrifugation, the supernatant (containing the plasmid DNA) was subjected to anion-
exchange chromatography. The negatively charged plasmid DNA binds strongly to the 
positively charged diethylaminoethyl (DEAE) resin beads, until eluted using a high-salt 
containing buffer. Intermediate washes with buffers of increasing salt concentrations 
ensured the removal of remaining contaminants. Once eluted, the DNA was precipitated 
and desalted using a series of alcohol washes before being dissolved in TE buffer. 
 
2.1.10.1  Materials, Reagents and Equipment 
 100mL TOP10F’ bacteria containing wanted plasmid  
 QIAGEN Plasmid Maxi Kit 
 1.5mL Eppendorf tubes 
 Oak Ridge polycarbonate centrifuge tubes 
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 Oak Ridge polypropylene copolymer centrifuge tubes 
 Sorvall RC 5B Centrifuge 
 70% Ethanol 
 Isopropanol  
 
Buffers and Solutions 
Buffer P1 = 50mM Tris.HCl (pH 8.0), 10mM EDTA, 100g/mL RNase A 
Buffer P2 = 200mM NaOH, 1% (w/v) SDS 
Buffer P3 = 3M Potassium Acetate  
Buffer QBT = 750mM NaCl, 50mM 3-(N-Morpholino)-propanesulfonic acid (MOPS), 15% 
(v/v) isopropanol, 0.15% (v/v) Triton X-100 
Buffer QC = 1M NaCl, 50mM MOPS, 15% (v/v) isopropanol 
Buffer QF = 1.25M NaCl, 50mM Tris.HCl (pH 8.5), 15% (v/v) isopropanol 
TE Buffer = 10mM Tris.HCl (pH 8), 1mM EDTA. 
 
2.1.10.2  Protocol 
1. Once pelleted, the bacteria were re-suspended in 10 mL buffer P1 and bacterial 
lysis was induced by addition of an equal volume of buffer P2. Mixing ensured 
complete lysis.  
2. Pre-chilled buffer P3 (10 mL) was added after a maximum of five minutes lysis and 
the solution was well mixed to ensure complete neutralisation.  
3. The solution was incubated on ice for approximately 15 minutes before being 
centrifuged at 20,200 g for 30 minutes at 4C. 
4. The supernatant was decanted into a fresh polycarbonate centrifuge tube and 
centrifuged at 20,200 g for 15 minutes at 4 C to ensure complete removal of all 
insoluble contaminants.  
5. The resulting supernatant was added to a pre-equilibrated QIAGEN-tip 500 and 
left to filter by gravity flow.  
95 
 
6. The tip was washed twice using 30 mL buffer QC before the plasmid DNA was 
eluted into a polypropylene copolymer centrifuge tube using 15 mL buffer QF. 
7. The DNA was precipitated by adding 10.5 mL isopropanol and pelleted by 
centrifugation for 30 minutes at 17,700 g and 4C. 
8. The pellet was washed with 5 mL 70% ethanol to remove the salt and the DNA 
pelleted by centrifugation at 20,000 g for 10 minutes.  
9. After removal of the supernatant and air-drying of the DNA pellet at 37C for 
approximately five minutes, the DNA was re-suspended in 200 L of TE buffer. 
10. Once the concentration of DNA had been calculated it was stored at -20C until 
required. 
 
2.1.11  Sequencing 
All the new constructs were sent for sequencing (SourceBioscience, UK) to confirm 
successful cloning. The results were analyzed with 4Peaks software and sequence 
alignment was performed on SerialCloner 2.5 software.   
 
2.2 Cell Culture Techniques 
2.2.1  Common Medias and Solutions 
D10 Media: 500mL Dulbecco’s Modified Eagle Medium (DMEM) (Lonza, UK) 
  50mL Foetal Calf Serum (Sigma-Aldrich, UK) 
  200mM GlutaMAX (Gibco, UK) 
  50,000U Penicillin (Gibco, UK) 
  50mg Streptomycin (Gibco, UK) 
 
RBS Media: 500mL Roswell Park Memorial Institute (RPMI) Medium (Lonza, UK) 
  50mL Foetal Calf Serum  
  200mM GlutaMAX  
  50,000U Penicillin  
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  50mg Streptomycin  
 
R10 Media: 500mL Roswell Park Memorial Institute (RPMI) Medium  
  50mL Human Male AB Serum (Gibco, UK) 
  200mM GlutaMAX  
  50,000U Penicillin  
  50mg Streptomycin  
 
CPDA:  Citrate Phosphate Dextrose Adenine Solution (Gibco, UK) 
  Anticoagulant solution used in 1:9 ratio with whole blood. 
 
Trypsin: 0.25% Trypsin-EDTA (Gibco, UK) 
 
CDB:  Cell Dissociation Buffer (Invitrogen Life Tech, UK) 
Isotonic, and enzyme-free solution of salts, chelating agents, and cell-
conditioning agents in Ca2+ and Mg2+-free phosphate-buffered saline 
 
1x PBS:  Phosphate Buffer Saline (Biochrom AG, UK) 
  9.55g/L PBS in deionised water 
 
2.2.2  Cell Lines 
All cells were incubated at 37C, 95%O2/5% CO2, unless otherwise stated.  
 
2.2.2.1  Materials, Reagents and Equipment 
 R10 media 
 D10 media 
 Interleukin-2 (IL-2) (Novartis, UK) 
 Interleukin-4 (IL-4) (Gentaur, UK) 
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 Tetracycline (Calbiochem, UK) 
 Puromycin (Merck, UK) 
 6-well tissue culture-treated plates (Greiner Bio-one, UK) 
 Tissue-culture treated Petri dishes (Greiner Bio-one, UK) 
 
2.2.2.2  Tumour Cell Lines 
To confirm the ability of CAR+ T-cells to target CSF-1R, 8 different cell lines (listed below) 
were used. All lymphoma cell lines (a generous gift from Dr Stephan Mathas, Max-
Delbrück-Center for Molecular Medicine, Berlin, Germany) were grown in RBS media in 
flasks while the breast cancer cell lines were propagated in D10 in serial dilutions and 
monolayers were passaged when appropriate. 
 
KM-H2: human Hodgkin's lymphoma cell line, established from the pleural effusion of a 
37-year old man with Hodgkin's disease (mixed cellularity type) in 1974, characterized by 
IgG4 rearrangement [253].  
 
K299: human CD30+ Anaplastic large cell lymphoma (ALCL) cell line, positive for 
t(2;5)(p23;q35), established from the peripheral blood of a 25-year-old man [254].  
 
K299 FMS: has been developed during this PhD by transducing K299 with SFG retroviral 
vector (please refer to section 2.2.3.1) containing the c-fms gene. Consequently, K299 
FMS expresses high levels of CSF-1R (Figure 5.8, A).  
 
DEL: human CD30+ ALCL cell line, negative for t(2;5)(p23;q35), established from the 
pleural effusion of a 12-year-old boy with malignant histiocytosis in 1987 [255]. 
 
FE-PD: human CD30+ ALCL cell line, negative for t(2;5)(p23;q35), established from the 





JB6: human CD30+ ALCL cell line, positive for t(2;5)(p23;q35), established from the 
peripheral blood of a 12-year-old boy [257].  
 
L540: human Hodgkin's lymphoma cell line, established from the bone marrow of a 20-
year-old woman with Hodgkin's disease (nodular sclerosis type), characterised by 
rearranged TCR gene [258]. 
 
T47D: established from a pleural effusion in a woman with breast cancer. It is both 
oestrogen and progesterone receptor positive [259].  
 
T47D FMS: has been developed in the lab prior to the start of this PhD by transducing 
T47D with SFG retroviral vector (please refer to section 2.2.3.1) containing the c-fms 
gene. Consequently, T47D FMS expresses high levels of CSF-1R making it an ideal 
positive control for CAR functionality assessment.  
 
Note: The six lymphoma cell lines (KM-H2, K299, DEL, FE-PD, JB6 and L540) have been 
transduced with an SFG retroviral vector (please refer to section 2.2.3.1) encoding for 
genes for firefly luciferase (ffLuc) and tdTomato, allowing for ease of tracking in co-
cultivation experiments as well as for in vivo imaging by bioluminescence.   
 
2.2.2.3  Retroviral Packaging Cell Lines 
Packaging cell lines are designed to synthesize and provide all retroviral proteins required 
for assembly of high-titre infectious virus, but should not produce any replication-
competent virus. To ensure no virion replication post infection, replication-defective 
vectors are used, in which the coding regions for the 4 genes gag, pro, pol and env, which 
are crucial for the completion of the retroviral life cycle, are deleted and replaced with the 
DNA sequence intended for transfer. Instead, those genes are expressed in trans, within 
the packaging cell line, which thereby provides all of the required proteins for viral 
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assembly. The retroviral genomic sequence (containing the desired gene) is subsequently 
packaged into viruses, which are capable of infecting their target cells and delivering the 
DNA of interest, but then fail to continue the typical lytic pathway that leads to cell lysis 
and death. 
 
The genome of every retrovirus consists of two RNA copies. These encode for the four 
specific genes mentioned above (gag, pro, pol and env) [260], which are crucial for the 
completion of the retroviral life cycle. The gag sequence encodes for the three main 
structural proteins: matrix (MA), capsid (CA) and nucleocapsid (NC) proteins. The pro 
sequence, encodes for proteases (PR) responsible for cleaving Gag and Gag-Pro-Pol 
during particles assembly, budding and maturation. The pol sequence encodes for the 
enzymes reverse transcriptase (RT) and integrase (IN), the former catalyzing the reverse 
transcription of the viral genome from RNA to DNA during the infection process and the 
latter responsible for integrating the proviral DNA into the host cell genome. The env 
sequence encodes for both surface (SU) and transmembrane (TM) subunits of the 
envelope glycoprotein. This is initially synthesized as a single polypeptide which 
undergoes cleavage by a cell-encoded protease to yield both subunits. All of the structural 
proteins of the virion are derived from three polyproteins: Gag, Gag-Pro-Pol, and Env 
(Figure 2.4). All viral proteins (MA, CA, NC, PR, RT and IN) are initially linked within the 
Gag and Gag-Pro-Pol proteins. The Gag protein is capable of directing budding at the 
plasma membrane, and the Pro-Pol polyproteins are incorporated into the resulting 
particle because they are linked to Gag. Subsequently, after budding the Gag and Gag-









Figure 2.4 Retroviral life cycle. 
Upon target cell infection, (step 1), the viral particle envelope and capsid are disassembled, 
releasing the viral genome and proteins into cytoplasm. The viral reverse transcriptase (RT) binds 
to a transfer RNA (tRNA) binding site in the 5’ LTR and synthesizes a complementary DNA strand 
(step 2). The template viral RNA is then degraded by the RNase H subunit of the reverse 
transcriptase allowing for synthesis of a second DNA strand (step 3). The resulting double stranded 
DNA (dsDNA) is integrated as a provirus into the host genome by the viral integrase (IN) (step 4). 
The host RNA polymerase transcribes the viral RNA (step 5), which is then exported from the 
nucleus and transcribed to give the gag, pro, pol and env proteins. These proteins, along with two 
copies of the untranslated viral RNA are packaged into a new viral particle (step 6), which 
subsequently buds from the target cell. MA – matrix proteins, CA – capsid proteins, NC - 
nucleocapsid proteins, PR – protease, RT – reverse transcriptase, IN – integrase, SU – surface 




To minimise the risk of producing replication-competent virus the gag-pro-pol and env 
genes are expressed on separate plasmids within the retroviral packaging cell line. The 
pro and pol genes are always expressed on the same plasmid as gag due to the fact that 
they are transcribed as a single gag-pro-pol mRNA transcript. Therefore three separate 
recombination events would need to occur before all genes are expressed in cis. To 
further decrease the risk of restoring replicative competence, heterologous promoters like 
CMV’s have been used [261, 262]. Thereby gag-pro-pol genes are expressed from a 
single construct driven by a heterologous promoter. The retroviral vector contains a 
cassette for transgene expression typically driven by the 5’LTR promoter [263] while the 
envelope expression is supplied by a third independent construct usually driven by a 
heterologous promoter.  
 
Three different types of retroviral packaging cell lines were used throughout this PhD, 
depending on the target cell species and the necessary viral tropism.  
 
H29D: The H29D retroviral packaging cell line (293GPG in reference [264]) is based on 
the human embryonic kidney adenoviral 5-transformed cell line (HEK 293, [265]) This 
packaging cell line expresses the MoMLV gag-pol genes under the control of the 
cytomegalovirus (CMV) immediately early (IE) promotor. Expression of the vesicular 
stomatitis virus-G (VSV-G) env proteins results in the production of viral particle displaying 
a broad tropism. Since constitutive expression of the VSV-G envelope protein is toxic, 
controlled expression was achieved by placing the VSV-G coding sequence under the 
control of a tetracycline-repressed promoter. Initiation of transcription from this promoter is 
dependent upon the binding of a tetracycline-transactivator (tTa) molecule. However, in 
the presence of tetracycline this binding is inhibited. Therefore, to prevent constitutive 
expression of the VSV-G env protein, H29D cells were maintained in D10 media 
supplemented with 2μg/mL tetracycline. Fresh media and tetracycline were provided 
every three days and the cells were passaged when confluent. Tetracycline was removed 
from the media for the production of VSV-pseudotyped virus and the toxicity of this 
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envelope protein meant that fresh H29D transductions were required for each preparation 
of fresh virus.     
 
PG13: retroviral packaging cell line based on mouse embryonic fibroblast cell line, NIH 
3T3, that has been transfected to express Moloney Murine Leukaemia Virus (MoMLV) 
gag-pol protein and Gibbon Ape Leukaemia Virus (GaLV) env protein (European 
Collection of Cell Cultures) [266]. PG13 viral particles are capable of infecting human cells 
and are used to produce stably expressing PG13 clones as the GaLV is not toxic to the 
cells. The PG13 packaging cells were grown in D10 media in serially diluted cultures and 
were passaged when confluent.  
 
293Vec RD114: retroviral packaging cell line based on the HEK 293 cell line, that has 
been transfected to express MoMLV gag-pol protein and feline leukaemia virus (RD114) 
env protein (BioVec Pharma) [267]. 293Vec RD114 produced retroviral vectors are 
pseudotyped by RD114 virus envelope protein and are capable of infecting human cells 
with titres of up to 0.5 x 107 infectious units per ml. Stable 293Vec RD114 clones were 
produced and grown in D10 media in serially diluted cultures and were passaged when 
confluent. 
 
2.2.3  Retroviral Vectors 
Efficient gene transduction depends on the inclusion in the retroviral vector of a number of 
cis-acting viral elements such as (1) a promoter and polyadenylation signal; (2) a viral 
packaging signal (ψ) required for packaging of the mRNA transcript into new viral 
particles; (3) signals required for reverse transcription, including a transfer RNA-binding 
site (PBS) and polypurine tract (PPT) for initiation of first- and second-strand DNA 
synthesis, and a repeated (R) region at both ends of the viral RNA required for transfer of 
DNA synthesis between templates; and (4) short, partially inverted repeats located at the 




All the CAR constructs in this thesis have been cloned in the SFG retroviral vector.  
 
2.2.3.1 SFG 
The SFG retroviral vector is based on the MFG vector [268], in which gene expression is 
driven by the MoMLV LTRs and the presence of the MoMLV  packaging signal ensures 
efficient packaging of the RNA into the virus. The presence of the splice donor and splice 
acceptor sites allow the production of the sub-genomic RNA transcripts usually required 
for the translation of the env gene [269]. The gene of interest is inserted at a naturally 
occurring NcoI restriction site, ensuring that its start codon is in the precise place 
previously occupied by the deleted env gene. This vector does not contain a eukaryotic 






Figure 2.5 Critical cis-acting elements in retroviral vectors and vector replication cycle.  
Critical cis-acting elements in retroviral vectors are indicated in the figure. After one round of viral 
replication, the U3 regions in both LTRs are derived from the original 3′LTR U3 region and both U5 
regions are derived from the U5 region originally present in the 5′LTR in the plasmid. Usually, R 
sequences arise from the 5′plasmid LTR, but they may also include 3′plasmid LTR sequences. 
(U3) Unique 3′LTR RNA; (U5) unique 5′LTR RNA; (R) repeat at both ends of the viral RNA; 
(poly[A]) polyadenylation; (LTR) long terminal repeat. Image is adapted from Figure 1, 




2.2.4  Production of Retroviral Packaging Cell Lines 
2.2.4.1 Materials, Reagents and Equipment 
 H29D cells  
 D10 medium 
 Plasmid DNA 
 Polyethylenimine (PEI) (Sigma, UK)  
 Vortex  
 PG13 cells 
 H29D retroviral supernatant 
 Plasmid of interest 
 Serum free media (DMEM without supplements) 
  
2.2.4.2  Transfection of H29D Cells 
1. Tetracycline was removed from the H29D cells a minimum of two hours prior to 
transfection by replacing the tetracycline-containing D10 with fresh D10 only. 
2. Total plasmid DNA was diluted in a sterile tube in serum-free DMEM (volume of 
media was 10% of final volume in culture vessel). 
3. PEI (1μg/μL) was added to the diluted DNA and mixed immediately by vortexing or 
pipetting. The volume of PEI used was based on a 3:1 ratio of PEI(μg):total 
DNA(μg). 
a. 6 well dish: 9μl of PEI (1μg/μl) = 9μg PEI + 3μg DNA 
b. 10cm dish: 21μl of PEI (1μg/μl) = 21μg PEI + 7μg DNA 
c. 15cm dish: 33μl of PEI (1μg/μl) = 33ug PEI + 11ug DNA 
4. The mixture was incubated at room temperature for 20 minutes, before being 
added drop-wise to the H29D cells. 
5. After gentle rocking ensuring complete mixing of the transfection mixture, the cells 
were incubated for 3 hours at 37oC. 
6. After 3 hours, the media was replaced with fresh D10. 
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7. Supernatants were harvested daily from day 3-7 and either directly used to infect 
target cells or snap frozen in an ethanol bath. Removed supernatants were 
replaced daily with fresh D10 media.  
 
2.2.4.3  PG13 and 293Vec RD114 Infection 
1. The media was removed from empty PG13 or 293Vec RD114 cells and replaced 
with 3mL H29D supernatant containing the VSV-pseudotyped virions. 
2. The packaging cells were subsequently incubated for 72 hours before they were 
analysed for transgene expression using flow cytometry. 
3. PG13 or 293Vec RD114 populations in which >80% of cells were expressing the 
virus of interest were used as stable packaging cell lines. 
 
2.2.5  Human Peripheral Blood Mononuclear Cell Isolation and Activation 
Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors by 
density gradient centrifugation using Ficoll Paque Plus (GE Healthcare, UK). Recruitment 
of healthy volunteer donors for this purpose was approved by the Guy’s Hospital 
Research Ethics Committee (09/H0804/92; Use of Donor Blood Samples for Pre-Clinical 
Development of Active and Passive Immunotherapy for Cancer and 09/H0707/086; 
Generation of clinical grade T-cells for adoptive cell therapy).  
 
2.2.5.1  Materials, Reagents and Equipment 
 Fresh blood 
 Citrate-Dextrose solution (ACD) 
 50mL Syringe (BD Bioscience, UK) 
 Butterfly needle 
 50mL Falcon tubes (Fisher Scientific, UK) 
 Ficoll-Paque Plus (GE Healthcare, UK) 
 Pasteur Pipettes (SLS, UK) 
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 Anti-CD3/Anti-CD28 Dynabeads (Invitrogen, UK) 
 R10 media 
 PBS 
 Eppendorf centrifuge 
 
2.2.5.2  Protocol 
 15mL Ficoll-Paque was aliquotted into two separate 50mL Falcon tubes. 
 Fresh Blood (25-50mL) (anticoagulated with 1x citrate-dextrose solution) was 
slowly layered onto the Ficoll-Paque and was centrifuged at 400g for 30 minutes 
(acc = 0, dec = 0). 
 The PBMC layer, present at the interface between the Ficoll-Paque and the 
plasma, was transferred into fresh 50mL Falcon tubes using a Pasteur pipette and 
diluted to a final volume of 50mL in pre-warmed PBS and centrifuged for 10 
minutes at 300g. 
 The cell pellet was re-suspended in 50mL pre-warmed PBS and centrifuged for 10 
minutes at 300g. 
 Following aspiration of the supernatant, the cell pellet was re-suspended in 10mL 
R10 media and cells were counted. 
 Cells were re-suspended in R10 media at a concentration of 3 x 106 cells/mL and 
activated with anti-CD3/anti-CD28 paramagnetic Dynabeads at a 1:3 cell:bead 
ratio. 
 
2.2.6  Production of RetroNectin Plates 
In order to improve T-cell transduction rates, the plates used were pre-treated with 
RetroNectin. RetroNectin is a fragment of the extracellular matrix protein fibronectin that 
binds the target T-cell through a CS-1 domain and a cell-binding domain (CBD), which 
interacts with the VLA-4 and VLA-5 integrin receptors respectively. Attachment of the virus 
to the heparin-binding domain present in RetroNectin between the CS-1 and CBD causes 
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co-localisation of the target cell and the virus, thus greatly improving gene transfer 
efficiency [271, 272]. 
 
2.2.6.1  Materials, Reagents and Equipment 
 RetroNectin (TaKaRa, UK) 
 Non-tissue culture treated 6-well plates (VWR, UK) 
 PBS 
 Pasteur pipettes 
 
2.2.6.2  Protocol 
1. 200μg of RetroNectin was re-suspended in 12mL PBS/plate 
2. 2mL of the resulting solution was transferred using a Pasteur pipette into each well 
of a non-tissue culture treated 6-well plate, thereby giving coverage of 
approximately 3.5μg/cm2 
3. Plates were incubated for a minimum of 2 hours at room temperature or 24 hours 
at 4°C prior to use. 
4. When the plate was to be used, unbound RetroNectin was transferred to a new 
plate using a Pasteur pipette. RetroNectin was used for a maximum of two 
transductions. 
 
2.2.7  Retroviral Transduction of Human T-cells 
To introduce the CAR constructs into T-cells, they were subjected to retroviral-mediated 
transduction. This ensured integration of the inserted coding DNA into the host T-cell 
genome, thereby permitting stable CAR expression. 
 
2.2.7.1  Materials, Reagents and Equipment 
 Activated T-cells 
 PG13 or 293Vec RD114 cells 
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 RetroNectin-coated plate 
 Pasteur pipettes 
 Trypan blue (Gibco, UK) 
 Centrifuge 
 
2.2.7.2  Protocol 
1. After the unbound RetroNectin had been transferred to a fresh plate using a 
Pasteur pipette, each well was coated with 3mL of retrovirus-containing 
supernatant from the desired packaging cell line. 
2. Activated T-cells were counted using trypan-blue exclusion and 1 x 106 viable cells 
added to each well. 
3. Each well was supplemented with 100U/mL of IL-2. 
4. Plates were centrifuged for one hour at 50g. 
5. Cells were subsequently incubated for 96 hours, after which the transduction rate 
was determined using flow cytometry. 
 
2.2.8  Assessment of CAR+ T-cell Anti-Tumour Efficacy 
In order to demonstrate the ability of CAR+ T-cells to recognise and destroy CSF-1R-
expressing targets, they were co-cultured with a variety of human tumour cell lines. Target 
recognition was monitored by measuring cytokine release, whilst anti-tumour activity was 
quantitated either using an MTT (3-[4,5-dimethylthiazol-2-yl]-2,5- diphenyltetrazolium 
bromide; thiazolyl blue) assay (please refer to section 2.2.9.1), a luciferase assay (please 
refer to section 2.2.9.3) or by CFSE (carboxyfluorescein succinimidyl ester) staining of 
lymphoma cell lines (please refer to section 2.2.9.2).  
 
2.2.8.1  Materials, Reagents and Equipment 
 Transduced T-cells 
 Tumour cells 
109 
 
 R10 media 
 rhIL-4 
 rhIL-2 
 24-well cell culture plate (Fisher Scientific, UK) 
 
2.2.8.2  Protocol 
1. Tumour cells were seeded into a 24-well cell culture plate and were either allowed 
to reach confluence (T47D / T47D FMS) or 1 x 106 cells (lymphoma cell lines) 
were seeded per well. 
2. T-cells were counted using trypan-blue exclusion and re-suspended in R10 media 
at a concentration of 1 x 106 cells/mL and gently pipetted onto the surface of the 
confluent tumour monolayer. 
3. After 24 and/or 48h hours of incubation, 500μL supernatant was removed for 
analysis of cytokine (IL-2 and interferon (IFN)-γ) secretion. 
4. Depending upon the experiment, the T-cells were either:  
a. supplied with fresh R10 until the desired monolayer destruction was 
achieved. Alternatively, lymphoma cells were regularly monitored for target 
cell destruction by flow cytometry  (lymphoma cell lines were CFSE labelled 
in advance) or luminescence assay (lymphoma cell lines were transduced 
to express firefly luciferase), 
b. removed, counted and re-stimulated on a fresh tumour monolayer, 
c. removed, counted and probed for enrichment of the CAR using flow 
cytometry. 
 
2.2.9  Quantification of Tumour-Cell Lysis 
2.2.9.1  MTT Assay 
Anti-tumour activity of CAR+ T-cells against adherent cancer cell lines (T47D / T47D FMS) 
was quantified using an MTT assay. MTT is a water soluble tetrazolium salt yielding a 
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yellowing solution when prepared in media. Mitochondrial dehydrogenases of viable cells 
cleave the tetrazolium ring in dissolved MTT, yielding purple formazan crystals, which are 
insoluble in aqueous solutions. The crystals are dissolved in acidified isopropanol. The 
resulting purple solution is spectrophotometrically measured at a wavelength of 570nm. 
Since dead cells do not cause this change, the number of viable cells determines the 
amount of formazan formed, indicating the degree of cytotoxicity caused [273].  
 
2.2.9.1.1  Materials, reagents and equipment 
 MTT (Sigma-Aldrich, UK) 
 PBS 
 DMSO (VWR, UK) 
 FLUOstar Omega (BMT Labtech, UK) 
 Omega Software (version 1.20) (BMT Labtech, UK) 
 
2.2.9.1.2  Protocol 
1. MTT was reconstituted in PBS at a concentration of 5mg/mL. 
2. Medium was aspirated from the co-culture and wells were washed with 500μL 
PBS. 
3. MTT stock solution was diluted 1/10 (to a concentration of 500μg/mL) in D10 
media and 500μL (250μg) was added to each well. 
4. Cell cultures were incubated for 2-4 hours at 37°C and 5% CO2. 
5. The supernatant was aspirated and the formed formazan crystals were dissolved 
in 300μL DMSO. 
6. Absorbance was measured spectrophotometrically at 570nm. 
7. Relative cell viability was calculated using the following equation: 
 




8. The data was presented either as percentage viable cells or percentage lysis. This 
was calculated using the following equations:  
Percentage viable cells = viability*100 
Percentage lysis = 100 – percentage viable cells 
 
2.2.9.2  CFSE Labelling of Lymphoma Cell Lines 
Quantification of lymphoma cell destruction by CAR-transduced T-cells was achieved by 
CFSE labelling the lymphoma cell lines prior to co-culture with the effector cells. CFSE 
crosses intact cell membranes and was used for target cell tracking. Once inside the cells, 
intracellular esterases cleave the acetate groups to yield the fluorescent 
carboxyfluorescein molecule. The dye is then cross-linked to intracellular proteins. Target 
cell death was measured as disappearance of the CFSE fluorescent signal.  
 
2.2.9.2.1  Materials, Reagents and Equipment 
 CFSE (eBioscience, UK) 
 PBS 
 15 mL Falcon tubes (Fisher Scientific, UK) 
 RBS media 
 
2.2.9.2.2  Protocol 
1. Lymphoma cells were washed twice with PBS to remove any serum. 
2. Cells were re-suspended at 5-10 x 106 cell/mL in PBS. 
3. CFSE was added to a final concentration of 1µM and cells were incubated for 
10min at room temperature. 
4. Labelling was stopped by adding 10mL cold RBS and cells were incubated on ice 
for 5min. 
5. Cells were washed 3 times with RBS. 
6. CFSE-labelled cells were used for CAR + T-cell co-culture within 24h. 
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7. CFSE-labelled lymphoma cells were co-cultured with CAR+ T-cells at 1:1 ratio in a 
6-well plate.  
8. Lymphoma cells were monitored daily for target cell destruction by flow cytometry.  
 
2.2.9.3  Luciferase Assay 
A more elegant alternative to the target cell CFSE labelling was achieved by stably 
expressing both a firefly luciferase enzyme and the red fluorescent protein tandem dimer 
(td)Tomato in the lymphoma cell lines. Expression of both genes was achieved using the 
SFG retroviral vector. Tandem dimer Tomato is a bright red fluorescent protein with 
emission wavelength of 581nm. It was used as a fluorescent reporter for the identification 
of tumour cells within a co-culture with CAR+ T-cells. Firefly luciferase catalyses the 
conversion of a molecule of D-luciferin to an electronically ‘excited’ molecule of 
oxyluciferin when in the presence of magnesium, ATP and oxygen. The subsequent 
relaxation of this oxyluciferin molecule to a lower energy state results in the release of a 
single photon, which can be detected by a super-cooled ‘charged-coupled device’ (CCD) 
camera or a luminometer [274-276]. Since dead cells cannot catalyze this reaction, the 
number of viable cells determined the amount of luminescence detected, indicating the 
degree of cytotoxicity caused. 
 
2.2.9.3.1  Materials, Reagents and Equipment 
 D-Luciferin (Perkin Elmer, UK) 
 PBS 
 RBS media 
 Co-cultured cells 
 OptiPlate white opaque 96-well luminometer plates (Perkin Elmer, UK) 
 FLUOstar Omega  




2.2.9.3.2  Protocol 
1. D-Luciferin was reconstituted in PBS at a concentration of 30mg/mL and filter 
sterilized through a 0.2μm filter. 
2. The stock D-luciferin was diluted in pre-warmed RBS media and added to the co-
culture wells at a final concentration of 0.3mg/mL. 
3. Luminescence was measured on FLUOstar Omega luminescence detection 
system. 
4. Luminescence values were compared with untreated lymphoma cells. 
 
2.3 In vivo Models 
All in vivo experimentation was done in accordance with the UK Home Office guidelines 
as stated in the project license (license number 70/7794) and personal license (license 
number I9CED56C0) that governed this work. 
 
2.3.1  Development of an in vivo Lymphoma Model 
In order to test the anti-tumour potential of CAR-transduced T-cells in vivo, it was 
necessary to establish a suitable xenograft model. Luciferase-expressing tumour cells 
were administered via various routes and monitored for growth and ease of imaging.  
 
2.3.1.1  Materials, Reagents and Equipment 
 D-Luciferin  
 1mL insulin syringes (29G x 13mm) (Terumo, UK) 
 IVIS Lumina II bioluminescent imaging platform (Caliper Life sciences, UK) 
 Isofluorane anaesthetic (Baxter, UK) 




2.3.1.2  Protocol 
1. SCID/Beige mice were randomised into the required number of groups and were 
inoculated with the following number of tumour cells re-suspended in 200μL PBS. 
a. 5 x 106 intraperitoneally (i.p.) 
b. 10 x 106 intravenously (i.v.) 
c. 5 x 106 intravenously (i.v.) 
d. 2 x 106 intravenously (i.v.) 
e. 1 x 106 intravenously (i.v.) 
f. 0.5 x 106 intravenously (i.v.) 
2. Tumour growth was monitored using bioluminescence imaging (BLI) at appropriate 
time-points for the duration of the study. 
 
2.3.2  Bioluminescence Imaging  
Bioluminescence imaging (BLI) is a sensitive, non-invasive technique for monitoring 
tumour growth in vivo. After delivery of the D-luciferin substrate, the luciferase-expressing 
tumours are visualised in-situ whilst the mice are under general anaesthesia. 
 
2.3.2.1  Materials, Reagents and Equipment 
 D-luciferin  
 Isoflurane 
 IVIS Lumina II imaging platform  
 1mL insulin syringes (29G x 13mm) 
 
2.3.2.2  Protocol 
1. Mice were injected i.p. with 3mg (200L) D-luciferin and placed back in their cages 
for seven minutes. 
2. Mice were anesthetised with 3-4% gaseous isoflourane and transferred to the IVIS 
Lumina platform  
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3. Nine images of increasing duration (1s, 2s, 5s, 10s, 30s, 45s, 60s, 120s, 300s) 
were taken using small binning. Throughout imaging mice were maintained under 
anaesthesia with 1.5% isoflourane and were kept warm.  
4. The mice were returned to their cages once the imaging was completed and were 
monitored until they had regained consciousness.  
 
2.3.3  Target Retention in In Vivo Lymphoma Models 
Prior to testing the therapeutic efficacy of CAR-grafted T-cells, it was important to assess 
whether surface CSF-1R expression was maintained following the in vivo passage of 
lymphoma cells. 
 
2.3.3.1  Materials, Reagents and Equipment 
 Saline solution 
 Cell strainer 40μm (Falcon, UK) 
 Petri dish 
 Flow cytometer BD Canto II and LSRFortessa Flow Cytometers (BD, UK) 
 Ice 
 Antibodies (please refer to section 2.4.2) 
 
2.3.3.2  Protocol 
1. Tumours were resected from tumour-bearing SCID/Beige mice post-mortem and 
transferred to a vial of saline solution. 
2. Each tumour was passed through a cell strainer ensuring single cell suspension 
(mechanical disaggregation). 
3. The resulting tumour cell suspension was subsequently probed for the presence of 




2.3.4 Therapeutic Study 
In order to test the therapeutic potential of CSF-1R re-targeted T-cells, they were 
administered to tumour-bearing mice and the growth of the tumour was subsequently 
monitored.  
 
2.3.4.1 Materials, reagents and equipment 
 D-luciferin 
 Isoflurane 
 IVIS Lumina II imaging platform 
 1 mL insulin syringes (29 G x 13 mm) 
 25 G syringes 
 
2.3.4.2 Protocol 
1. On Day 0, thirty female SCID/Beige mice were inoculated intravenously with 2 x 
106 sK299 LT or alternatively with 2 x 106 K299 FMS LT tumour cells. The mice 
underwent BLI following tumour cell inoculation in order to confirm successful 
tumour cell delivery. These mice were subsequently used in the proceeding study.  
2. Six days post-tumour inoculation, the mice were imaged to confirm tumour take. 
Mice were subsequently sorted into six groups depending upon the level of tumour 
signal. Each group displayed a similar average signal level. 
3. On the same day, the groups were treated as follows; 
a. 20 x 106 (or alternatively 10 x 106) C4B+ T-cells i.v. (n=5) 
b. 20 x 106 (or alternatively 10 x 106) C34B+ T-cells i.v. (n=5) 
c. 20 x 106 (or alternatively 10 x 106) 43428Bζ+ T-cells i.v. (n=5) 
d. 20 x 106 (or alternatively 10 x 106) 34CB T-cells i.v. (n=5) 
e. 20 x 106 (or alternatively 10 x 106) UT T-cells i.v. (n=5) 
f. PBS i.v. (n=5) 




2.3.5 Assessment of target retention by sK299 LT and K299 FMS LT tumours 
As stable in vivo expression of CSF-1R by the tumour is central to its continued targeting, 
it was important to assess whether surface CSF-1R expression was maintained following 
in vivo passage.  
 
2.3.5.1 Materials, reagents and equipment 
 Saline solution 
 Petri dish 
 Scalpel 
 Cell strainer 
 Antibodies 




1. Tumours were resected from SCID/Beige mice post-mortem and immediately 
transferred in a vial of saline solution and placed on ice. 
2. Each tumour was placed on a Petri dish, cut into pieces with a scalpel and put 
through a cell strainer to obtain single cell suspension (mechanical 
disaggregation). 
3. The resulting tumour cell suspension was then probed for surface level of 
expression of CSF-1R, as detailed in section 2.4. 
 
2.4 Flow Cytometry 
Multicolour flow cytometry was used to detect cell surface protein expression and thereby 
to assess CAR expression and immunophenotype of transduced T-cells in addition to 




2.4.1  Materials, Reagents and Equipment 
 Antibodies (please refer to section 2.4.2) 
 FACSCanto II and LSRFortessa Flow Cytometers (BD, UK) 
 Diva software (BD, UK) 
 5mL polystyrene round-bottom flow cytometry tubes (BD Falcon, UK) 
 Cell Dissociation Buffer (Gibco, UK) 
 Trypsin/EDTA (Gibco, UK) 
 
2.4.2  Antibodies 
Staining for human CSF-1-based CARs 
Polyclonal goat anti-human CSF1 500ng/μL (Sigma-Aldrich, UK) 
Anti-goat Ig FITC-conjugated 1μg/μL (DAKO, UK) 
 
Staining for human IL-34-based CARs: 
Mouse anti-human IL-34 (clone 1D12) (Abcam, UK) 
Goat anti-mouse IgG PE-conjugated (Invitrogen, UK) 
 
Staining for human 4αβ: 
Mouse IgG1 anti-human CD124 PE-conjugated (BD Pharmingen, UK) 
 
Staining for human CSF-1R: 
Rat anti-human CSF-1R (clone 3-4A4) (Santa-Cruz, UK) 
Goat anti-rat IgG PE-conjugated (Invitrogen, UK) 
 
Staining for human memory T-cell phenotype: 
Mouse anti-human CD8 PE-Cy7-conjugated (BioLegend, UK) 
Mouse anti-human CD45RO PerCP-Cy5.5-conjugated (BioLegend, UK) 
119 
 
Mouse anti-human CCR7 APC-conjugated (BioLegend, UK) 
Mouse anti-human CD28 FITC-conjugated (BioLegend, UK) 
Mouse anti-human CD27 APC-Cy7-conjugated (BioLegend, UK) 
DAPI (4',6-diamidino-2-phenylindole) viability stain 
 
Staining for human T-cell anergy: 
Mouse anti-human CD8 PE-Cy7-conjugated (BioLegend, UK) 
Mouse anti-human PD1 APC-Cy7-conjugated (BioLegend, UK) 
Mouse anti-human TIM3 PerCP-conjugated (BioLegend, UK) 
Mouse anti-human LAG3 APC-conjugated (R&D, UK) 
Mouse anti-human 2B4 FITC-conjugated (BioLegend, UK) 
DAPI viability stain (Life Technology, UK) 
 
Staining for mouse macrophages: 
Rat anti-mouse CD16/CD32 (Fc receptor block) (BioLegend, UK) 
Rat anti-mouse CD11b PE-Cy7-conjugated (BioLegend, UK) 
Rat anti-mouse F4/80 PerCP-conjugated (BioLegend, UK) 
DAPI viability stain (Life Technology, UK) 
 
Staining for mouse myeloid derived suppressor cells: 
Rat anti-mouse CD16/CD32 (Fc receptor block) (BioLegend, UK) 
Rat anti-mouse CD11b PE-Cy7-conjugated (BioLegend, UK) 
Rat anti-mouse GR1 APC-conjugated (BioLegend, UK) 
DAPI viability stain (Life Technology, UK) 
 
2.4.3  Protocol  
1. A pre-determined number of cells (1 x 105 – 1 x 106) were placed in a flow-
cytometry tube and incubated with previously titrated primary antibody for 30 
minutes on ice. 
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2. Samples were washed using 2mL cold PBS, and centrifuged at 300g for 5 minutes 
until pelleted. 
3. Each sample was incubated with 3-7μg (fluorophore-conjugated) secondary 
antibody for 30 minutes on ice in the dark. 
4. Samples were again washed with cold PBS, centrifuged and subsequently re-
suspended in 300μL PBS immediately prior to analysis. Samples were kept in the 
dark and on ice until analysed by flow cytometry. 
 
NOTE: When directly conjugated antibodies were used for staining, cells were re-
suspended in 300μL PBS after completion of 1. and 2. above  and then analysed by flow 
cytometry. 
 
2.5 Detection of Cytokine Release  
2.5.1 Enzyme-Linked Immunosorbent Assay (ELISA) 
The enzyme linked immunosorbent assay (ELISA) was used for the detection and 
quantification of cytokine release in the co-culture supernatants, which occurred as a 
result of target engagement by the CAR and subsequent CAR+ T-cell activation. Plates 
were pre-coated with a ‘capture’ antibody specific for the cytokine of interest (IL-2 or IFN-
γ). Once bound to the capture antibody the cytokine was detected using a second, biotin-
labelled, antibody and subsequently with avidin-labelled horseradish peroxidase (HRP). 
Visualisation was achieved using a 3,5,3’,5’-tetramethylbenzadine (TMB)/hydrogen 
peroxide solution. Oxidation of the colourless TMB reagent to a blue solution (an 
equilibrium between the TMB cation radical and the diamine-diimine charge transfer 
complex [277]) highlighted assay progression. After 15 min the reaction was stopped 
using 2M sulphuric acid. The reduction in pH induced formation of the yellow diimine 
product and prevented further development by denaturation of the HRP. Plates were 
subsequently read at 450nm and the concentrations of each sample calculated with 




2.5.1.1  Materials, Reagents and Equipment 
 High-binding flat-bottom 96-well ELISA plates  (Iwaki, UK)  
 IFN- Ready-Set-Go ELISA Kit (eBioscience, UK) 
 IL-2 Ready-Set-Go ELISA kit (eBioscience, UK) 
 IL-34 Duoset ELISA Kit (R&D Systems, UK) 
 M-CSF Duoset ELISA Kit (R&D Systems, UK) 
 Colour Reagent A (Stabilised Peroxide Solution) (R&D Systems, UK) 
 Colour Reagent B (Stabilised TMB Reagent) (R&D Systems, UK) 
 Wash Buffer (please see below) 
 Sulphuric Acid (H2SO4) (BDH, UK) 
 Fluostar Omega plate reader 
 Omega Software (version 1.20) 
 MARS data analysis software (version 1.20 R2) 
 
 
Buffer and solutions: 
Wash buffer = PBS + 0.05% Tween-20 
 
2.5.1.2  Protocol 
1. A 96-well ELISA plate was coated with 100μl/well of capture antibody diluted 1/250 
in coating buffer. The plate was sealed and incubated at 4oC overnight. 
2. The plate was washed 5 times with 300μl/well wash buffer and blocked with 
200μl/well of 1x assay diluent for 1 hour at room temperature. 
3. The plate was washed as described above. 
4. Standard curve samples were serially diluted in a two-fold manner in assay diluent. 
A seven point standard curve ranging from 500pg/mL to 3.9pg/mL was plated in 
triplicate. Background absorbance was measured by plating assay diluent alone. 
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Supernatant samples from co-cultivation were diluted between 1:20 to 1:200 in 
assay diluent prior to plating in triplicate. The plate was sealed and incubated 
overnight at 4oC. 
5. The plate was washed as described above. 
6. Detection antibody was diluted 1/250 and 100μl/well were added. 
7. The plate was incubated for 1 hour at room temperature. 
8. Wash step executed as in step 3. 
9. Avidin-HRP was diluted 1/250 and 100μl/well were added. 
10. The plate was incubated for 30 min at room temperature. 
11. Wash step executed as in step 3. 
12. 100μl/well of TMB substrate solution was added to each well and the plate was 
incubated for 15 min.  
13. The reaction was stopped by adding 50μl/well of stop solution (2M H2SO4) 
14. Absorbance was read at 450nm using the Fluostar Omega plate reader. 
15. Standard curves and cytokine concentrations were calculated using the MARS 
data analysis software.  
 
2.6  Immunoblot analysis 
Analysis of protein expression using western blot has been used to confirm expression of 
the various CAR constructs in T-cells and of the CSF-1R receptor in the lymphoma cell 
lines. 
 
2.6.1  Materials, Reagents and Equipment 
 RIPA lysis buffer (please see below) 
 cOmplete, mini, EDTA-free Protease inhibitor cocktail tablets (Roche, UK)  
 Whole Cell Lysates 
 NuPAGE Novex 4-12% Bis-Tris Protein Gels (Life Technologies, UK) 
 NuPAGE MOPS SDS Running Buffer (20X) (Life Technologies, UK) 
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 Transfer buffer (please see below) 
 Loading buffer (please see below) 
 TBST buffer (please see below) 
 Glycine (MP Biomedicals, UK) 
 Tris Base (Fisher Scientific, UK) 
 Nitrocellulose membrane (PALL Life Sciences, UK) 
 Antibodies (please see section 2.6.2) 
 Enhanced Chemiluminescence (ECL) Kit (GE Healthcare, UK) 
 Distilled water 
 Full range rainbow recombinant protein markers (GE Healthcare, UK) 
 High performance Chemiluminescent Hyperfilm (GE Healthcare, UK) 
 Optimax X-ray developer (Jet, UK) 
 Methanol (Fisher Scientific, UK) 
 Ponceau S Solution (Sigma, UK) 
 Skimmed milk powder (Oxoid, UK) 
 Electrophoresis tank (Invitrogen, UK) 
 Whatman 3MM Chr paper (SLS, UK) 
 Techne Dri-blok DB-2A heated block (Techne, UK)  
 Saran wrap (Dow, UK) 
 
Buffers and Solutions 
RIPA lysis buffer = 50mM Tris.HCl pH 7.5, 150mM NaCl, 1% NP-40, 1% sodium 
deoxycholate, 0.1% SDS, 1x Protease inhibitor cocktail tablet.  
Loading Buffer = 50 mM Tris.HCl, 100 mM DTT, 2% (w/v) SDS, 0.1% (w/v) bromophenol 
blue, 10% (v/v) glycerol. 
TBST = 50mM Tris, 150mM NaCl, 0.05% Tween-20 




Blocking Buffer = TBS, 5% (w/v) skimmed milk powder 
 
NOTE: Roche do not release the details of the protease inhibitors contained within the 
cOmplete, mini, EDTA-free protease inhibitor cocktail tablets.  
 
The SDS in SDS-PAGE electrophoresis is responsible for both denaturing the proteins in 
the sample as well as for providing them with a net negative charge. Therefore protein 
separation is determined by differences in size, which is influenced by the percentage of 
polyacrylamide present within the resolving gel [278]. The proteins were separated on pre-
cast reducing 4-12% NuPAGE gradient gels using MOPS running buffer, which allowed 
for a separation range of 15 to 260 kDa.  
 
2.6.2  Antibodies 
Probing for human CSF-1R 
Rabbit anti-human CSF-1R polyclonal antibody* 
Goat anti-rabbit HRP-conjugated antibody (Dako, UK) 
*Generous gift from Dr Nicholas Dibb, Hammersmith Hospital Campus, Imperial College 
London  
 
Probing for human PTPζ 
Rabbit anti-human PTPζ (Santa Cruz, UK) 
Goat anti-rabbit HRP-conjugated antibody (Dako, UK) 
 
Probing for human KU-70 (loading control) 
Goat anti-human KU-70 antibody (Santa Cruz, UK) 
Rabbit anti-goat HRP-conjugated antibody (Dako, UK) 
 
Probing for CAR constructs 
Mouse anti-human CD247 (CD3ζ) (BD, UK) 
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Goat anti-mouse HRP-conjugated antibody (Dako, UK) 
 
2.6.3 Protocol  
1. Whole cell lysates were produced by syringe homogenization of the cells in RIPA 
lysis buffer.  
2. Cell lysates were thawed and centrifuged at 16,200 g to pellet the insoluble 
material.  
3. A sufficient volume of supernatant was removed and mixed 3:1 with the protein-
loading buffer before being boiled at 90 C for 10 minutes.  
4. Lysates were centrifuged at 16,200 g before being loaded into the wells of the pre-
casted gel. 
5. The gel was run at 20V/cm for 120 minutes. 
6. Proteins were transferred from the polyacrylamide gel to a nitrocellulose 
membrane using the Mini Trans-Blot system (Bio-Rad) at 30V/90mA overnight at 
4oC. 
7. The membrane was blocked for 1 hour at room temperature in blocking buffer to 
prevent non-specific binding. 
8. The primary antibody was diluted to the recommended concentration in blocking 
buffer and incubated with the membrane for 1 hour at room temperature. 
9. The membrane was washed three times for 10 min each in TBST. 
10. An HRP-conjugated secondary antibody was diluted to the recommended 
concentration in blocking buffer and incubated with the membrane for 1 hour at 
room temperature.  
11. Following an additional three washes in TBST, the membrane was covered with a 
pre-mixed ECL solution. 
12. After 1 min incubation, excess ECL solution was drained and the membrane 
covered in Saran wrap.  
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13. The membrane was fixed inside a film cassette and a chemiluminescent hyperfilm 
placed on top (in the dark). 
14. After a sufficient exposure time had been observed, the film was removed and 
developed using a Jet Optimax X-ray developer. Membranes were often exposed 
for differing durations in order to optimise the signal gained. 
 
Densitometry analysis of western blots was performed using ImageJ 4.1 software 
(National Institute of Health, USA).  
 
2.7  Statistical Analysis 
To investigate for statistical significance, unless stated otherwise, values were subjected 
to a two-way ANOVA, followed by a Bonferroni post-hoc test and p-values < 0.05 were 






Chapter 3 Investigation into CSF-1R expression in cHL and ALCL 
 
3.1 Introduction  
Cancer cells employ a variety of mechanisms to evade apoptosis and senescence. Pre-
eminent among these is the aberrant co-expression of growth factors and their ligands, 
forming an autocrine growth loop that promotes tumour formation and progression. One 
growth loop whose transforming potential has been repeatedly demonstrated is the CSF-
1/CSF-1R axis [279].  
 
3.1.1 The CSF-1/CSF-1R axis in cancer  
Expression of CSF-1 and/or CSF-1R has been documented in several human 
malignancies including breast, cervical, endometrial, ovarian, lung, prostate and kidney 
cancer, as well as in classical Hodgkin’s lymphoma (cHL) and anaplastic large cell 
lymphoma (ALCL) [34, 280-283]. Indeed, elevated serum levels of CSF-1 have been 
demonstrated in patients with breast [284, 285], ovarian [286, 287], colorectal [288, 289] 
and pancreatic cancer [290] and Hodgkin’s lymphoma [291-293]. The oncogenic potential 
of the CSF-1/CSF-1R axis generally results from the co-expression of the growth factor 
and its receptor rather than mutations that render the receptor constitutively active [294]. 
In this respect, CSF-1R can be activated either in an autocrine manner (e.g. co-expressed 
with CSF-1 by the tumour cells) or in a paracrine manner – for example where CSF-1 is 
secreted by cancer-associated fibroblasts. The transforming potential of the CSF-1/CSF-
1R axis has been confirmed by expressing c-fms in CSF-1-producing fibroblasts and 
epithelial cells, resulting in tumour formation in Balb/c mice [279]. The role of the CSF-
1R/CSF-1 axis has been most extensively studied in breast and ovarian cancer, with a 




3.1.1.1 Breast cancer  
Among epithelial cancers, the role of CSF-1/CSF-1R has been most extensively studied in 
breast cancer. Normally, breast tissue does not express CSF-1R and only low levels of 
CSF-1 are detected [294, 295]. By contrast, serum CSF-1 levels are elevated in patients 
with metastatic breast cancer [295] and may be 10 fold higher than normal in advanced 
disease [294]. Furthermore, 58% of all human breast tumours express CSF-1R [296] and 
at least 85% of invasive breast carcinomas express c-fms [281, 295] while 36% co-
express both the receptor and CSF-1 [297].   
 
In the context of breast cancer risk, a large cohort breast cancer tissue array revealed a 
strong association between c-fms expression and both lymph node metastasis and poor 
survival of breast cancer patients [298]. In support of this, an independent study has 
linked c-fms over-expression in breast cancer to invasive and metastatic properties [299]. 
In an elegant study using mice in which the polyoma middle T antigen is expressed under 
the mouse mammary tumour virus promoter, Lin et al. revealed a causal relationship 
between the CSF-1/CSF-1R axis and metastatic dissemination [299]. When these mice 
were crossed onto the op/op background, the resultant absence of CSF-1 did not affect 
the growth of primary mammary tumours, but retarded both tumour cell invasion and 
formation of lung metastases. Restoration of CSF-1 expression in the mammary 
epithelium alone restored tumour progression and metastasis. Similarly, disease 
progression was accelerated when CSF-1 was over-expressed in wild type mice [299].  
 
Consistent with its role in tumour progression and metastasis, the expression of CSF-1R 
and its ligand CSF-1 in neoplastic epithelial cells has been strongly correlated with poor 
prognosis and is predictive for ipsilateral recurrence in breast cancer patients [298, 300]. 
In addition, CSF-1 has been reported to stimulate angiogenesis through recruitment of 
macrophages, which in turn secrete pro-angiogenic factors (eg VEGF), growth factors (eg 
epidermal growth factor) and matrix metalloproteases (MMPs) important for invasion and 
motility of tumour cells [301]. In CSF1 nullizygous mice, angiogenesis is markedly blunted 
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whereas forced CSF-1 over-expression causes increased tumour vessel density and 
oncogenicity [302, 303]. 
 
Apart from promoting angiogenesis, CSF-1-educated tumour-associated macrophages 
(TAM) have a central role in supporting tumour cell survival, proliferation, motility and drug 
resistance as well as suppressing anti-tumour immunity [304]. The production and 
recruitment of TAMs is regulated by the CSF-1/CSF-1R axis. Interruption of the axis 
through CSF-1 antisense oligonucleotides [301], CSF-1R and CSF-1 small interfering 
RNA (siRNA) [301] or anti-CSF-1 antibody [305] resulted in up to 50% suppression of 
growth of human MCF-7 mammary carcinoma cell xenografts in mice. This was 
accompanied by inhibition of host-derived macrophage recruitment to those tumours and 
hence inhibition of MMPs and VEGF production [301]. Furthermore, anti-CSF-1 treatment 
reversed the chemo-resistance of MCF-7 xenografts, suggesting a role for CSF-1 in drug-
resistance [305]. In keeping with these data, down-regulation of CSF-1 targeting miRNA 
(MiR-130a) was reported in several chemo-resistant ovarian cancer cell lines [306].  
 
Collectively, these data supports the paradigm that the CSF-1/CSF-1R axis plays a crucial 
role in regulation of tumourigenesis and angiogenesis via its effect on tumour-surrounding 
stroma, contributing to both permissive and instructive signals to tumour growth and 
progression. 
 
3.1.1.2 Ovarian cancer  
Broadly similar findings have been observed in studies of the role of CSF-1/CSF-1R axis 
in ovarian cancer progression, as described above for breast cancer. Expression of CSF-1 
has been detected in 75% of primary ovarian tumours and 69% of metastases while 92% 
of primary tumours and 83% of metastases express CSF-1R [307]. Co-expression of this 
ligand/ receptor pair by metastatic deposits is an independent poor prognostic factor, 
shortening the mean time to recurrence by 11 months (from 24.1 +/- 3.9 to 13.5 +/- 4 
months) [307]. Furthermore, elevated CSF-1 levels in serum and ascitic fluid has been 
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associated with poor outcome in this disease [308, 309]. Indeed, measurement of serum 
CSF-1 is one of a number of candidate biomarkers that has been proposed to aid the 
early detection of ovarian cancer [310].  
 
The pro-tumourigenic effects of the CSF-1/CSF-1R axis in ovarian cancer was 
demonstrated by over-expression of CSF-1 in c-fms+ ovarian cancer cells. As a result, 
cells became more invasive, motile, adhesive and tumourigenic in vivo [311]. These 
phenotypic changes were all reversed upon disruption of the autocrine loop using 
antisense oligomer therapy directed against c-fms and CSF-1 mRNA knock down [311].  
 
The mechanisms by which CSF1/ CSF-1R promotes ovarian cancer progression remain 
under investigation. One relevant candidate is urokinase plasminogen activator (uPA) 
[312]. This serine protease is a CSF-1-inducible mediator of tissue re-modelling and is 
known to play a significant role in ovarian tumour invasion and metastasis. Both uPA and 
the related plasminogen activator inhibitor-1 (PAI-1) have been shown to be elevated in 
malignant ovarian tumours, compared to benign counterparts or normal ovarian epithelium 
[313, 314]. Furthermore, antisense inhibition of uPA reduces the metastatic peritoneal 
spread of human ovarian cancer in nude mice [315].  
 
In contrast to malignant ovarian tumours, co-expression of CSF-1/ CSF-1R is not found in 
non-invasive tumours [316]. Furthermore, minimal to non-existent expression of CSF-1 or 
CSF-1R has been detected in normal ovarian epithelium [316]. These considerations raise 
the possibility that targeting of the CSF-1/CSF-1R axis may achieve therapeutic benefit in 
this disease.  
 
3.1.1.3 Classical Hodgkin’s lymphoma and anaplastic large cell lymphoma 
Aberrant CSF-1R expression has also been reported in both Hodgkin and Reed-Sternberg 
(HRS) cell lines and primary HRS and ALCL cells. This represents an example of lineage-
inappropriate expression of downstream genes that promote survival of a lymphoid 
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neoplasm [34]. The mechanism underlying deregulated expression in cHL and ALCL is 
remarkable because expression of CSF-1R transcripts, unlike in epithelial cancers, is 
driven by an endogenous long terminal repeat (LTR) sequence upstream of the CSF-1R 
gene [34]. Specifically, Lamprecht et al. have demonstrated that the promoter of the 
THE1B LTR is aberrantly activated, both due to demethylation of the region and also DNA 
methylation-induced silencing of the gene that encodes the THE1B LTR transcriptional 
repressor CBFA2T3 [34]. Aberrantly expressed CSF-1R is generally constitutively 
activated, most likely due to an autocrine and paracrine CSF-1 loops. Furthermore, CSF-
1R signalling was demonstrated to be necessary for HRS cell growth and survival [34].  
 
In the same study, it was shown that that CSF-1R expression is restricted to cHL and 
anaplastic large cell lymphoma (ALCL) since the promoter of the THE1B LTR is not 
activated in most non-Hodgkin’s lymphomas. In light of these findings, quantification of 
CSF-1R transcripts may aid in both diagnosis and detection of minimal residual disease in 
treated cHL or ALCL patients [34].   
 
In terms of prognostic value, CSF-1R expression in HRS cells is significantly correlated 
with treatment failure. In multivariate analysis of 132 cHL patients, Steidl et al. have 
demonstrated that a combined score of CSF-1R expression and high number of CD68+ 
infiltrating macrophages is an independent predictor of short progression-free survival. 
[317] 
 
Expression of CSF-1 is also linked to cHL progression, both as an autocrine HRS cell 
growth factor and as a stimulus to monocyte/ macrophage growth and survival [35, 317]. 
Only few studies have examined circulating CSF-1 levels in cHL patients, but collected 
data suggest that patients present with significantly higher levels than healthy persons. 
Furthermore, among cHL patients, those with bulky mediastinal mass and systemic 




Collectively these data suggest that in cHL and ALCL, the CSF-1/CSF-1R axis is linked to 
lineage infidelity, cellular reprogramming and treatment resistance, raising the possibility 
that CSF-1R expression and signalling may constitute new therapeutic targets for these 
lymphomas. Consequently, further investigations are required in order to determine 
whether targeting of the CSF-1/CSF-1R axis may achieve therapeutic benefit in these 
diseases.  
 
3.2  Results 
3.2.1  CSF-1R expression by a panel of cHL and ALCL cell lines 
In order to determine the suitability of CSF-1R as a therapeutic target in cHL and ALCL, 
its expression profile on a panel of six human lymphoma cell lines was investigated 
(Figure 3.1). Western blotting analysis demonstrated the expected two bands at 
approximately 165kDa and 140kDa in all six cases, albeit at variable intensity. These 
band sizes correlate well with those reported for the two major glycosylated variants of 
human CSF-1R (Figure 3.1, A) [319]. The lower band seen in all lanes in this blot (top 
panel) is believed to represent an undefined protein that is cross-reactive with this 
polyclonal antiserum. A loading control is shown in the bottom panel. To confirm these 
results, flow cytometry was undertaken after incubation of these cells with a CSF-1R-
specific monoclonal antibody. This analysis confirmed that CSF-1R was detectable on the 
cell surface of these tumour cells, at varying levels of expression (Figure 3.1, B). The 
human breast cancer cell line T47D has been previously reported to lack CSF-1R 
expression and was therefore used as a negative control for these analyses [320]. In 
order to create a positive control, the parental T47D cell line was genetically engineered to 
express high levels of CSF-1R (T47D FMS), as confirmed by both western blotting and 






Figure 3.1 CSF-1R expression by a panel of cHL and ALCL cell lines.  
(A) Each lymphoma cell line as well as T47D and T47D FMS (5 x 106 cells) were lysed in reducing 
lysis buffer. The lysates were separated using SDS-PAGE and protein was transferred onto a 
nitrocellulose membrane. The presence of CSF-1R was (legend continues on next page)  
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3.2.2 Ligand expression by the panel of lymphoma cell lines 
Given the transforming potential of CSF-1R upon its co-expression with CSF-1 (see 
section 3.1.1), I next investigated the expression of both CSF-1R ligands (CSF-1 and IL-
34) in the panel of cHL and ALCL cell lines (Figure 3.2). In accordance with published 
data, the cHL cell lines KM-H2 and L540 both produced low levels of CSF-1 [34]. Notably 
however, IL-34 production was detected by 5 of the 6 lymphoma cell lines tested. 
Furthermore, cell culture supernatants were collected for ELISA in the absence of anti-
CSF-1R blocking antibody, raising the possibility that the detected cytokine levels are a 






detected using a polyclonal primary antibody, followed by an HRP-conjugated anti-rabbit IgG 
antibody and subsequent development using enhanced chemiluminescence (top panel). The 
lysates were also probed for the presence of the nuclear membrane protein, KU-70, as a 
loading control (bottom panel). (B) The panel of lymphoma cell lines was probed for the cell 
surface expression of CSF-1R using a monoclonal rat anti-human CSF-1R antibody followed 
by a goat anti-rat PE conjugated secondary antibody (red histograms). Cells were also stained 
using the secondary antibody only (blue histograms) to show the specificity of staining. (C) 
The parental T47D breast cancer cell line (green histogram) and T47D FMS, a derivative that 
has been genetically engineered to express high levels of CSF-1R (orange histogram) were 
both stained with the same antibody combination. Results are representative of 2 (A) and 7 (B 








Figure 3.2 CSF-1 and IL-34 expression by the panel of lymphoma cell lines.  
For collection of cell culture supernatants for ELISA, cells were plated at 0.8 x 106 cells/ml, and 
supernatants were collected after 48 hours. As controls, standard medium and the reagent diluent 
for the standards (RD) were included. Data are presented as mean ± standard deviation from three 
independent experiments.  
 
 
3.2.3 PTPζ expression by the panel of lymphoma cell lines 
Since it was established that 5/6 lymphoma cell lines secrete IL-34, it was of crucial 
importance to determine whether they also express the alternative IL-34 receptor, PTPζ 
[131]. The PTPζ receptor is primarily expressed on neural progenitors and glial cells. [132] 
Unsurprisingly, IL-34 is highly expressed in the brain and has an important role in 



















































Figure 3.3 PTPζ expression by a panel of cHL and ALCL cell lines.  
Each lymphoma cell line as well as T47D and T47D FMS (5 x 106 cells) was lysed in reducing lysis 
buffer. The Daudi cell line was used as a positive control as recommended by the anti-PTPζ 
antibody supplier. The lysates were separated using SDS-PAGE and the protein subsequently 
transferred onto a nitrocellulose membrane. The presence of PTPζ was detected using a polyclonal 
primary antibody, followed by an HRP-conjugated anti-rabbit IgG antibody and subsequent 
development using enhanced chemiluminescence (top panel). The lysates were also probed for the 
presence of the nuclear membrane protein, KU-70, as a loading control (bottom panel). 
 
 
In order to investigate PTPζ expression, each lymphoma cell line (5 x 106 cells) was lysed 
under reducing conditions and probed for the receptor by western blotting (Figure 3.3). 
Importantly, the Daudi cell line was used as a positive control as recommended by the 
antibody supplier. As expected, a band at approximately 90 kDa was detected in the 
Daudi lane, which correlated well with the reported size of PTPζ (Figure 3.3). However, 
none of the lymphoma cell lines showed evidence of expressing this receptor. Absence of 
PTPζ expression, even though confirmed by western blotting, could not be further verified 




3.2.4 Investigation of the ability of corticosteroids to up-regulate CSF-1R 
expression by lymphoma cells  
Recently, it has been demonstrated that dexamethasone induces substantial up-
regulation of CSF-1R expression at mRNA and protein levels in a number of breast 
cancer cell lines [321-323]. This effect has been attributed to the presence of functional 
glucocorticoid response elements in both c-fms promoters, which mediate this effect via 
binding to the glucocorticoid receptor [323]. In order to investigate whether 
dexamethasone treatment can similarly induce up-regulation of CSF-1R expression in 
cHL and ALCL cells, the previously described panel of lymphoma cell lines was treated 
with 1M dexamethasone. Cells were lysed every 12 hours under reducing conditions and 
western blots were probed for the expression of CSF-1R (Figure 3.4). As indicated by the 
bar graphs, dexamethasone treatment did not induce a significant upregulation of CSF-1R 
expression in these cells with the exception of the FE-PD cell line at 48h (Figure 3.4, D). 
These results were verified using flow cytometry analysis of cell surface CSF-1R 
















3.2.5 Investigation of the ability of corticosteroids to up-regulate CSF-1R 
expression by human monocyte-derived macrophages 
Colony stimulating factor-1 receptor is naturally expressed on macrophages and a 
small subset of monocytes (CD14+CD16+). In order to characterize the effect of 
systemic administration of dexamethasone on CSF-1R expression level on 
macrophages, an in vitro assay was carried out. Human monocytes were isolated from 
PBMC using CD14+ magnetic selection and differentiated to either M1 (in the presence 
of 20 ng/ml recombinant human GM-CSF [324]) or M2 macrophages (in the presence 
of 50 ng/ml recombinant human CSF-1 [324]) [325]. After 7-day culture in the described 
above conditions, macrophages were immunophenotyped to confirm M1 or M2 
polarisation (Appendix, Figure S1) and were then exposed to 1μM dexamethasone or 
alternatively left in medium for further 48h. Macrophages were then lysed in reducing 
conditions and probed for CSF-1R expression. As indicated in Figure 3.6, 
dexamethasone treatment induced up-regulation of CSF-1R protein level in both M1 
and M2 macrophages after 48 hours.  
 
  
Indicated lymphoma cells were exposed to 1μM dexamethasone and 5 x 106 cells were lysed 
in reducing lysis buffer every 12 hours for 4 days. Lysates were separated using SDS-PAGE 
and the protein subsequently transferred onto a nitrocellulose membrane. The presence of 
CSF-1R was detected using a polyclonal primary antibody, followed by an HRP-conjugated 
anti-rabbit IgG antibody and subsequent development using enhanced chemiluminescence 
(top panel). The lysates were also probed for the presence of the nuclear membrane protein, 
KU-70, as a loading control (bottom panel). A representative western blot is shown for each 
cell line. Bar graphs were obtained by densitometry analysis (ImageJ) performed on three 
independent replicate experiments. Data were expressed as a ratio between CSF-1R and KU-
70 expression (normalized to 0h time point), and shown as mean ± SD. Data were analysed 






Figure 3.5. Surface CSF-1R expression by lymphoma cells cultured +/- dexamethasone.  
(A) The panel of six lymphoma cell lines was either treated with 1M dexamethasone or left 
untreated for 48 hours. Next, cell surface CSF-1R expression was determined by flow 
cytometry. The presence of CSF-1R was detected using a rat monoclonal anti-human CSF-1R 
antibody, followed by a FITC-conjugated secondary antibody (blue histogram – in the absence 
of dexamethasone treatment at 48h; green histogram – following exposure to 1M 
dexamethasone for 48h). Cells were also stained using the secondary antibody only (grey 
histograms) to show the specificity of staining. (B) Median fluorescence intensity was plotted for 




Figure 3.6 CSF-1R expression by human monocyte-derived macrophages cultured +/- 
dexamethasone. 
MACS-separated CD14+ human monocytes were differentiated into M1 or M2 macrophages by 
cultivation for 7 days in GM-CSF or CSF-1 respectively. For the next 48h, cells were cultured in 
presence or absence of 1M dexamethasone and levels of CSF-1R protein were analysed by 
western blotting. Lysates produced under reducing conditions were separated using SDS-PAGE 
and subsequently transferred onto a nitrocellulose membrane. The presence of CSF-1R protein 
was determined using a rabbit anti-CSF-1R primary antibody, followed by a goat anti-rabbit IgG 
HRP-conjugated secondary antibody. The presence of bound secondary antibody was detected 
using enhanced chemiluminescence (ECL) (A, top panel). The lysates were also probed for the 
presence of the nuclear membrane protein, KU-70, as a loading control (A, bottom panel). Bar 
graphs were obtained by densitometric analysis (ImageJ) of western blot data (B).   
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3.3 Discussion  
In order to elucidate whether CSF-1R expression in cHL and ALCL would be amenable 
to CAR-re-directed T-cells, a panel of 6 lymphoma cell lines (2 cHL, 2 ALK+ ALCL, 2 
ALK- ALCL cell lines) was probed for CSF-1R expression by western blotting 
(assessing total relative levels of expression; Figure 3.1, A) and flow cytometry 
(providing comparative information on cell surface expression; Figure 3.1, B). Varying 
levels of CSF-1R expression were detected in all six lymphoma cell lines. Additionally, 
an autocrine loop was confirmed by CSF-1 and IL-34 ELISA (Figure 3.2). Expression 
levels of both ligands was determined in the absence of anti-CSF-1R blocking 
antibody, raising the possibility that the detected cytokine levels underestimate the true 
amount produced due to continuous internalization of the ligand-receptor complex. 
Importantly, while the involvement of CSF-1 in the pathogenesis of cHL and ALCL has 
been reported previously, these results suggest for the first time a role for IL-34 in this 
process [35, 292, 318, 326]. However the role of IL-34 in cHL and ALCL has not been 
addressed in this project and warrants further study. Knocking down IL-34 by si/shRNA 
would shed light on its involvement in proliferation and migration, as well as on its 
potential role as a mediator of cellular cross talk and an influential factor in the tumour 
microenvironment. 
 
Colony-stimulating factor-1 receptor has been shown to translocate to the nucleus in 
both breast cancer cell lines and patient tumour samples where it acts as a 
transcriptional factor [327]. It is hypothesized that since CSF-1R does not contain a 
nuclear localization signal (NLS) it can only translocate into the nucleus when 
complexed with CSF-1, which does contain an NLS [327]. Once in the nucleus, CSF-
1R binds to the promoter region of CSF-1 thus not only driving a self-sustaining loop by 
regulating CSF-1 expression but also shedding light on its association with treatment 
resistance and poor prognosis. No such role has been described in the literature for the 
CSF-1R/ IL-34 receptor-ligand complex. Upon entering the IL-34 amino acid sequence 
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in the online database NucPred (http://www.sbc.su.se/~maccallr/nucpred), which 
predicts putative NLS’s in any given amino acid sequence, a score of 0.22 was 
generated for IL-34, suggesting that it lacks a NLS [328]. NucPred assigns a likelihood 
score of 1 to an amino-acid sequence with a known well-defined NLS. Sequences, 
which score  0.7 with NucPred have been shown to be 81% correct with a coverage of 
44%. By contrast, when CSF-1R was run, the NLS score obtained was 0.15, while 
CSF-1 (Gene ID: 1435; isoform 1) was scored as 0.63. These data strongly suggest 
that an NLS is lacking in CSF-1R but present in CSF-1 and, by implication, the complex 
of this cytokine with its receptor. By contrast, this situation would not be expected to 
apply to IL-34 when complexed with CSF-1R. This hypothesis can be tested by 
provision of exogenous CSF-1 or IL-34 in a CSF-1R expressing model system, in 
which nuclear localization of CSF-1R will be confirmed by immunofluorescence.  
 
Recently, a novel IL-34 receptor was identified termed PTPζ [131]. Physiological 
expression of PTPζ is largely restricted to the central nervous system and this receptor 
is overexpressed in some malignancies, most notably in glioblastomas [329-331]. 
Furthermore, increased expression levels of PTPζ in astroctyomas has been correlated 
with a poor clinical prognosis. [330] Functionally, PTPζ is known to facilitate tumour cell 
adhesion and migration through interactions with extracellular matrix components and 
the growth factor pleiotrophin [332, 333]. Given the detected IL-34 production by the 
lymphoma cell lines and in light of its role in glioblastomas, PTPζ expression level was 
investigated in the panel of lymphoma cell lines (Figure 3.3). While none of the 
lymphoma cell lines showed evidence of PTPζ expression, a band of the expected size 
(approximately 90 kDa) was detected in the Daudi cell line, which served as a positive 
control. Consequently, it was concluded that all six lymphoma cell lines express 
variable levels of CSF-1R, but not PTPζ, and secrete either one or both ligands for the 
former receptor. Therefore, the limiting step in targeting CSF-1R in this system would 
be the availability of the receptor on the cell surface, which is determined by its 




The mature CSF-1R is relatively stable in the absence of CSF-1 and IL-34 with a half-
life of three to four hours [334]. However, upon ligand binding, receptor expression is 
down-regulated rapidly (receptor-ligand complex half-life  5 min) [335] by 
internalization of the ligand-receptor complex. This provides a mechanism for 
attenuation of the growth factor receptor signalling [336]. In contrast to other tyrosine 
kinase receptor-ligand complexes that are subjected to proteasome-dependent 
proteolytic process (e.g. Platelet-derived Growth Factor β –Receptor [337], Met [338], 
Epidermal Growth Factor [339]), CSF-1R is degraded lysosomally. Upon interaction of 
c-cbl with the C-terminal Y969 of CSF-1R, the receptor complex becomes ubiquitinated 
and, after association with clathrin-dependent coated pits, it is pinocytosed and 
subsequently degraded in lysosomes [334, 340]. For the purpose of CSF-1R targeting 
using CAR-engineered T-cells, the rapid rate of internalization of the ligand-receptor 
complex is potentially unfavourable. Consequently, I considered the use of agents such 
as glucocorticoids that are known to up-regulate steady state expression of this 
receptor at the cell surface. 
 
Gluccorticoids (GC) are a class of pharmaceuticals that attenuate many aspects of the 
inflammatory process. These agents bind to glucocorticoid receptors (GR), which 
associate with glucocorticoid response elements (GREs) that are found in the 
promoters of many target genes. In turn, these complexes recruit co-activator proteins 
to increase histone acetylation, thereby allowing enhanced gene transcription to occur 
[341]. Expression of several anti-inflammatory genes is increased in this manner, 
including IL-10, inhibitor of -κB (IκBα) and MAPK-phosphatase-1. In addition, 
glucocorticoids have been reported to inhibit the transcription of a number of 
inflammatory cytokines (e.g. IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-11, TNF-α and GM-
CSF) and chemokines (e.g. IL-8, RANTES, MCP-1, MCP-3, MCP-4 and MIP-1α) [342]. 
This results in disruption of immune cell recruitment (neutrophils, monocytes, 
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macrophages, T-cells and granulocytes) to the site of inflammation as well as in 
inhibition of their activation and consequent proliferation.  
 
Exposure to GC, including dexamethasone, results in c-fms overexpression through 
the activation of a GR-mediated pathway. This effect has been attributed to functional 
GREs located in both c-fms promoters [323]. The c-fms gene has two described 
promoters, separately directing expression in monocytic and trophoblast cell lineages. 
In placental trophoblasts, the c-fms transcript is initiated from the first promoter, which 
is 26 kb upstream of exon 2 and includes a non coding first exon, while in the 
monocytic lineage CSF-1R expression is initiated from the second c-fms promoter, 
immediately upstream of exon 2 [119, 323, 343]. As demonstrated by Roberts et al., 
both promoters of the c-fms gene contain functional GREs, which can mediate the 
observed GC effect through the glucocorticoid receptor [343]. 
 
Expression of c-fms has been reported to be dramatically up-regulated by GC both in 
breast cancer cell lines in vitro as well as in breast cancer metastasis in vivo [295, 321, 
344]. Even low physiological levels of GC induce elevated c-fms expression in vivo 
[345]. In cHL and ALCL, unlike in epithelial cancers, CSF-1R expression is driven by an 
aberrantly activated endogenous LTR, located ~6.2 kb upstream of the monocytic 
lineage promoter [34]. In order to investigate whether dexamethasone treatment can 
induce similar up-regulation of c-fms expression in cHL and ALCL, the panel of 
lymphoma cell lines was treated with 1M dexamethasone. Cells were lysed every 12 
hours under reducing conditions and probed for the expression of CSF-1R. Analysis of 
the band intensities from 3 separate donors (shown in the bar graphs), indicates 
transient, but not statistically significant (with the exception of the FE-PD cell line) CSF-
1R up-regulation at 48h (Figure 3.4). More importantly, surface level of CSF-1R 
expression was not affected by dexamethasone treatment (with the exception of the 
FE-PD cell line), as indicated by flow cytometry (Figure 3.5). Taken together, these 
results suggest that in the context of cHL and ALCL dexamethasone treatment would 
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fail to confer a therapeutic benefit related to targeting CSF-1R using CAR-engineered 
T-cells (Appendix, Figure S2). 
 
Glucocorticoid receptors are largely expressed in inflammatory cells, notably 
macrophages, which play a key role in inflammation [346]. As expected, 
dexamethasone treatment of human monocyte derived macrophages resulted in 
marked up-regulation of CSF-1R at 48h (Figure 3.6).  
 
Overall, the data presented in this chapter show that CSF-1R is an attractive candidate 
target in cHL and ALCL. However, it is also a challenging target in these diseases 
owing to the endogenous production of both ligands (CSF-1 and IL-34), feeding into an 
autocrine loop that is likely to promote rapid internalisation of the ligand-receptor 
complex. Furthermore, dexamethasone treatment of the panel of lymphoma cell lines 
failed to induce a significant up-regulation of CSF-1R expression, unlike the situation 
observed in dexamethasone-treated macrophages. Consequently, I next set out to 
examine if CAR T-cells would be able to detect cell surface expression of CSF-1R by 








Chapter 4 Design, cloning and in vitro characterization of CSF-
1R-targeted chimeric antigen receptors  
 
4.1  Introduction  
In recent years, we have witnessed a sea-change in the manner with which cellular 
therapies are viewed by the clinical community and the pharmaceutical industry. 
Building on the exciting momentum engendered by CD19 CAR T-cells, there is every 
prospect that genetically engineered lymphocytes will provide a rich source of new 
medicines to treat human disease. 
 
Several challenges will guide the next stages of development of CAR T-cell 
immunotherapy of cancer. First, development of effective therapeutic regimens for solid 
tumours will require renewed efforts to address the problem of the tumour 
microenvironment, which imposes a hypoxic, metabolic and immunological ambiance 
that is poorly conducive to effective immunotherapy. A number of approaches to 
address this issue have been presented below and doubtless several more strategies 
will emerge in the near future.  
 
4.1.1 Recent developments in pre-clinical CAR engineering  
Several new approaches have been described recently that aim to refine the precision, 
potency and safety of immunotherapy using CAR T-cells. 
 
4.1.1.1 Dual Targeting Using CAR T-cells 
One emerging strategy involves the separation of signalling domains between two co-
expressed CARs with distinct target specificities, thereby delivering complementary 
signals in trans (Figure 4.1, B). Exemplifying this approach, HER2- and MUC1-specific 
CARs were co-expressed that signal through CD3ζ and CD28 respectively [347]. 
Tumour cell lysis and efficient T-cell proliferation was only achieved upon interaction  
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Figure 4.1 Chimeric antigen receptor configurations.  
(A) First generation CARs contain a single endodomain module that delivers signal 1, most 
commonly CD3ζ or FcR1. Second and third generation CARs contain in addition either one or 




with cells that expressed both CAR targets. Recently Kloss et al. [348] refined this 
strategy using a model in which CARs for two prostate cancer antigens were co-
expressed. Each CAR promoted sub-optimal T-cell activation when engaged alone. 
However, potent anti-tumor activity was observed upon simultaneous target binding. 
Such a dual targeting system can potentially reduce reactivity against healthy tissues 
that may express single targets but, on the other hand, it may also increase the 
possibility of tumour escape through antigen loss. The latter is illustrated by the 
unfortunate outgrowth of CD19neg blast cells in a number of patients with acute 
lymphoblastic leukaemia (ALL) following treatment with CD19-targeted CAR T-cells 
(Table 1.4) [202, 210]. 
 
  
(B) Dual targeted CARs bind to distinct targets and signal via complementary endodomains 
(e.g. providing signal 1 and 2 respectively). (C) “TanCARs” contain two targeting moieties, 
joined in tandem in the CAR ectodomain. (D) An alternative device to deliver co-stimulation to 
CAR T-cells entails the co-expression of one or more co-stimulatory ligands. In the example 
shown, the CAR T-cells co-express B7-1 and 4-1BB ligand, which can provide co-stimulation 
by engagement of CD28 and 4-1BB, both in the same T-cell (auto-costimulation) and 
neighbouring T-cells (trans-costimulation). (E) Inhibitory CARs may be co-expressed that 
serve to attenuate positive signals delivered by activating CARs. By this means, T-cell 
activation can be restricted to target cells that only express the ligand for the activating but not 






A further modification of the dual targeting approach involves the expression of CARs 
that can simultaneously bind to more than one target molecule in tandem (Figure 4.1, 
C). Such “TanCARs” are designed as a single CAR molecule in which two or more 
scFvs are joined using a linker, thereby conferring a plurality of target specificities 
[349]. An advantage of the TanCAR approach is that T-cells exhibit cytolytic activity 
against tumour cells that express only one of the targets while synergistic 
enhancement of effector function may be achieved when more than one antigen is 
encountered [349]. 
 
A further dual targeting system entails the co-expression of one or more co-stimulatory 
ligands with a first generation CAR (Figure 4.1, D). This approach has proven to be 
strongly efficacious in some pre-clinical models [350] although concerns remain that 
such constitutive co-stimulation may promote autoimmune toxicity. 
 
4.1.1.2 Optimizing safety of CAR T-cells 
Clinical experience with CAR T-cells has highlighted the significant risk of these cells to 
induce cytokine release syndrome (CRS) and other on-target toxicities. Consequently, 
a number of “suicide gene” systems have been developed that can be co-expressed 
with the CAR of interest and which may be activated when required in a 
pharmacologically-regulated manner. Greatest clinical experience has been gained 
with the herpes simplex virus thymidine kinase gene, which confers sensitivity to 
ganciclovir, but which is immunogenic when infused in immune competent recipients 
[351]. An increasingly used alternative is inducible caspase 9, which can be activated 
by a chemical inducer of dimerization and leads to extraordinarily rapid ablation of 
gene-modified cells [352, 353]. Thirdly, an epitope tag may be co-expressed in CAR T-
cells, allowing their elimination upon administration of a clinically licensed monoclonal 




While all of these ablative strategies have their merits, it is ultimately preferable to 
devise safer systems that would not require the elimination of therapeutically active 
cells. Some recent developments suggest that this may be an attainable goal. Since 
there is a paucity of tumour-specific targets, CAR T-cells are commonly engineered to 
bind molecules that are over-expressed in transformed cells, but are found at lower 
levels in healthy tissues. Consequently, it is desirable to enable therapeutically active 
cells to discriminate between tumour cells that express targets at high levels while 
ignoring healthy tissues where lower amounts may be present. One strategy to achieve 
this entails the co-expression of activating and inhibitory CARs in the same lymphoid 
population (Figure 4.1, E) [356]. The principle underlying this approach is that a potent 
inhibitory CAR (e.g. containing a PD-1 endodomain) can be used to neutralize the 
activating signal delivered by a co-expressed CAR in healthy tissues in which both 
targets are co-expressed at comparable levels. By contrast, if a transformed cell only 
expresses the target recognized by the activating CAR, but not that bound by its 
inhibitory counterpart, then tumour cell destruction occurs. Clinically applicable systems 
that exploit this principle have great potential to facilitate the safer development of CAR 
T-cell immunotherapy for common solid tumour types. 
 
4.1.1.3 Potentiating CAR T-cells by co-expression of cytokines 
While CAR T-cells have achieved notable successes against haematological 
malignancy, impact against solid tumours has proven more elusive. However, several 
strategies that are undergoing experimental development may help to address this 
deficit. One approach entails the co-expression of a tumour-specific CAR and a 
cytokine that can potentiate anti-tumour activity. Several groups have co-expressed 
CARs with IL-12, [357-360] a cytokine that exerts pleiotropic supportive effects upon 
innate immune cells within the tumour microenvironment [359]. Use of IL-12-expressing 
CAR T-cells obviated the need for prior lymphodepletion in one model system [361]. 
Alternatively, in vivo longevity and potency of CAR T-cells may be enhanced by co-
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expression of a common gamma cytokine in these cells, such as IL-2, IL-7, IL-15 or IL-
21 [362, 363]. 
 
4.1.1.4 Potentiating CAR T-cells by co-expression of cytokine receptors 
Persistence of CAR T-cells may also be enhanced by co-transfer of genes that confer 
responsiveness to a cytokine that can be administered with therapeutic intent, such as 
IL-7 [364] or IL-4 [365]. Alternatively, responsiveness may be conferred in a similar 
manner to cytokines that are naturally over-produced in the tumor microenvironment, 
such as IL-4 [365] or colony-stimulating factor-1 (CSF-1) [366]. 
 
4.1.1.5 Potentiating CAR T-cells by co-expression of chemokine receptors 
In a related approach, migration of CAR T-cells to the tumour microenvironment may 
be enhanced by co-expression of a receptor that confers responsiveness to one or 
more tumour-associated chemokines (e.g. CXCR2, which binds several chemokines 
including CXCL1 and 8; [367, 368] CCR2b, which binds CCL2; [369, 370] or CCR4, 
which binds CCL17) [371]. Alternatively, T-cells may be harnessed to undergo 
chemotactic migration in response to other tumour-derived cytokines (e.g. by 
expression of CSF-1 receptor, which binds CSF-1) [372]. 
 
4.1.1.6 Optimizing differentiation status of CAR T-cells 
Another approach to improve efficacy of CAR T-cell immunotherapy involves the use of 
specific lymphoid subsets that have greater potential for in vivo persistence, such as 
central memory T-cells [373]. Indeed, recent evidence suggests that T-cells lying 
between the naive and central memory stages of differentiation may be even more 
suitable for this purpose [374, 375]. These so-called memory stem cell T-cells (TSCM) 
express a CD45RA+CD62L+CCR7+CD95+ phenotype and can be propagated ex vivo 
after CD3/CD28 engagement in the presence of IL-7 and IL-15. This expansion 
protocol allows for both a high efficiency expansion with retention of self-renewal 
155 
 
potential, rendering these cells of great interest for use in adoptive T-cell 
immunotherapy [376, 377]. 
 
In summary, a large number of innovative approaches continues to be described that 
have the potential to enhance the efficacy of CAR T-cell immunotherapy. This provides 
a rich pipeline of candidate approaches for future clinical evaluation across a spectrum 
of malignant disorders. 
 
4.2 Results 
I set out to develop a CAR-based immunotherapeutic approach directed against the 
up-regulated expression of CSF-1R in cHL and ALCL. Both naturally occurring CSF-1R 
ligands were used as antigen recognition domains in the design of a panel of eight 
CSF-1R targeting CARs, which can be provisionally divided into 3 groups:  
 CSF-1-based CARs – CSF-1 was used as a targeting moiety for the 
construction of a second generation CAR (CD28-CD3ζ) termed “C4”, a third 
generation CAR (CD28-4-1BB-CD3ζ) termed “C4B” and a truncated CAR with 
no signalling domains, named “CT4”.  
 IL-34-based CARs – this group comprises a truncated CAR (“434Tr”), a second 
(“43428ζ”) and a third generation (“43428Bζ”) CARs similar to the CSF-1-based 
CARs, but employing IL-34 as antigen-recognition domain.  
 Double targeting CARs – employ both CSF-1 and IL-34 as targeting domains, 
which are coupled to CD28-CD3ζ and 4-1BB, or vice versa (termed “C34B” and 
“34CB” respectively). The dual targeted CAR combinations were then 
stoichiometrically co-expressed in the same T-cell population using a Thosea 
Asigna (T)2A-containing retroviral vector. 
 
Please refer to Figure 2.1 (page 74) and Figure 2.2 (page 80) for schematic 




4.2.1 Cloning of CSF-1R-targeting CAR constructs 
All CARs have been expressed using the SFG onco-retroviral expression vector [268]. 
All constructs apart from SFG C28ζ and SFG CTr were designed and cloned over the 
course of the project using the Polymerase Incomplete Primer Extension (PIPE) 
cloning method (please refer to section 2.1.2).  
 
Construction of SFG C4 (4αβ + C28ζ) was achieved by PIPE PCR. Two fragments of 
the SFG C28ζ plasmid containing PIPE overhangs were amplified and are denoted as 
fragment 1 (4819 bp) and fragment 2 (2756 bp) (Figure 4.2, A and B). Then, the 4αβ-
furin-T2A cassette was PIPE PCR amplified from the SFG T4 plasmid (courtesy of Dr 
David Davies, King's College London) to generate a 4αβ fragment (1714 bp) with PIPE 
overhangs. Next, all PIPE PCR products were subjected to DpnI digestion in order to 
destroy any remaining intact SFG template, which would contaminate the subsequent 
ligation reaction. Following the DpnI digestion, the three un-purified self-complementary 
PIPE PCR products were mixed in 1:1:1 molar ratio, incubated at 60oC for 30 min and 
transformed into E.coli. Successful transformants were verified by analytical digestion 
with NcoI/NotI and run on 1% agarose gel (Figure 4.3, A). Restriction digestion yielded 
the following 3 bands, which were separated by agarose gel electrophoresis: SFG 
backbone (≈7000 bp), 4αβ (≈1700 bp) and the targeting moiety CSF-1 (≈500 bp). All 
bands were of the predicted sizes. A similar cloning strategy was employed for SFG 
CT4 using SFG CTr as template (Figure 4.3, A).  
 
The construct SFG C34B (4αβ + C28ζ + 34B) was designed to explore the possibilities 
of dual CAR-based targeting of CSF-1R (Figure 2.1 and 2.2). In order to construct this, 
a second CSF-1R-targeting CAR was designed, termed 34B. The 34B construct was 
designed together with a second codon “wobbled” T2A DNA sequence, placed in the 
upstream position. Sequences were codon optimised as a cDNA cassette, which was 
synthesised by GenScript. Cloning of SFG C34B was achieved by PIPE PCR 
linearising SFG C4 and PIPE PCR amplifying the cDNA cassette. The self-
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complementary PIPE PCR products were then mixed to assemble the complete SFG 
C34B construct. Successful cloning was confirmed by restriction pattern agarose gel 
analysis. An NcoI/XhoI restriction digestion generated the predicted 3 bands as follows: 
SFG backbone (≈6300 bp), 4αβ (≈1700 bp) and both CAR cDNAs contained within one 
band (≈2400 bp) (Figure 4.3, B).  
 
The constructs SFG 43428ζ (4αβ + 3428ζ) and SFG 434Tr (4αβ + 34Tr) were PIPE 
cloned by swapping the CSF-1 targeting moiety in SFG C28ζ and SFG CTr 
respectively with IL-34. To achieve this, three primer pairs were designed (please refer 
to Table 2.1). The first two vector-specific primer pairs, flanking the existing CSF-1, 
were used for amplification of two vector fragments, while the last primer pair, with 5′-
vector-fragment-end overlapping sequences, was used for amplification of the 
incoming IL-34 sequence. Successful transformants were characterized by loss of the 
second NcoI site flanking 4αβ and upon NcoI/XhoI restriction digestion generated 2 
bands, separated on a gel: SFG backbone (≈6000 bp) and 4αβ + CAR in one band (for 
SFG 43428ζ ≈3100 bp while for SFG 434Tr ≈2700 bp) both bands with the predicted 
sizes (Figure 4.3, C and D). 
 
To generate the SFG 34CB construct (4αβ + 3428ζ + CB), the SFG C34B construct 
was used as template and four primer pairs were designed. The first two vector-specific 
primer pairs, flanking the existing CSF-1 and IL-34 sequences, were used for 
amplification of 2 vector fragments. The second two primer pairs, with 5′-vector-
fragment-end overlapping sequences, were used for amplification of the incoming IL-34 
and CSF-1 sequences with swapped places. The four PCR products were used in an 
enzyme-free ligation to generate the SFG 34CB construct. Successful cloning was 
verified by BamHI restriction digestion, which generated 3 bands, separated on a gel: 
SFG backbone + 4αβ in one band (≈7700bp), 3428ζ (≈1800bp) and CB (≈950bp) all of 




For the construction of SFG C4B (4αβ + C28Bζ) and SFG 43428Bζ (4αβ + 3428Bζ), 
SFG C4 and SFG 43428ζ were used as templates respectively. In each case template-
specific primers were used for PCR SFG template linearization at the site of fusion 
between the intracellular domains of CD28 and CD3ζ within the C28ζ construct or the 
3428ζ construct, thereby generating single-stranded 5′-ends. Simultaneously, the 4-
1BB sequence was PCR amplified using a pair of 40 bp primers with 5′-end 
overlapping sequences, thereby generating single-stranded template-end homologous 
products, which were then used in a enzyme-free ligation to generate the SFG C4B 
and SFG 43428Bζ constructs. Successful cloning was confirmed by restriction pattern 
agarose gel analysis. A NotI/XhoI restriction digestion generated 2 bands: SFG 
backbone along with 4αβ and the targeting moiety from the respective CAR (≈9000 
bp), and a smaller band representing the signalling domains CD28 + 41BB + CD3ζ 
(≈800bp) (Figure 4.3, F).  
 
All SFG constructs were subsequently sequenced and no mutations were identified 






Figure 4.2 Schematic representation of SFG C4 PIPE cloning strategy.  





(A) SFG C28ζ was linearised using PIPE PCR (fragment 1 and 2). Simultaneously, the 4αβ-
furin-T2A cassette was PIPE PCR amplified generating fragment 3. The resultant three PIPE 
PCR products were subjected to DpnI digestion and incubated for 30min at 60oC and then 
transformed into E. coli. (B) PIPE PCR products were run on 1% agarose gel electrophoresis 





Figure 4.3 Restriction pattern agarose gel analysis of SFG C4, C4B, CT4, C34B, 43428ζ, 
43428Bζ, 434Tr and 34CB.  
Successful transformants were verified by analytical digestion with appropriate restriction 
enzymes so that the pattern of fragments on the gel can indicate if the plasmid contains the 






(A) NcoI/NotI restriction digestion of SFG C4 and SFG CT4 generated 3 bands with the 
predicted sizes: SFG backbone (≈7000 bp), 4αβ (≈1700 bp) and the targeting moiety CSF-1 
(≈500 bp). (B) SFG C34B was subjected to NcoI/XhoI restriction digestion yielding 3 bands of 
expected sizes: SFG backbone (≈6300 bp), 4αβ (≈1700 bp) and both CARs in one band 
(≈2400 bp). (C) and (D) SFG 43428ζ and 434Tr were digested with NcoI/XhoI generating 2 
bands, separated on a gel: SFG backbone (≈6000 bp) and 4αβ + CAR in one band (for SFG 




4.2.2 Establishing stable CAR-expressing retroviral packaging cell lines 
In general, gene transfer undertaken in this project has been achieved using 
engineered retroviruses, thereby permitting stable CAR expression. This has been 
achieved through the establishment of two stable CAR-expressing retroviral packaging 
cell lines derived from PG13 and 293Vec RD114 cell lines (see section 2.2.2.3). Of 
note, 293Vec RD114 packaging cell line produces about 100-fold higher viral titres than 
PG13 cells do. Both retroviral packaging cell lines were generated in a two-step 
process involving transfection of H29D retroviral packaging cells (see section 2.2.2.3) 
and subsequent PG13 or 293Vec RD114 retroviral transduction using the transiently 
produced H29D-derived viral particles (Figure 4.4 and 4.5).  
 
 
(E) SFG 34CB was digested with BamHI and run on a 1% gel. Upon restriction, 3 bands were 
visible on a gel: SFG backbone + 4αβ in one band (≈7700bp), 3428ζ (≈1800bp) and CB 
(≈950bp) all of them with the predicted sizes. (F) SFG C4B and SFG 43428Bζ were digested 
with NotI/XhoI generating 2 bands, separated on a gel: SFG backbone along with 4αβ and the 
targeting moiety from the respective CAR (≈9000 bp), and a smaller band representing the 





Figure 4.4 Establishing stable PG13 C4, C4B, CT4, 43428ζ, 43428Bζ, 434Tr, C34B and 34CB packaging cell 
lines. The H29D retroviral packaging cell line was transfected with the appropriate SFG CAR-containing vector and 
viral particles were used to generate stable PG13 retroviral packaging cell lines. (A) and (E) PG13 cells were stained 
with goat anti-human CSF-1 antibody followed by anti-goat-Ig-FITC conjugate for the detection of CSF-1-based CARs 
(red histogram). (C) and (F) were stained with mouse anti-human IL-34 PE-conjugated antibody for the detection of IL-
34-based constructs (purple histogram). (B), (D) and (G) PG13 cells were stained with anti-IL4Rα-PE for the detection 






Figure 4.5 Establishing stable 293Vec RD114 C4, C4B, CT4, 43428ζ, 43428Bζ, 434Tr, C34B and 34CB 
packaging cell lines. Stable 293Vec RD114 CAR-expressing packaging cell lines were established by H29D 
transfection with the appropriate SFG CAR-containing vector and subsequent transduction. (A) and (E) 293Vec cells 
were stained with goat anti-human CSF-1 antibody followed by anti-goat-Ig-FITC for the detection of CSF-1-based 
CARs (red histogram). (C) and (F) were stained with mouse anti-human IL-34 PE antibody for the detection of IL-34-
based constructs (purple histogram). (B), (D) and (G) 293Vec cells were stained with anti-IL4Rα-PE for the detection 




4.2.3 Expression of CSF-1R-targeting CARs on primary human T-cells 
Prior to testing the anti-tumour activity of the CSF-1R-targeting CARs, it was crucial to 
demonstrate their stable expression in primary human T-cells. Following gamma 
retroviral-mediated gene transfer from PG13 or 293Vec RD114 packaging cell lines, T-
cells were tested for cell surface expression of the CARs using flow cytometry. As 
shown in Figure 4.6, A, the CARs could be detected at the cell surface, thus indicating 
that the constructs were expressed, folded and trafficked correctly to the plasma 
membrane. 
 
The expression of the 4αβ construct by T-cells provides means for selective expansion 
and enrichment of CAR+ T-cells in the presence of IL-4 [378]. Consequently, when 
cultured in the presence of IL-4 for 12 days, the CAR+ T-cells received an IL-2/IL-15-
like signal, thereby gaining a distinct proliferative advantage over untransduced T-cells. 
This resulted in the selective enrichment of the CSF-1R-targeting CAR+ T-cell 
population, even in the absence of antigen (Figure 4.6, B).  
 
To further confirm CAR expression, T-cells were lysed following retroviral-mediated 
gene transfer and investigated for the presence of the genetically engineered receptor 
using western blotting. Samples were run under reducing conditions to allow for the 
detection of monomeric CAR chains. Lysates were probed for the presence of the CAR 
through detection of the CD3ζ chain. The presence of 44-55kDa bands within the C4, 
C4B, C34B, 43428ζ, 43428Bζ and 34CB samples correlate well with the predicted 
molecular weights of the CAR constructs (44kDa, 48kDa, 44 kDa, 51kDa, 55kDa and 
51kDa respectively) for all but the double targeting constructs C34B and 34CB, which 
travelled as 2kDa heavier bands than their predicted molecular weight (Figure 4.6, C). 
The absence of banding within the CT4 and 434Tr samples was expected due to the 
lack of the CD3ζ domain. The endogenous CD3ζ chain (16kDa) served as a 




As shown on Figure 4.6, D, the average T-cell transduction efficiency was comparable 
across the panel of CSF1-R-targeting CARs, following IL-4-mediated enrichment for 12 
days. These data have been normalized against untransduced T-cells from the same 
donors stained using the same antibody combination. 
 
Taken together, these data demonstrate that T-cells can be efficiently transduced to 
express a variety of CSF-1R-targeted CARs. Moreover, CAR expression remained 
stable for a number of days, even in the absence of antigen, which is crucial for the 






Figure 4.6 Expression of a panel of CSF-1R-targeting CARs in primary human T-cells.  
Expression of various CAR constructs was detected at the cell surface of primary human T-cells as assessed by flow cytometry at Day 3 post T-cell transduction (A) 









using a goat polyclonal anti-human CSF-1 antibody, followed by a FITC-conjugated secondary antibody (pink histogram). Level of expression of IL-34-based CARs 
was assessed using mouse anti-human IL-34 antibody directly conjugated to PE. The level of expression in both cases was compared to untransduced T-cells 
probed with the same antibody combinations (blue histogram). (C) CAR-grafted T-cells were lysed under reducing conditions and the lysates probed for the 
presence of the CAR using SDS-PAGE. Detection of the CAR and the CD3ζ chain loading control was achieved using a mouse monoclonal anti-human CD3ζ 
antibody followed by a rabbit anti-mouse IgG HRP-conjugated secondary antibody and subsequent development using enhanced chemiluminescence (ECL). (D) 
Average T-cell transduction efficiency for the different CAR constructs was calculated from 10 separate experiments. Data are presented as mean ± standard 




4.2.4 Validation of the anti-tumour potential of CSF-1R-targeted CAR+ T-
cells 
In order to determine the cytotoxic activity of CSF-1R-targeted CAR+ T-cells, 
experiments were performed with human breast cancer monolayers that were 
discordant for target antigen expression. This was achieved by co-cultivating CAR+ T-
cells with T47D breast cancer cells and T47D FMS, a derivative that has been 
genetically engineered to express high levels of CSF-1R (Figure 3.1, C).  
 
An MTT assay was used to measure tumour cell destruction, which negatively 
correlates with formazan dye production. In this assay, mitochondrial dehydrogenase-
catalysed conversion of a tetrazolium salt to a formazan dye indicates metabolic 
activity and therefore the presence of viable cells. The absorbance of the formazan dye 
product may be subsequently quantified and compared to the maximal formazan dye 
production (as determined by target cells grown in the absence of T-cells), providing a 
measure of target cell viability (please refer to section 2.2.9.1 for more details).  
 
As shown in Figure 4.7, A, co-culture of T47D FMS with CSF-1R re-directed CAR+ T-
cells overnight at a 1:1 ratio resulted in complete target cell lysis in the presence of 
C4+, C4B+, C34B+, 43428ζ+, 43428Bζ+ and 34CB+ T-cells, while no cytotoxicity was 
recorded in the control groups (CT4+, 434Tr+ and UT T-cells). No significant destruction 
of the parental T47D cell line was detected (Figure 4.7, B). These data confirm that 
both CSF-1 and IL-34-targeted CARs can specifically engage CSF-1R-expressing 








Figure 4.7 Target cell destruction following T-cell co-culture.  
Human T-cells were engineered to express the indicated CARs and were cultured in IL-4 for 12 
days. Engineered T-cells were then co-cultivated overnight (1:1 ratio) with T47D FMS (A) or 
T47D (B) target cells. Residual tumour cell viability was determined using the MTT assay. 
Following gentle removal of T-cells by washing, the monolayers were incubated with a 
tetrazolium salt solution for 2 hours and the production of a formazan dye measured by 
absorbance at 570nm thereafter. Data were normalized against the maximal formazan dye 
production, as generated by tumour cells grown in the absence of T-cells. Normalization was 

























































































4.2.5 Antigen-specific activation of CSF-1R-targeted T-cells 
The activation of CSF-1R re-targeted CAR+ T-cells in the presence or absence of the 
target (T47D FMS/ T47D co-cultures) was compared to that achieved with 
untransduced T-cells and the matched signalling-incompetent truncated CAR 
constructs. During the co-culture period, T-cell activation was monitored by 
measurement of the release of IFN-γ (Figure 4.8, A) and IL-2 (Figure 4.8, B). 
Significantly higher levels of both cytokines were produced upon co-culture of C4+, 
C4B+, C34B+, 43428ζ+, 43428Bζ+ and 34CB+ T-cells with the T47D FMS monolayer, 
when compared to matched co-cultures with untransduced, CT4+ or 434Tr+ control T-
cells. No cytokine release was detected when CAR T-cells were cultured alone or co-
cultivated with unmodified T47D cells (Figure 4.8), thereby confirming that CAR+ T-cell 













Tumour cell viability = (Sample MTT value/Average no T-cell MTT value)*100 
Data were analysed using one-way ANOVA followed by a Tukey post-hoc test and were 
presented as mean ± standard deviation of 12 independent replicate experiments. 








Figure 4.8 Antigen-dependent production of IFN-γ and IL-2 by CAR+ T-cells.  
A panel of CSF-1R-targeting CAR-engrafted and untransduced (UT) T-cells were co-cultured 
with T47D FMS and T47D cell lines. Supernatants were removed after 24 hours and analysed 
for IFN-γ (A) and IL-2 (B) release using a sandwich ELISA. Data is presented as mean ± 
standard deviation from three independent experiments. **** = p<0.0001; *** = p<0.001; ** = 
p<0.01; * = p<0.05. Unless indicated otherwise, asterisks above a bar indicate that the CAR+ T-
cells secrete significantly more cytokine on that particular cell line than on any other cell line or 














































































































































































































A.                  T47D FMS                 T47D          T-cells alone 
B.                  T47D FMS                 T47D          T-cells alone 
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4.2.6 Proliferative capacity of CSF-1R re-targeted T-cells upon serial re-
stimulation 
In order to investigate the ability of CSF-1R re-targeted CARs to promote T-cell 
proliferation upon multiple rounds of in vitro antigen exposure, co-culture experiments 
were performed with T47D FMS breast cancer cells. T-cells were subjected to 
successive rounds of antigen stimulation in the absence of exogenous cytokines. 
Stimulation was provided by weekly culture on T47D FMS monolayers and T-cell 
numbers were enumerated at the indicated intervals (Figure 4.9).  
 
Pooled data from 7 similar replicate experiments are shown in Figure 4.9, indicating the 
fold expansion of CAR T-cells that occurred in the week after each cycle of stimulation. 
At the time of each re-stimulation cycle, T-cells were tested for their ability to kill T47D 
FMS and unmodified T47D monolayers (Figure 4.10). One day after each cycle of 
stimulation, supernatant was removed from these cultures and tested for IL-2 and IFN-
γ content by ELISA (Figure 4.11). As shown on Figures 4.9, 4.10 and 4.11, the double 
targeting C34B CAR repeatedly outperformed conventional second and third 
generation CARs by maintaining high proliferative capacity, cytotoxic potential and 









































Figure 4.9 Antigen (Ag)-dependent proliferation of CAR+ T-cells.  
Human T-cells were engineered to express the indicated CARs. CAR T-cells were subjected to successive rounds of antigen 
stimulation (fresh T47D FMS monolayers at 7-day intervals) in the absence of exogenous cytokines and T-cell numbers were 





Figure 4.10 Antigen (Ag)-specific cytotoxicity of CAR+ T-cells is maintained upon serial 
re-stimulation.  
A panel of CSF-1R-targeting CAR-grafted T-cells were subjected to successive rounds of 
stimulation in the absence of exogenous cytokine support either in the presence (T47D FMS 
monolayer) or absence (T47D monolayer) of the antigen. At the time of each re-stimulation 
cycle, cell viability following overnight incubation with CAR+ or untransduced T-cells (1:1 ratio) 





Normalization was achieved using the following equation:  
Tumour cell viability = (Sample MTT value/Average no T-cell MTT value)*100 
Upon each cycle of re-stimulation, cytotoxicity was quantified at 24h with the exception of the 
last Ag-stimulation (Ag-stimulation 14), which was measured at 72h. Data are representative 







Figure 4.11 Antigen-specific cytokine release by CAR+ T-cells is maintained upon serial 
re-stimulation.  
A panel of CSF-1R-targeting CAR-grafted T-cells were subjected to successive rounds of 
stimulation on T47D FMS monolayers, in the absence of exogenous cytokine support. One day 
after each cycle of stimulation, supernatant was removed from these cultures and tested for IL-2 
(A) and IFN-γ (B) release by sandwich ELISA. Data are representative of seven experiments 




4.2.7 Targeting cHL and ALCL cell lines using CSF-1R re-targeted T-cells 
In order to investigate whether CSF-1R re-targeted T-cells have the ability to recognize 
lymphoma cells in vitro, a series of co-culture experiments were undertaken with a 
panel of cHL and ALCL lymphoma cell lines. One possible way of determining the 
cytotoxic potential of T-cells is by target cell labelling prior to co-culture with T-cells. 
Common labelling reagents include the radioisotope 51chromium [149], the fluorescent 
ester calcein-acetoxymethyl (calcein-AM) [379] and carboxyfluorescein succinimidyl 
ester (CFSE) [380]. 
 
A more elegant alternative to the target cell CFSE labelling approach (Appendix, Figure 
S3) was achieved by stably expressing both a firefly luciferase enzyme and the red 
fluorescent protein tdTomato in the lymphoma cell lines. Expression of both genes from 
one open reading frame was achieved by inserting a furin cleavage site followed by a 
flexible serine-glycine linker and a T2A sequence between them. Both genes were 
cloned as a single cDNA cassette, flanked by NcoI/XhoI restriction sites within the SFG 
retroviral vector (SFG LuciTom) (Figure 4.12, A). The tdTomato red fluorescent protein 
emits bright red fluorescence at a peak wavelength of 581nm. It was used as a 
fluorescent reporter for the identification of tumour cells within a co-culture with CAR+ 
T-cells. Firefly luciferase catalyses the conversion of a molecule of D-luciferin to an 
electronically ‘excited’ molecule of oxyluciferin when in the presence of magnesium, 
ATP and oxygen. Since dead cells cannot catalyze this reaction, the number of viable 
cells determined the amount of luminescence detected, indicating the degree of 
cytotoxicity caused (please refer to section 2.2.9.3 for more details).  
 
A PG13 LuciTom retroviral packaging cell line was generated in a two-step process 
involving H29D transfection and subsequent PG13 retroviral transduction (Figure 4.12, 
B). The PG13-derived viral particles were then used to establish stable expression of 
the SFG LuciTom construct in the panel of lymphoma cell lines (Figure 4.12, C, D and 
E). Transduced lymphoma cells were then cell sorted to achieve >90% LuciTom+ (LT+) 
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expression in the population. Furthermore, LuciTom expression was maintained over a 
prolonged period in culture, highlighting successful integration of the cDNA into the 
recipient genome. 
 
As the overall aim of this project was to determine whether CSF-1R re-targeted T-cells 
represent a potential therapy for cHL and ALCL, it was important to determine their 
ability to destroy cHL and ALCL cell lines in vitro. Lymphoma cell lines were co-cultured 
at a 1:1 ratio with CAR+ or untransduced (UT) T-cells and co-cultures were probed for 
luciferase activity at 24h, 48h, 72h, 96h, 120h, and 144h, providing a measure of target 
cell viability. The data was normalized against the maximal luminescence, as shown by 
tumour cells grown in the absence of T-cells. As shown on Figure 4.13, 4.14, 4.15, 
4.16, 4.17 and 4.18 co-culture of CAR+ T-cells resulted in variable clearance of the 
target cells – from complete destruction (DEL cell line at 48h) to 50% residual viable 
cells (K299 cell line at 144h). Results are representative of 5 separate experiments. 
Overall, CSF-1-based CARs elicited higher target cell lysis than IL-34-based CARs, 
with no significant difference in the cytotoxic potency of second and third generation 
CARs within each group (Appendix, Table S1). Importantly, there was no reduction in 
lymphoma cell viability upon incubation with either CT4+, 434Tr+ or UT T-cells, when 





   
Figure 4.12 Stable expression of the SFG LuciTom construct in lymphoma cell lines. (legend continues on next page) 
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4.2.8 Determination of CSF-1R re-targeted T-cell activation on cHL and 
ALCL cell lines. 
The secretion of IFN-γ and IL-2 by CSF-1R re-targeted T-cells was dependent upon 
recognition of target antigen, as indicated by detection of high levels of both cytokines 
following co-culture with T47D FMS cells. Furthermore, CAR-transduced cells were not 
constitutively active as demonstrated by the lack of cytokine secretion upon co-culture 
with T47D cells (Figure 4.8).  
 
To investigate whether expression of CSF-1R-targeted CARs enabled re-direction of T-
cell specificity against cHL and ALCL, engineered T-cells were co-cultured with a panel 
of lymphoma cell lines (Figure 4.19 and 4.20). A substantially (and in many cases 
significantly) greater concentration of IFN-γ (Figure 4.19) and IL-2 (Figure 4.20) was 
detected in the co-cultures with C4+, C4B+, C34B+, 43428ζ+, 43428Bζ+ and 34CB+ T-
cells when compared to CT4+, 434Tr+ or UT T-cells. No statistically significant 
differences in cytokine production were detected between double targeting, second and 
third generation CARs or between CSF-1-based and IL-34-based CAR-grafted T-cells 
(Appendix, Table S2).  
 
Taken together, cytotoxicity and cytokine release data show that CSF-1R re-targeted 
T-cells but not control T-cells can be specifically re-directed in vitro against cHL and 
ALCL cell lines.  
 
(A) Structure of the SFG LuciTom retroviral vector. Stoichiometric co-expression of ffLuciferase 
and tdTomato is achieved through the use of a T2A sequence. (B) A stable PG13 LuciTom 
expressing retroviral packaging cell line was established, as verified by flow cytometry and the 
collected viral particles were used for transduction of a panel of lymphoma cell lines. Successful 
transduction was verified by fluorescence microscopy (C) and flow cytometry (D). Transduced 
lymphoma cell lines were annotated with “LT” after their name (e.g. DEL LT) and, following cell 










































































Figure 4.13 Cytotoxicity of CSF-1R-retargeted T-cells against the KM-H2 cell line in vitro.  
The cHL cell line KM-H2 was co-cultured with a panel of CAR-grafted T-cells at a 1:1 ratio for the indicated period of time. The level of 
target cell viability following co-culture was monitored using a luciferase assay. Data were normalised against the maximal luminescence, 
as shown by tumour cells grown in the absence of T-cells. Normalization was achieved using the following equation: Tumour cell viability 
= (Sample luminescence value / Average luminescence value when no T-cells added)*100. Data are presented as mean ± SD from five 




























































Figure 4.14 Cytotoxicity of CSF-1R-retargeted T-cells against the K299 cell line in vitro.  
The ALCL cell line K299 was co-cultured with a panel of CAR-grafted T-cells at a 1:1 ratio for the indicated period of time. The level of 
target cell viability following co-culture was monitored using a luciferase assay. Data were normalised against the maximal luminescence, 
as shown by tumour cells grown in the absence of T-cells. Normalisation was achieved using the following equation: Tumour cell viability 
= (Sample luminescence value / Average luminescence value when no T-cells added)*100. Data are presented as mean ± SD from five 


























































































Figure 4.15 Cytotoxicity of CSF-1R-retargeted T-cells against the DEL cell line in vitro.  
The ALCL cell line DEL was co-cultured with a panel of CAR-grafted T-cells at a 1:1 ratio for the indicated period of time. The level of 
target cell viability following co-culture was monitored using a luciferase assay. Data were normalised against the maximal luminescence, 
as shown by tumour cells grown in the absence of T-cells. Normalisation was achieved using the following equation: Tumour cell viability 
= (Sample luminescence value / Average luminescence value when no T-cells added)*100. Data are presented as mean ± SD from five 



















































































Figure 4.16 Cytotoxicity of CSF-1R-retargeted T-cells against the FE-PD cell line in vitro.  
The ALCL cell line FE-PD was co-cultured with a panel of CAR-grafted T-cells at a 1:1 ratio for the indicated period of time. The level of 
target cell viability following co-culture was monitored using a luciferase assay. Data were normalised against the maximal luminescence, 
as shown by tumour cells grown in the absence of T-cells. Normalisation was achieved using the following equation: Tumour cell viability 
= (Sample luminescence value / Average luminescence value when no T-cells added)*100. Data are presented as mean ± SD from five 












































































Figure 4.17 Cytotoxicity of CSF-1R-retargeted T-cells against the JB6 cell line in vitro.  
The ALCL cell line JB6 was co-cultured with a panel of CAR-grafted T-cells at a 1:1 ratio for the indicated period of time. The level of 
target cell viability following co-culture was monitored using a luciferase assay. Data were normalised against the maximal luminescence, 
as shown by tumour cells grown in the absence of T-cells. Normalisation was achieved using the following equation: Tumour cell viability 
= (Sample luminescence value / Average luminescence value when no T-cells added)*100. Data are presented as mean ± SD from five 



























































Figure 4.18 Cytotoxicity of CSF-1R-retargeted T-cells against the L540 cell line in vitro.  
The cHL cell line L540 was co-cultured with a panel of CAR-grafted T-cells at a 1:1 ratio for the indicated period of time. The level of 
target cell viability following co-culture was monitored using a luciferase assay. Data were normalised against the maximal luminescence, 
as shown by tumour cells grown in the absence of T-cells. Normalisation was achieved using the following equation: Tumour cell viability 
= (Sample luminescence value / Average luminescence value when no T-cells added)*100. Data are presented as mean ± SD from five 






The overall aim of this project was to investigate whether T-cells can be genetically re-
targeted against CSF-1R and consequently to test the feasibility of this approach, as a 
novel CAR-based adoptive T-cell therapy for cHL and ALCL.  
 
A major obstacle to effective CAR-based T-cell immunotherapy of cancer is poor 
survival in vivo of the genetically modified infused cells. T-cell expansion is generally 
induced by IL-2. However IL-2 is toxic when administered in high doses and 
furthermore it exerts similar stimulatory effects on gene modified, non-gene modified 
and regulatory T cells (Treg). The 4αβ chimeric cytokine receptor addresses exactly 
this limitation. It is designed as a fusion protein of the IL-4 receptor alpha (IL-4Rα) 
ectodomain and the common beta subunit (βC) shared by IL-2 and IL-15 (Figure 2.1, 
page 74) [365]. Upon administration of IL-4 (a poor T-cell mitogen), 4αβ 
heterodimerises with the common gamma chain (γC) delivering proliferation signals 
selectively to 4αβ+ T-cells. Thus 4αβ+ T-cells achieve a strong selective advantage over 
untransduced cells when cultured in IL-4, which makes 4αβ a useful tool for ex vivo 
expansion and enrichment of CAR+ T-cells. Additionally some tumours secrete IL-4 in 
the immediate microenvironment, which could theoretically induce 4αβ-CAR+ T-cell 
trafficking towards the tumour site followed by local expansion and survival of the 
genetically modified T-cells. In the case of cHL, primary HRS cells have been shown to 
express IL-4R but no endogenous IL-4 production has been detected. However, low 
levels of IL-4 have been detected within the reactive infiltrate but there is no evidence 
that it acts as a growth factor for Hodgkin’s Reed Sternberg (HRS) cells [381]. In the 
context of ALCL, endogenous IL-4 secretion has been the subject of little investigation. 
One study has outlined that five out of eight ALCL cell lines express low levels of IL-4 
[382]. In light of these findings, stoichiometric co-expression of 4αβ and CSF-1R-
targeting CAR was sought to support CAR-based immunotherapy of CSF-1R-



























































































































































































Figure 4.19 Antigen-specific IFN- release during co-culture with a panel of cHL and ALCL cell lines.  
Untransduced T-cells or those expressing a CSF-1R-targeting CAR were co-cultured with a panel of lymphoma cell 
lines. After 48 hours, supernatants were removed and the concentration of IL-2 measured by ELISA. At least three 
independent experiments are shown with data presented as mean ± SD. Data were analysed using one-way ANOVA 













































































































































































Figure 4.20 Antigen-specific IL-2 release during co-culture with a panel of cHL and ALCL cell lines.  
Untransduced T-cells or those expressing a CSF-1R-targeting CAR were co-cultured with a panel of lymphoma cell 
lines. After 24 hours, supernatants were removed and the concentration of IL-2 measured by ELISA. Three 
independent experiments are shown with data presented as mean ± SD. Data were analysed using one-way ANOVA 
followed by a Tukey post-hoc test. *p<0.05; **p<0.01; ***p<0.001. 
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A panel of eight CSF-1R-targeting CARs were cloned using the PIPE cloning method, 
which is a PCR-based alternative to the conventional restriction enzyme- and ligation-
dependent cloning methods (Figure 4.2 and 4.3) [249]. This approach eliminates the 
use of restriction enzymes and ligation, and thus the incorporation of restriction sites, 
which could encode extra, unwanted residues into expressed proteins [250]. To enable 
stoichiometric co-expression of 4αβ and a CSF-1R targeting CAR in the same cell, a 
self-cleaving 2A peptide sequence was introduced between the two constructs.  
 
For the design of the panel of CSF-1R-targeting CARs, both naturally occurring CSF-
1R ligands (CSF-1 and IL-34) were used as antigen-recognition domains. Please refer 
to Figure 2.1 (page 74) and Figure 2.2 (page 80) for schematic representation of the 
various CSF-1R-targeting CAR constructs used in this chapter. Taking into 
consideration that IL-34 has been reported to have considerably higher affinity towards 
the target than CSF-1 does, double targeting, second and third generation CARs 
utilizing each of those peptides as targeting moieties have been engineered [102]. This 
approach was undertaken in an attempt to explore the potential impact that target-
binding affinity could have on CAR function, both in the context of a single CAR and a 
co-expressed pair of fusion receptors. 
 
In order to achieve stable transduction of human T-cells, two CAR-expressing retroviral 
packaging cell lines have been generated – PG13 and 293Vec RD114. Successful 
generation of CAR-expressing packaging cell lines was confirmed by flow cytometry. 
Cell surface expression of both 4αβ and each CAR construct was confirmed in 
retroviral packaging cells. Despite expecting stoichiometric co-expression of 4αβ and 
each CAR in the same cell, slight variations in mean fluorescence intensity (MFI) were 
observed, which could be attributed to the different binding affinities of the antibodies 




Prior to investigating whether T-cells can be genetically re-targeted against CSF-1R, it 
was of initial importance to demonstrate that the panel of eight CARs can be expressed 
at the T-cell surface following gamma retroviral-mediated gene transfer. This was 
confirmed by flow cytometry on a number of occasions (Figure 4.6, A) and suggests 
correct folding and trafficking of all chimeric constructs to the plasma membrane. The 
4αβ chimeric cytokine receptor proved useful as a device to achieve selective 
expansion and enrichment of CAR+ T-cells, as demonstrated by increase in the 
percentage of CAR+ T-cells when grown in IL-4 in the absence of antigen (Figure 4.6, 
B). This enabled experiments to be performed using T-cell populations in which the 
proportion of gene-modified cells was similar. Furthermore, CAR expression was 
maintained over the 12-day culture period in IL-4, highlighting successful integration of 
the receptor cDNA into the recipient T-cell genome. 
 
Further analysis of CAR expression in primary human T-cells was performed by 
western blotting analysis (Figure 4.6, C). Whole cell lysates were run on SDS-PAGE 
under reducing conditions, subjected to immunoblotting and then probed using a CD3ζ-
specific antibody. The lower band (16kDa) is the endogenous CD3ζ chain, which was 
used as a loading control. The monomeric CAR chains were detected at the expected 
molecular weight for all but the double targeting constructs C34B and 34CB, which 
were seen as 46kDa and 53kDa bands respectively as opposed to the predicted 44kDa 
(C34B) and 51kDa (34CB). The most likely explanation for this discrepancy is a non-
functional second furin cleavage site leading to inclusion of the T2A sequence at the C-
terminal end of the C28ζ and 3428ζ constructs respectively. Even though not desirable, 
this fusion does not seem to interfere with T-cell activation or cytotoxicity as 
demonstrated in Figure 4.7 and 4.8.  
 
Despite using the 4αβ chimeric cytokine receptor for enrichment of CAR-grafted T-
cells, the level of T-cell transduction varied between experiments and between the 
constructs being expressed (Figure 4.6, D). This in part can be attributed to intrinsic 
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difference associated with using T-cells from a variety of donors. For example, donor 
cell responsiveness to activation with anti-CD3/28 beads is central to effective T-cell 
transduction because retrovirally mediated infection is dependent on progression 
through the cell cycle. Additionally, viral titres were not determined prior to T-cell 
transduction, allowing for different levels of virus exposure of the recipient T-cells. 
Lastly, the surface level of expression of the GALV receptor, Pit1 and the RD114 
receptor, RDR, may have varied between donors, accounting for inter-donor variation 
of the transduction efficiency [383, 384].   
 
In order to assess whether T-cells can be genetically re-targeted against CSF-1R, co-
cultures were set up with T47D FMS cells, which have been shown to express high 
levels of the target CSF-1R in a stable manner. Cancer cell destruction was measured 
in an MTT assay. As shown on Figure 4.7, A, overnight co-culture of T47D FMS with 
CSF-1R re-targeted CAR+ T-cells resulted in complete target cell lysis in the presence 
of C4+, C4B+, C34B+, 43428ζ+, 43428Bζ+ and 34CB+ T-cells. No significant destruction 
was detected against the parental T47D cell line, which does not express the target 
CSF-1R and thus serves as a negative control (Figure 4.7, B).  
 
Destruction of the T47D FMS monolayers was correlated with preceding CAR+ T-cell 
activation. The release of significant amounts of both IFN-γ (Figure 4.8, A) and IL-2 
(Figure 4.8, B) by CSF-1R-targeting T-cells (C4+, C4B+, C34B+, 43428ζ+, 43428Bζ+ and 
34CB+ T-cells), but not by control T-cell populations (CT4+, 434Tr+ and UT T-cells) 
shows that these CARs must be able to bind the target receptor and are subsequently 
capable of activating primary human T-cells. This is further strengthened by the fact 
that CAR+ T-cell activation occurred only in the presence of the antigen (T47D FMS 
cells) and not upon co-culture with the negative control T47D cell line (CSF-1RNEG) or 
in the absence of monolayer (T-cells group), thereby confirming that activation of these 




Despite similar cytotoxicity exerted by all signalling-capable CSF-1 and IL-34-based 
CARs, cytokine release as measured by ELISA revealed a considerable difference 
between those two groups. Although not statistically significant, there was a trend 
towards release of greater concentrations of both IFN-γ and IL-2 by CSF-1-based 
CAR+ T-cells compared to IL-34-based CAR+ T-cells. This observation can be 
attributed to a number of factors. Differences in transduction efficiency and CAR 
density on the cell surface provide one possible explanation, but given that all CAR+ T-
cells were expanded and enriched in IL-4 that seems unlikely. It is important to note 
that immunophenotyping of the CAR+ T-cells was not undertaken. Therefore the 
possibility of CAR molecules being predominantly expressed in different T-cell subsets 
cannot be ruled out, though it is highly unlikely given that T-cell transduction was 
achieved using identical viruses. The most probable explanation for the observed 
differences in T-cell activation lies in the CAR design itself. The higher affinity of IL-34 
interaction with the target might prove an impediment to serial target engagement and 
disengagement by CAR+ T-cells. In fact, a similar phenomenon has been described 
with TCR-peptide-MHC (TCR-pMHC) interaction. In an elegant study, Valitutti and 
colleagues have demonstrated that a single pMHC complex appears to engage and 
downregulate up to 200 TCR molecules per T-cell in a process they refer to as “serial 
triggering” [385]. This serial triggering of TCRs has since been widely accepted as 
central to optimal signalling of the T-cell. Consequently, long TCR-pMHC lifetimes of 
dissociation might prevent serial triggering and thus signalling. In support of this notion 
are a number of studies demonstrating that T-cells that have TCRs with higher affinity 
or slower off-rates for pMHC exhibit reduced activity for the pMHC [386-389]. Of 
particular interest is a recent study that examined two different class I-reactive T-cell 
systems concluding that higher affinity (slower off-rates) for a pMHC yielded reduced 
activity [390]. Taking these findings into account it was suggested that the higher 
affinity of IL-34 interaction with the target is the most probable cause for the lower 




Interestingly, no considerable differences in cytokine release or cytotoxicity were 
observed between double targeting, second or third generation CARs in the CSF-1-
based group (Figure 4.8, A). In the IL-34-based group however, significantly higher 
concentration of IFN-, but not IL-2, was produced by the double targeting CAR 34CB 
in comparison to either second or third generation CARs. This observation could reflect 
the improved activation status of 34CB+ T-cells as a result of the second CSF-1-based 
CAR providing co-stimulation through 4-1BB upon target recognition.  
 
As T-cell proliferation is a key aspect of the activation process, it was used as an 
additional marker to assess efficient target engagement and optimal T-cell activation. 
All signalling-competent CSF-1R-targeting CAR constructs showed identical cytolytic 
capacity in vitro upon encountering the target for the first time (Figure 4.7). However, 
upon exposing CAR-grafted T-cells to successive rounds of antigen stimulation (in the 
absence of exogenous cytokines), while at the same time measuring their proliferative 
capacity, the C34B CAR repeatedly outperformed matched second and third 
generation CARs (Figure 4.9). In addition, the proliferation of the C34B+ T-cells, ability 
to maintain their cytotoxic potency and to release IL-2 was maintained over 15 
repeated rounds of stimulation with antigen-expressing tumour cells (Figure 4.9, 4.10 
and 4.11). Interestingly, the proliferative advantage of C34B+ T-cells was not retained 
in 34CB-bearing T-cells. This underlines the importance of fine-tuning signal 
transduction upon CAR engagement in respect to the balance of co-stimulatory signals 
provided and their functional outcome. Although more needs to be learned about CD28 
and 4-1BB function as co-stimulatory domains within CARs, recent data indicates that 
CD28 signalling results in brisk proliferative response and boost effector functions, 
whereas 4-1BB signalling induces a progressive T-cell accumulation which may 
compensate for reduced immediate potency [391]. Consequently, in the setting of 
double targeting CARs, CAR affinity, along with CAR expression levels, will determine 
the potency of the constructs. Since IL-34 has higher affinity for the target than CSF-1 
(coincidentally 34 times higher), target engagement by the C34B construct would 
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provide predominant signalling through 4-1BB while in the 34CB construct intracellular 
signal transduction would predominantly employ CD28 and CD3ζ signalling. This could 
potentially account for the superior in vitro proliferative capacity of C34B- over 34CB-
grafted T-cells.  
 
The reason for the striking difference in expansion and retention of in vitro cytotoxicity 
and cytokine release by C34B+ T-cell compared to those expressing other CAR 
constructs warrants further discussion. One possibility is that target-dependent 
activation of CAR+ T-cells may also have resulted in different levels of T-cell death. 
Indeed, it has been suggested that T-cell apoptosis, through activation-induced cell 
death (AICD), may be a downstream effect of IFN-γ release [392, 393]. Consequently, 
it was hypothesised that whilst second and third generation CAR+ T-cells were 
undergoing proliferation, a number of them may also have been eliminated through 
AICD, while C34B+ T-cells were being protected. Contrary to this, however, is the fact 
that all CAR+ T-cell populations produce very similar levels of IFN-γ (Figure 4.8). 
Furthermore, no significant differences in Fas ligand expression, a marker of AICD, 
were detected in double targeting CAR+ T-cells in comparison to conventional second 
and third generation CAR+ T-cells post-activation (Appendix, Figure S4) [394]. The 
sustained functionality of C34B+ T-cells upon repeated in vitro stimulation can most 
probably be attributed to the arrangement of the elements in the double targeting CAR, 
which may be facilitating activity. For example, by definition, one of the co-stimulatory 
modules in a 3rd generation CAR (in this case 4-1BB) must be placed away from its 
natural location close to the inner leaflet of the plasma membrane. This may cause it 
not to signal normally owing to impaired access to obligate membrane-associated 
partner molecules. Alternatively, close proximity of 2 co-stimulatory signalling modules 
in a 3rd generation CAR, like CD28 and 4-1BB in C4B and 43428Bζ, might lead to 
steric issues, preventing full engagement of one or more downstream signalling 
pathways. Both of these issues are avoided in the arrangement of the double targeting 
CARs, where the signalling moieties have been fused directly to a transmembrane 
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domain, ensuring that they are both adjacent to the plasma membrane within the cell. 
Furthermore, they may be spaced within the cell so that they will not interact sterically 
with each other. Overall, despite similar cytotoxicity exerted by all signalling-competent 
CSF-1 and IL-34-based CARs, repeated antigen re-stimulations revealed that the 
double targeting C34B CAR maintains proliferative capacity, cytotoxic potency and 
ability to release IL-2 for several more rounds of antigen-stimulation than any other 
CAR configuration tested. 
 
Following proof of successful CAR+ T-cell re-direction against a CSF-1R-expressing 
cell line (T47D FMS cells) (Figure 4.7), it was crucial to demonstrate that this 
retargeting was maintained against cHL and ALCL cell lines. In order to allow for in 
vitro measurement of target cell destruction and in vivo quantification of tumour burden, 
the lymphoma cell lines were transduced to stably express firefly luciferase (ffLuc) and 
the fluorescent protein tdTomato (Figure 4.12). Following flow sorting for transduced 
cells, lymphoma cell lines were co-cultured in 1:1 ratio with CAR+ T-cells and co-
cultures were probed every 24h for 6 days. As shown on Figure 4.13, 4.14, 4.15, 4.16, 
4.17 and 4.18 co-culture of CAR+ T-cells resulted in variable level of clearance of the 
target cells, correlating with the surface level of expression of CSF-1R on the 
lymphoma cell lines (Figure 3.1). The high level of CSF-1R expression on DEL and FE-
PD cell lines resulted in complete clearance of the cancer cells within 24h and 72h 
respectively. Substantial target cell lysis was also observed with KM-H2 and JB6 cell 
lines. By contrast, the modest function of CAR+ T-cells against K299 and L540 cells 
may have resulted from the low level of CSF-1R expression by these cells (Figure 3.1, 
A and B). This observation raises the possibility that the activation of CAR+ T-cells 
requires CSF-1R expression by the target cells to be above a certain level. If correct, 
this may be beneficial for clinical translation of CAR+ T-cells as it suggests that low 
levels of CSF-1R expressed by healthy tissues may be below the activation threshold, 




One potential impediment to CSF-1R targeting of the lymphoma cell lines is the 
previously documented (Figure 3.2) endogenous expression of either one or both CSF-
1R ligands, which may induce receptor down-regulation by internalization of the 
receptor-ligand complex.  
 
An important observation is that across the six-lymphoma cell lines, consistently, the 
IL-34-based CAR-grafted T-cells exerted inferior cytotoxicity compared to CSF-1-based 
CAR-transduced T-cells. This can be attributed to the poorer activation of IL-34-based 
CAR+ T-cells, which has already been observed upon co-culture with the positive 
control T47D FMS (discussed in detail above) but was also confirmed by the detection 
of minimal cytokine release upon engagement with the lymphoma cell lines (Figure 
4.19 and 4.20). In general, levels of IFN-γ and IL-2 were significantly lower in 
lymphoma co-cultures than following co-culture with cells that ectopically express CSF-
1R, a finding that is likely to reflect the higher levels of cell surface CSF-1R expression 
and the lack of endogenous CSF-1R ligand secretion by the latter. 
 
No significant differences in cytokine release or cytotoxicity were observed in co-
cultures of T47D FMS (on first cycle of Ag-stimulation) or lymphoma cells with T-cells 
engineered to express second or third generation CARs or double targeting CARs in 
either the CSF1- or IL-34-based groups.  
 
Overall, the data presented in this chapter demonstrate that CSF-1R-targeted CAR+ T-
cells can be effectively and specifically redirected against a panel of cHL and ALCL cell 
lines in vitro, unlike control CAR+ or untransduced T-cells. Furthermore, CSF-1-based 
CAR+ T-cells undergo more robust activation upon target engagement in comparison to 
IL-34-based CAR+ T-cells, which can most likely be attributed to the higher affinity of 
CSF-1R interaction of the latter. Lastly, C34B-grafted T-cells exhibited enhanced 
proliferative capacity upon successive rounds of re-stimulation while maintaining their 
cytotoxic potency and ability to release IL-2. This suggests that providing co-stimulation 
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in trans results in favourable spatial and temporal differences in the recruitment, 
kinetics and regulation of co-stimulation. However, simply adopting the double targeting 
strategy does not translate into augmented functionality, as illustrated by the 34CB 
construct. This raises the possibility that fine-tuning of the relative affinities of dual 
targeted receptors for their targets may be necessary to achieve optimal potency of the 
constructs. Taken together, these data warrant investigation of the in vivo anti-tumour 






Chapter 5 Determining the anti-tumour potential of CSF-1R-
targeting CAR+ T-cells in vivo 
 
5.1  Introduction  
The CSF-1/CSF-1R axis has been demonstrated to play a key role in supporting 
tumour cell survival, proliferation and enhanced motility (discussed in details in section 
3.1). Expression of CSF-1R has been reported in diverse cancer types. In cHL and 
ALCL, CSF-1R expression has been shown to originate from an aberrantly activated 
endogenous long terminal repeat (LTR) suggesting that the origin of the unnatural 
CSF-1R expression found on HRS and ALCL cells is loss of epigenetic control [141, 
142]. Aberrant CSF-1R expression is also commonly documented in tumours of 
epithelial origin such as breast [143, 144] and ovarian cancer [145]. Additionally, CSF-
1R expression has been strongly associated with poor prognosis in those cancers, 
which makes it an attractive target for cancer immunotherapy [146-148].  
 
5.1.1 Targeting the CSF-1/CSF-1R axis in cancer 
The majority of tumour-associated antigens (TAA) are not restricted to the tumour 
alone but are also expressed on non-diseased tissue. Instead, it is usually the relative 
expression levels that differ between malignant and healthy tissue. Consequently, as 
complete avoidance of toxicity can be difficult to achieve, therapeutic targeting of TAA 
needs to achieve a satisfactory balance whereby sufficient benefit is achieved while 
avoiding unacceptable toxicities. As discussed in section 1.3, CSF-1R expression is 
restricted to cells of the mononuclear phagocyte lineage. In order to assess the 
potential toxicities associated with targeting this antigen, Hume and colleagues have 
developed the ‘MacGreen’ transgenic mouse, in which an enhanced green fluorescent 
protein (EGFP) reporter gene is driven by the Csf1r promoter, allowing for visualisation 
of the participation of CSF-1R+ cells in tumour progression and metastasis [395]. This 
mouse model was used for assessment of the number, phenotype and fate of CSF-1R+ 
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cells upon administration of an anti-CSF-1R M279 antibody, which resulted in selective 
reduction of Ly6C- stationary monocytes, but not of their precursors Ly6C+ 
inflammatory monocytes [396]. Furthermore, antibody-mediated targeting of CSF-1R 
did not affect Ly6C+ inflammatory monocytes numbers nor did it abrogate their 
recruitment or function in LPS-induced lung inflammation, wound healing and acute 
graft versus host disease. It did, however, decrease the number of tumour-associated 
macrophages (TAMs) in syngeneic mesothelioma and Lewis lung carcinoma tumour 
models, despite the fact that tumours were established prior to starting treatment. This 
work shed further light on the consequences of targeting CSF-1R, confirming its role in 
the maturation of monocytes into tissue resident macrophages though at the same time 
indicating that CSF-1R signalling may not be absolutely necessary for monocyte 
production or for effective function of inflammatory monocytes. These findings reinforce 
CSF-1R as an attractive target for drug discovery. 
 
Current development of targeted therapies in oncology concerns principally two types 
of agents: monoclonal antibodies (Mabs) and tyrosine kinase inhibitors (TKIs).  
 
5.1.1.1 Tyrosine kinase inhibitors 
At present there are 28 tyrosine kinase inhibitors that have been approved for cancer 
treatment in the clinic, of which half were approved in the last 3 years, and more than 
100 kinase inhibitors are at different stages of clinical development [397]. Most of those 
inhibitors compete with ATP for the ATP-binding site [136]. Clinically relevant receptor 
TKIs known to inhibit CSF-1R are imatinib, dasatinib, nilotinib, pazopanib, sorafenib 
and sunitinib [398, 399]. More selective inhibitors are tandutinib [400] (phase II), PLX-
3397 (phase III), PLX-5622 (phase I) and JNJ-28312141 (phase I); and the research 
tool compounds GW-2580 [401], and Ki-20227 [402]. Imatinib has been shown in a 
case report to induce complete remission in relapsing diffuse type tenosynovial giant 
cell tumour (dt-GCT), a rare proliferative disorder affecting synovial joints and tendon 
sheaths [403]. The observed complete response has been attributed to its ability to 
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block CSF-1R activation, inhibiting the paracrine loop responsible for the growth of 
these tumours [404]. However, further studies assessing the efficacy of imatinib [405] 
and subsequently of related TKIs such as nilotinib [406] showed tumour shrinkages in 
only a few cases of patients with dt-GCT [407]. Unfortunately kinase inhibitors are well 
known to engage multiple off-targets usually among structurally similar kinases from 
the same family, which is a major limitation for their widespread use. 
 
5.1.1.2  Antibodies 
Currently there are 3 monoclonal antibodies targeting CSF-1R in Phase I clinical trials. 
Ries and colleagues generated a high-affinity, humanized anti-CSF-1R monoclonal 
antibody termed RG7155 that inhibited both ligand-dependent and ligand-independent 
activation of CSF-1R by blocking receptor dimerization [408]. Treatment with RG7155 
selectively induced apoptosis of M2-like macrophages but not M1-like macrophages in 
vitro. In animal models of colorectal adenocarcinoma and fibrosarcoma, CSF-1R 
blockade depleted TAMs and resulted in a relative increase in cytotoxic effector CD8+ 
T-cells and a decrease in CD4+FOXP3+ regulatory T-cells and ultimately delayed 
tumour growth and metastasis. Consistent with this finding, in a phase I study of 
patients with locally advanced and/or metastatic ovarian and breast carcinoma, 
RG7155 treatment significantly diminished CSF-1R+ and CD68/CD163+ TAMs and 
triggered a shift toward an increased CD8/CD4 T-cell ratio [409]. Disease stabilization 
was observed in 6/40 patients with ovarian or breast cancer. Additionally, 28 patients 
with dt-GCT were recruited and treated in the same trial (NCT01494688) and objective 
response was observed in 24 of them. RG7155 treatment also led to significant 
reduction of surrogate skin tissue resident macrophages and rapid elimination of 
CD14+CD16+ peripheral monocytes. Overall RG7155 treatment was well tolerated with 
only 18% patients (21/114) experiencing grade 3/4 adverse events (asthenia, 
peripheral edema and pyrexia). These results strongly suggest that TAMs represent a 
promising therapeutic target in various solid tumours and support further testing of 
CSF-1R blockade in combination with chemotherapeutic agents or immunotherapies. 
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RG7155 is currently being tested in combination with an anti-PD1 (MPDL3280A) 
monoclonal antibody in a Phase Ib study for locally advanced or metastatic solid 
tumours (NCT02323191). 
 
The other two monoclonal antibodies (Mabs) targeting CSF-1R (named IMC-CS4 and 
FPA008) are both currently in Phase I evaluation in patients with advanced solid 
tumours and PVNS/dt-GCT (NCT01346358 and NCT02471716 respectively). Results 
from both trials are still currently pending. 
 
Colony stimulating factor-1 receptor is a major therapeutic target in cancer due to its 
overexpression in a number of different malignancies. Preliminary results from CSF-
1R-targeting Mabs in Phase I, even though not sufficient for evaluating the overall 
safety profile of targeting this receptor, are encouraging. Taken together, these data 
reinforce CSF-1R as an attractive therapeutic target for cancer immunotherapy.  
 
5.2 Results 
The overall goal of this PhD was to determine whether CSF-1R-re-targeted T-cells 
represent a potential therapeutic approach for patients with refractory cHL and ALCL. A 
key step in the testing of every novel therapeutic anticancer agent is the evaluation of 
therapeutic efficacy of the agent itself using appropriate in vivo tumour models. 
Consequently, there was a need to develop a clinically relevant lymphoma mouse 
model that accurately represents CSF-1R-expressing lymphoma subtypes.  
 
5.2.1  Development of an in vivo CSF-1R expressing lymphoma model 
First, I investigated xenograft formation by six CSF-1R-expressing lymphoma cell lines, 
derived from both ALCL and cHL. SCID/Beige mice were inoculated i.v. with either 10 x 
106 or 5 x 106 tumour cells (Figure 5.1). All six lymphoma cell lines had been 
transduced to stably express firefly luciferase (ffLuc) and the fluorescent protein 




Figure 5.1 Development of a lymphoma in vivo model.  
SCID/Beige mice (n=3 per dose) were inoculated intravenously (i.v.) with 5 x 106 (grey line) or 
10 x 106 (red line) cells from the appropriate luciferase-expressing lymphoma cell line or PBS 
(dotted line) (A-F). Tumour growth was monitored over the indicated timeframe by BLI. 
Quantification of luminescent signal released from each mouse was determined by drawing a 
region of interest (ROI) around each individual animal. Using Living Image 4.1 software, photon 
release within the ROI was calculated and standardised to account for the scan duration. Data 
are expressed as mean total photon flux (photons/s) ± standard error of the mean. 
206 
 
using bioluminescence imaging (BLI). Bioluminescence imaging provides a sensitive 
method for monitoring tumour growth in vivo by measuring photon release upon D-
luciferin breakdown by the luciferase enzyme present within the tumour cells (please 
refer to section 2.3.2). Transduced lymphoma cell lines were annotated with “LT” after 
their name (e.g. KM-H2 LT) and following cell sorting for tdTomato they received an “s” 
in front of their name, which stands for “sorted” (e.g. sKM-H2 LT).  
 
As shown in Figure 5.1, reproducible tumour engraftment within a reasonable time 
frame was only achieved following inoculation with the sK299 LT cell line (Figure 5.1, 
B). In contrast, no increase in total flux was observed in the sKM-H2 (Figure 5.1, A), 
sDEL LT (Figure 5.1, C) or sFE-PD LT (Figure 5.1, D) groups, when compared to 
baseline (PBS administration - dotted line). After a prolonged interval, a low level of 
signal was detected inconsistently in the sJB6 LT (n=2/3 mice) and sL540 LT (n=1/3 
mice) groups, and only after injection of the higher cell dose (10 x 106 cells)(Figure 5.1, 
E and F). This experiment demonstrated that only the sK299 LT lymphoma cells 
achieved reproducible and robust tumour xenograft formation in SCID/Beige mice 
following i.v. administration of either 10 x 106 or 5 x 106 cells.  
 
To further characterise the sK299 LT xenograft model, the number of administered 
cancer cells was titrated to determine the lowest number that reproducibly engraft in 
SCID/Beige mice. This was done in anticipation that the lower number of inoculated 
cancer cells would reduce tumour-related morbidity and potentially extend the 
therapeutic window for adoptive CAR+ T-cell transfer. The observed growth kinetics 
were very similar in all five groups with a slight delay in the exponential growth phase 
between day 6 and day 20 in the groups that received 2 x 106, 1 x 106 and 0.5 x 106 
cells compared to the higher dose groups (10 x 106 and 5 x 106) (Figure 5.2, A). A dose 
of 2 x 106 sK299 LT cells was chosen for all future experiments (Figure 5.2, B) since 





Figure 5.2 Characterisation of the sK299 LT lymphoma xenograft model.  
SCID/Beige mice (n=3 per dose) were inoculated i.v. with 10 x 106, 5 x 106, 2 x 106, 1 x 106 and 
0.5 x 106 sK299 LT cells or PBS (dotted line). (A) Tumour growth was monitored over the 
indicated timeframe by BLI. Data represent mean total photon flux (photons/s) ± SEM for each 
group. The images shown in (B) highlight tumour progression over time in the group that 
received 2 x 106 sK299 LT cells. Tumour cell dissemination to lymph nodes only was confirmed 
at post-mortem, with no signal detected in the heart, lungs, liver or spleen (C). No tumour cells 







 flow cytometry (D). Tumours from five mice from different inoculation conditions were excised 
post mortem and investigated for the expression of CSF-1R by flow cytometry. To ensure 
retention of cell surface proteins, the tumours were mechanically disaggregated to yield a single 
cell suspension which was stained with a rat anti-human (legend continue on next page) 
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(indicated by increased size of error bars) without any additional slowing of disease 
progression.  
 
Post-mortem BLI analysis indicated that the intravenously delivered sK299 LT 
lymphoma cells traffic to the lymph nodes where solid tumours were established, 
providing a clinically relevant representation of the human disease. No 
bioluminescence signal was detected from the excised lung, liver, spleen or heart 
(Figure 5.2, C). Tumour dissemination was further investigated by flow cytometry. 
Peripheral blood was collected and analysed along with spleen and lymph nodes for 
the presence of the fluorescent protein tdTomato characteristic of the infused sK299 LT 
cells. This analysis confirmed that tumour cells had only disseminated to lymph nodes 
(Figure 5.2, D). 
 
In order to confirm that the sK299 LT tumours retain CSF-1R expression after passage 
in vivo, flow cytometry was performed on a single tumour, excised from each group 
post mortem (Figure 5.2, E). Mechanical separation was chosen over enzymatic 
digestion to achieve a single cell suspension, thereby ensuring the retention of cell 
surface markers. To minimize unspecific staining, all tumours were treated with mouse 
Fc block prior to any further staining and a viability dye (DAPI) was used to exclude 
background staining from dead cells. The excised tumours displayed similar levels of 
CSF-1R expression when compared to the sK299 LT cell line propagated at the same 
time in vitro (Figure 5.2, F). Consequently, this suggests that these tumours will remain 
suitable targets for CAR T-cells re-directed against CSF-1R.   
CSF-1R antibody, followed by a goat anti-rat FITC conjugated secondary antibody. Non-specific 
binding of the antibodies was limited by using mouse Fc block prior to the staining steps. All 
gates were set using fluorescence minus one (FMO) controls. All tumours were gated as shown 
in (E) using DAPI as viability stain. The expression pattern of CSF-1R in vivo was compared 
with that of the sK299 LT cell line that had been cultured in vitro (F). Data are represented as 




5.2.2 Anti-tumour activity of CAR-grafted T-cells in the sK299 LT xenograft 
model 
Mindful of the modest anti-tumour activity of CSF-1R-re-targeted T-cells against sK299 
LT cells in vitro (Figure 4.14), I next set out to investigate their therapeutic activity in 
vivo, following adoptive transfer in SCID/Beige mice with established sK299 LT 
xenografts. Fifty four mice were inoculated i.v. with 2 x 106 sK299 LT cells (data are 
pooled from two separate experiments). Five days post tumour cell administration, the 
mice were imaged using BLI to confirm tumour engraftment and were then randomised 
into 6 groups with equal mean tumour burden. From this point on, treatment groups 
were assigned numbers and all treatment, imaging and evaluation was done in a 
blinded fashion. On the same day, mice were treated with either C4B+, C34B+, 
43428Bζ+, 34CB+ (all cultured in IL-4) or untransduced (UT) T-cells (cultured in IL-2) as 
control (Figure 5.5, A). Prior to infusion, the T-cells were probed for surface expression 
of the CAR constructs (Figure 5.3, A and B; Figure 5.4, A and B) and an infusion dose 
of 20 x 106 CAR+ T-cells was calculated for each group according to transduction 
efficiency. Furthermore, cell viability and cytotoxic potential were maintained during the 
preparations required for T-cell infusion in mice as surplus CAR+ but not UT T-cells 
conferred complete target cell lysis of T47D FMS monolayers in vitro (Figure 5.3, C and 
Figure 5.4, C). No antigen-independent killing was detected against the parental cell 
line T47D, which lacks target expression (Figure 5.3, D and Figure 5.4, D). To quantify 







Figure 5.3 Assessing the suitability of T-cells for adoptive transfer into mice with 
established sK299 LT xenografts (experiment 1).  
Prior to administration into mice, a small sample of each T-cell population was probed for CAR 
expression. Detection of the CSF-1-based CARs was achieved by flow cytometry using a goat 
polyclonal anti-human CSF-1 antibody, followed by a FITC-conjugated secondary antibody (pink 
histograms) (A). The level of expression of IL-34-based CARs was assessed using mouse anti-
human IL-34 antibody directly conjugated to PE (purple histograms) (B). Staining was 
compared to untransduced T-cells probed using the same antibody combinations (blue 




To investigate anti-tumour activity in vitro, surplus T-cells from the populations infused into 
mice were co-cultured at a 1:1 ratio with the T47D FMS and T47D cell lines (C) and (D). 
Target cell destruction was measured at 24h using an MTT assay. Each sample was run in 
triplicate and data are presented as mean ± standard deviation. Furthermore T-cell phenotype 
was investigated in all CAR T-cell populations. Proportion of CD8+ T-cells (E), memory 
phenotype (F) and expression of a number of anergy markers (G) was determined by flow 
cytometry using a panel of directly conjugated mouse anti-human antibodies consisting of 
CD3 APC-Cy7, CD8 PE-Cy7, CD45RO PerCP-Cy5.5, CCR7 APC, 2B4 FITC, TIM3 PerCP-





Figure 5.4 Assessing the suitability of T-cells for adoptive transfer into mice with 
established sK299 LT xenografts (experiment 2) 
Prior to administration into mice, a small sample of each T-cell population was probed for CAR 
expression. Detection of the CSF-1-based CARs was achieved by flow cytometry using a goat 
polyclonal anti-human CSF-1 antibody, followed by a FITC-conjugated secondary antibody (pink 
histograms) (A). The level of expression of IL-34-based CARs was assessed using mouse anti-
human IL-34 antibody directly conjugated to PE (purple histograms) (B). Staining was 
compared to untransduced T-cells probed using the same antibody combinations (blue 







To investigate anti-tumour activity in vitro, surplus T-cells from the populations infused into 
mice were co-cultured at a 1:1 ratio with the T47D FMS and T47D cell lines (C) and (D). 
Target cell destruction was measured at 24h using an MTT assay. Each sample was run in 
triplicate and data are presented as mean ± standard deviation. Furthermore T-cell phenotype 
was investigated in all CAR T-cell populations. Proportion of CD8+ T-cells (E), memory 
phenotype (F) and expression of a number of anergy markers (G) was determined by flow 
cytometry using a panel of directly conjugated mouse anti-human antibodies consisting of 
CD3 APC-Cy7, CD8 PE-Cy7, CD45RO PerCP-Cy5.5, CCR7 APC, 2B4 FITC, TIM3 PerCP-
Cy5.5, KLRG1 PE, PD1 APC-Cy7, CD57 FITC and LAG3 APC.  
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In order to investigate the immunophenotype of the CAR+ T-cells prior to in vivo 
administration, the expression levels of a number of cell surface markers was 
investigated. This analysis showed that the cells expressed a predominantly effector 
memory (EM) phenotype (CD45RO+CCR7-) with roughly half expressing the CD8 co-
receptor (Figure 5.3, E and F; Figure 5.4, E and F). Furthermore, T-cells were stained 
for expression of a panel of anergy markers (2B4, TIM3, LAG3, PD1, KLRG1 and 
CD57) (Figure 5.3, G and Figure 5.4, G). No significant difference in the 
immunophenotype was noted between UT T-cells and CAR+ T-cells despite the 
different expansion protocols employed (the first were expanded in IL-2 while the latter 
were expanded in IL-4). 
 
Initially, it appeared that mice treated with CAR+ T-cells showed no treatment benefit 
when compared to those receiving UT T-cells or PBS. However, a marked delay in 
tumour progression emerged in the C34B+ T-cell treated group, which became 
statistically significant at day 24 compared to UT T-cell treated group (Figure 5.5, B). 
Furthermore, towards the end of the study there were 3 tumour-free long-term surviving 
mice in the C34B+ T-cell treated group (Figure 5.5, B and D). Mice were weight 
regularly throughout the study. Independent of the T-cell population administered, the 
average weight of each group slowly increased over the course of the study indicating 
that no significant toxicity had occurred (Figure 5.5, C). In support of this, our group 
had previously shown that the SCID/Beige xenograft model could detect cytokine 
release syndrome induced by the adoptive transfer of CAR T-cells [240]. As highlighted 
in Figure 5.5 E, differences in tumour progression in individual mice were observed. 
One mouse in the C34B and 34CB groups showed stabilisation of tumour progression 
between day 24 and day 37 despite detectable high tumour burden, ultimately leading 
to tumour eradication in one case (C34B group) and tumour progression in the other 
(34CB group). Another 2 mice in the C34B group showed delayed tumour progression 




Figure 5.5 In vivo anti-tumour potential of CAR+ T-cells in the sK299 LT xenograft model.  
(A) SCID/Beige mice were inoculated i.v. with 2 x 106 sK299 LT cells and five days later were 
treated i.v. with 20 x 106 CAR+ T-cells or UT T-cells or PBS (n=9). Animals were weighed (C) 







conclusion of the study (B). To investigate further anti-tumour efficacy, total flux for individual 
animals within each group has been plotted (E). Kaplan-Meier survival analysis showed 
difference in survival for mice treated with C34B+ T cells and the rest of the groups (D). The data 
are pooled from two separate experiments and presented as mean value for each group ± SEM. 




Figure 5.6 Long-term survivors from the C34B+ T-cell treated group.  
Three mice from the C34B+ T-cell treated group remained tumour-free after initial inoculation 
with 2 x 106 sK299 LT cells followed by treatment with 20 x 106 C34B+ T-cells 5 days later. 
Tumour growth was subsequently studied by BLI imaging on the indicated days. The data 
collected over every given time point is presented using the same scale. Mouse 3 has only been 
followed up for 40 days at the time of writing. 
219 
 
Consequently, long-term survival was achieved in 33% of the C34B group at the end of 
the study. Images of tumour burden as detected by BLI of the long-term survivors in the 
C34B+ T-cell-treated group are presented in Figure 5.6. 
 
At the end of the study, peripheral blood was collected by cardiac puncture. Tumours 
and spleen were excised from at least two mice per treatment group and investigated 
by flow cytometry for target retention post treatment and human T-cell infiltration. To 
ensure retention of cell surface proteins, the tumours and spleens were mechanically 
disaggregated to yield a single cell suspension. All samples were treated with mouse 
Fc block prior to staining and an identical gating strategy was employed as shown on 
Figure 5.2, E. Surface levels of expression of CSF-1R in the 5 treatment groups and 
the control PBS group was summarised on Figure 5.7 Staining for human CD3 
revealed absence of viable T-cells in the peripheral blood, spleen or tumours (data not 
shown). Additionally, tail vein-derived peripheral blood was collected from the three 
long-term surviving mice from the C34B T-cell treated group (at day 30 for one mouse 
and day 52 for the other two post tumour inoculation) but no circulating human T-cells 








Figure 5.7 Surface levels of CSF-1R expression post treatment of the sK299 LT xenograft 
model.  
Tumours from two to four mice per treatment group were excised during post mortem and 
investigated for the expression of CSF-1R by flow cytometry. Single cell suspension was 
achieved by mechanical disaggregation. Non-specific binding of the antibodies was limited by 
using mouse Fc block prior to staining with a rat anti-human CSF-1R antibody, followed by a 
goat anti-rat FITC conjugated secondary antibody. All gates were set using FMO controls. The 
employed gating strategy was described previously (Figure 5.2, E). No statistically significant 
difference was found between groups as determined by one-way ANOVA, followed by 
Bonferroni post-hoc test. Data were presented as mean ± SEM. 
  

































5.2.3 Development of K299 FMS LT xenograft lymphoma model 
One possible explanation for disease progression in mice after CSF-1R re-targeted 
CAR T-cell treatment is inadequate target expression on tumour cells. To test this, I 
established a CSF-1RHI expressing lymphoma model by retrovirus-mediated over-
expression of CSF-1R in K299 cells, which naturally express low levels of this receptor 
(Figure 5.8, A). To characterise the effect of ectopic CSF-1R expression upon growth 
kinetics, the cell line K299 FMS LT and the parental cell line sK299 LT were cultured in 
vitro over a nine-day period and counted every third day (Figure 5.8, B). This 
experiment indicated that over-expression of CSF-1R had no effect on the in vitro 
growth kinetics of the K299 cell line. In order to determine whether the high level of 
CSF-1R expression rendered the K299 FMS LT cell line more susceptible to CSF-1R-
re-targeted T-cells, a co-culture experiment was undertaken. The K299 FMS LT cell 
line was co-cultured at 1:1 ratio with CAR+ or untransduced (UT) T-cells and co-
cultures were probed for luciferase activity at 24h, 48h, 72h, 96h, 120h, and 144h, 
providing a measure of target cell viability. Data were normalized against the maximal 
luminescence, as shown by tumour cells grown in the absence of T-cells. As shown on 
Figure 5.8 C, co-culture of CAR+ T-cells with the K299 FMS LT cell line resulted in 
considerably higher target cell lysis in comparison to co-culture with the parental cell 
line. Target cell lysis was accompanied by T-cell activation as indicated by IFN- and 
IL-2 release (Figure 5.8, D). Taken together, these data indicate that the K299 FMS LT 
cell line could be a useful model of CSF-1RHI-expressing lymphoma. 
 
In order to investigate the in vivo growth of the K299 FMS LT cell line, SCID/Beige 
mice were inoculated i.v. with either 5 x 106 or 2 x 106 tumour cells and tumour growth 
was compared to the parental cell line administered at the same doses (Figure 5.9, A). 
Tumour progression was monitored by BLI for a period of 31 days. This experiment 
indicated that over-expression of CSF-1R in the K299 cell line resulted in slower in vivo 





Figure 5.8 In vitro characterisation of the K299 FMS LT cell line.  
The sK299 LT cell line has been retrovirally transduced to express high 
levels of CSF-1R. Successful transduction was verified by flow cytometry 
(A). K299 FMS LT cells were stained with rat anti-human CSF-1R 
antibody followed by anti-rat-Ig-FITC conjugate (red histogram) or with 




secondary antibody alone (blue histogram). The in vitro growth kinetics of K299 FMS LT cells 
was compared to sK299 LT cells (B). Both cell lines were cultured at initial starting density of 0.5 
x 106 cells per well for the indicated timeframe. Results are pooled from 3 wells. (C) The K299 
FMS LT cell line was co-cultured with a panel of CAR-grafted T-cells at 1:1 ratio for the indicated 
period of time. The level of target cell viability following incubation with CAR+ or UT T-cells was 
monitored using a luciferase assay. Data were normalized against the maximal luminescence, 
as shown by tumour cells grown in the absence of T-cells. Normalization was achieved using 
the following equation:  
Tumour cell viability = (Sample luminescence value / Average Tumour alone luminescence 
value)*100 
(D) Antigen-specific IFN- and IL-2 release were measured by ELISA at 48h and 24h 
respectively after co-culture with K299 FMS LT cell line. Data presented in that figure are 
represented as mean ± standard deviation. **** = p<0.0001; *** = p<0.001; ** = p<0.01; * = 




Figure 5.9 Characterisation of the K299 FMS LT in vivo lymphoma model.  
SCID/Beige mice (n=2 per dose) were inoculated i.v. with 5 x 106 and 2 x 106 sK299 LT cells or 
K299 FMS LT cells or PBS. (A). Tumour growth was monitored over the indicated timeframe by 
BLI. Data presented in the graph represent mean total photon flux (photons/s) ± SEM for each 
group. The images shown in (B) highlight tumour progression in the group that received 2 x 106 









lymph node tumour cell dissemination was confirmed with no 
signal detected in the heart, lungs, liver or spleen (C). No 
tumour cells were detected in the blood or spleen by flow 
cytometry (D). Tumours from one mouse that received 2 x 106 
K299 FMS LT cells were excised post mortem and investigated 
for the expression of CSF-1R by flow cytometry. Single cell 
suspension was achieved by mechanical disaggregation. Non-
specific binding of the antibodies was limited by using mouse 
Fc block prior to staining with a rat anti-human CSF-1R 
antibody, followed by a goat anti-rat FITC secondary antibody. 
All gates were set using FMO controls. The employed gating 




LT cells grew with equivalent velocity as sK299 LT cells administered at the lower dose 
(2 x 106 cells). A dose of 2 x 106 K299 FMS LT cells was chosen for all future 
experiments. 
 
Tumour dissemination was identical to that observed in the sK299 LT xenograft model, 
with solid tumours forming in the lymph nodes and no tumour detected in heart, liver, 
lungs, spleen or peripheral blood (Figure 5.9, C and D). The high level of CSF-1R 
expression, characteristic for the K299 FMS LT cell line, was maintained after in vivo 
tumour formation (Figure 5.9, E). Collected data indicated that the K299 FMS LT 
xenograft bearing mice would be a suitable model to test the in vivo therapeutic 
potential of CSF-1R-re-targeted T-cells.  
 
5.2.4 Anti-tumour potential of CAR-grafted T-cells in the K299 FMS LT 
xenograft model 
Given the high surface level of CSF-1R expression on K299 FMS LT cell line, it was 
hypothesized that a more significant treatment benefit could be obtained following 
adoptive transfer of CSF-1R-re-targeted T-cells. In order to investigate this, K299 FMS 
LT xenografts were established intravenously in 30 SCID/Beige mice by administering 
2 x 106 cancer cells per mouse. Six days later the mice were imaged using BLI, 
randomized into groups with similar mean tumour burden and treated with either C4B+, 
C34B+, 43428Bζ+, 34CB+ or untransduced (UT) T-cells in a blinded manner (Figure 
5.11, A). Prior to infusion, the T-cells were probed for surface level of expression of the 
CAR constructs (Figure 5.10, A and B) and each group was treated with 10 x 106 CAR+ 
T-cells. Cell viability and antigen-specific cytotoxic potential were maintained during the 
preparations required for T-cell infusion as surplus CAR+ but not UT T-cells elicited 
complete destruction of T47D FMS (Figure 5.10, C) but not of target-null T47D 
monolayers in vitro (Figure 5.10, D). To quantify tumour progression in the absence of 





Figure 5.10 Assessing the suitability of T-cells for in vivo administration to K299 FMS LT 
xenograft bearing mice.  
Transduction efficiency of each CAR+ T-cell population was investigated prior to administration 
into mice. Detection of the CSF-1-based CARs was achieved by flow cytometry using a goat 
polyclonal anti-human CSF-1 antibody, followed by a FITC-conjugated secondary antibody (pink 
histograms) (A). The level of expression of IL-34-based CARs was assessed using mouse anti-
human IL-34 antibody directly conjugated to PE (purple histograms) (B). Staining was 
compared to untransduced T-cells probed using the same antibody combinations (blue 





To investigate in vitro anti-tumour activity, surplus T-cells from the populations infused into the 
mice were co-cultured at 1:1 ratio with the T47D FMS and T47D cell lines (C) and (D). Target 
cell destruction was measured at 24h using an MTT assay. Each sample was run in triplicate 
and data are presented as mean ± standard deviation. T-cell phenotype was investigated in all 
CAR T-cell populations. Proportion of CD8+ T-cells (E), memory phenotype (F) and 
expression of a number of anergy markers (G) was determined by flow cytometry using a 
panel of directly conjugated mouse anti-human antibodies consisting of CD3 APC-Cy7, CD8 
PE-Cy7, CD45RO PerCP-Cy5.5, CCR7 APC, 2B4 FITC, TIM3 PerCP-Cy5.5, PD1 APC-Cy7 
and LAG3 APC.  
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As described previously, the immunophenotype of the CAR+ T-cells was investigated 
prior to in vivo administration. The isolated and expanded T-cells expressed a 
predominantly effector memory (EM) phenotype (CD45RO+CCR7-) with roughly half of 
the cells expressing the CD8 co-receptor (Figure 5.10, E and F). T-cells were also 
probed for a number of anergy markers and as observed previously no significant 
difference in the immunophenotype was noted between UT T-cells and CAR+ T-cells 
(Figure 5.10, G). 
 
Despite the fact that K299 FMS LT xenografts retained high surface level of CSF-1R 
expression (Figure 5.9, E), mice treated with CAR+ T-cells showed no significant 
therapeutic response compared to those receiving UT T-cells or PBS. There was a 
slight delay in tumour progression in the C34B+ and 34CB+ T-cell treated groups, but 
ultimately this did not translate into a significant survival benefit (Figure 5.11, B and D). 
No treatment-related toxicities were observed over the duration of the study as 
indicated by the expected weight gain in all mice, irrespective of treatment group 
(Figure 5.11, C). As highlighted by Figure 5.11 E, some differences in tumour 
progression in individual mice were observed. Two mice in the C4B group had an initial 
drop in tumour burden 4 days post CAR+ T-cell treatment and one mouse from the 
C34B group showed consistently slower tumour progression throughout the study.   
 
At the end of the study, peripheral blood was collected by cardiac puncture and 
tumours and spleen were excised from three mice per treatment group and 
investigated by flow cytometry for target retention post treatment and human T-cell 
infiltration. As expected, no circulating T-cells were detected in the peripheral blood, 
spleen or tumours (data not shown) and surface levels of expression of CSF-1R in the 
5 treatment groups and the control PBS group remained high in vivo (Figure 5.12). It 
was concluded that the poor treatment outcome despite the abundant target availability 






Figure 5.11 In vivo anti-tumour activity of CAR+ T-cells in the K299 FMS LT xenograft 
model.  
(A) 30 SCID/Beige mice were inoculated with 2 x 106 K299 FMS LT cells and 6 days later were 
treated i.v. with 10 x 106 CAR+ T-cells or UT T-cells or PBS (n=5). Animals were weighed (C) 
and tumour burden was monitored using BLI until the conclusion of the study (B). Relative flux 







Relative Flux = (Total Flux at any given time point / Total Flux at day 0 post cancer cell 
administration)*100 
Kaplan-Meier survival analysis showed no significant survival difference between treatment 
groups (D). To investigate further anti-tumour efficacy within each group, total flux for individual 







Figure 5.12 Surface levels of CSF-1R expression post treatment of the K299 FMS LT 
xenograft model.  
Tumours from three mice per treatment group were excised post mortem and investigated for 
the expression of CSF-1R by flow cytometry. Single cell suspension was achieved by 
mechanical disaggregation. Non-specific binding of the antibodies was limited by using mouse 
Fc block prior to staining with a rat anti-human CSF-1R antibody, followed by a goat anti-rat 
FITC conjugated secondary antibody. All gates were set using FMO controls. The employed 
gating strategy was described previously (Figure 5.2 E). No statistically significant difference 
was found between groups as determined by one-way ANOVA, followed by Bonferroni post-hoc 
test.  Data are presented as mean ± SEM.  
 
  

































opposed to 20 x 106 CAR+ T-cells) in this experiment as well as to the general poor T-
cell persistence in SCID/Beige mice.   
 
5.3 Discussion 
The major aim of this study was to evaluate the therapeutic activity of CSF-1R-re-
targeted T-cells following adoptive transfer to mice with established CSF-1R-
expressing human lymphoma xenografts. Therefore it was of initial importance to 
develop a suitable xenograft lymphoma mouse model. Subcutaneous mouse models 
are widely used for preclinical drug testing due to ease of tumour establishment and 
measurement, but they do not represent clinically relevant models of the disease. 
Therefore in order to assess factors such as T-cell trafficking and the suppressive 
tumour microenvironment upon adoptive T-cell transfer we have employed the 
intravenous administration route for tumour cell delivery as the closest possible 
representation of the clinical disease.  
 
Out of the six lymphoma cell lines administered i.v. at 2 doses (10 x 106 and 5 x 106 
cells), only the sK299 LT cell line engrafted stably, yielding a xenograft model of 
disseminated human CSF-1R+ lymphoma in SCID/Beige mice (Figure 5.1, B). 
Following i.v. administration, the sK299 LT cells trafficked to the lymph nodes where 
solid tumours were established (Figure 5.2, C and D). In that respect, generating CAR+ 
T-cells with central memory phenotype for adoptive transfer is desirable, as these cells 
home primarily to the lymph nodes, thereby increasing the chance for tumour 
encounter and eradication [410, 411]. Consequently, all T-cells were phenotyped prior 
to adoptive transfer but it was established that they consistently lacked CCR7 
expression and exhibited predominantly effector memory T-cell phenotype (Figure 5.3, 
F; Figure 5.4, F and Figure 5.10, F). This could be attributed to the duration of the in 
vitro T-cell culture as well as to the cytokine milieu of the expansion protocol. At all 
instances, prior to in vivo administration transduced T-cells were expanded for 14 to 17 
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days in the presence of IL-4, which delivered a pseudo IL-2/IL-15 signal to transduced 
T-cells through the 4αβ chimeric cytokine receptor (please refer to 2.1.1.3 for more 
details). Alternative expansion protocols were not tested as the provided IL-4 was 
harnessed for its ability to induce selective expansion and enrichment of transduced T-
cells [246]. One exciting possibility would be attempting to induce long-living memory 
stem T-cells in the presence of IL-7 and IL-15 [376, 377, 412]. These T-cells not only 
retain high levels of CCR7 expression but they have also been reported to have 
improved in vivo persistence when compared to T-cells expanded in IL-2 [413, 414]. 
 
To investigate their in vivo efficacy, CAR-grafted T-cells were adoptively transferred 
into mice bearing sK299 LT xenografts and their subsequent effect on tumour growth 
was investigated. At the same time, 3rd generation CAR+ T-cells were compared to 
double targeting CAR+ T-cells, for their in vivo persistence and therapeutic activity. The 
subsequent level of tumour burden displayed by CAR+ T-cell-treated mice was 
compared with those treated with UT T-cells, or with PBS alone. As demonstrated in 
Figure 5.5 B and E, double targeting CAR-grafted T-cells demonstrated significant anti-
tumour activity in vivo in this model, whereas 3rd generation CAR-grafted T-cells 
conferred no therapeutic benefit. Mice that received one of the two alternative double 
targeting CAR T-cells (C34B) maintained the lowest tumour burden throughout the 
study, reaching significance by day 24. This result shows that double targeting CAR-
grafted T-cells but not 3rd generation CAR+ T-cells are capable of promoting anti-
tumour activity in vivo, in keeping with the superior performance of this CAR when 
tested in vitro (Figure 4.9; Figure 4.10 and Figure 4.11). Moreover, by the end of the 
study 3 mice from the C34B-treated group were tumour-free conferring 33% long-term 
survival of the C34B+ T-cell-treated group (Figure 5.5, D and Figure 5.6).  
 
Despite the demonstrated significant anti-tumour activity in vivo of the C34B+ T-cells, 
67% (6/9) of mice receiving C34B+ T-cells showed visible evidence of tumour at post-
mortem analysis. In two of these six mice, a substantial delay in tumour progression 
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was observed when compared to mice treated with either UT T-cells or PBS. 
Nonetheless, tumour burden began to increase exponentially after day 24, indicating 
that the initial anti-tumour activity of C34B+ T-cells in these mice did not clear the entire 
tumour burden. One possible explanation for this is downregulation of the target CSF-
1R by tumour cells under the selective pressure of the C34B+ T-cells, thereby 
interfering with T-cell recognition. Post-mortem analysis demonstrated that CSF-1R 
expression was detected in all treatment groups (Figure 5.7) and levels of expression 
corresponded to those found in the pilot study undertaken to investigate sK299 LT 
growth in vivo (Figure 5.2, E and F). Consequently, no in vivo antigen loss had 
occurred post CAR+ T-cell treatment as demonstrated by these experiments. Despite 
this fact, cell surface expression of CSF-1R both in vitro and in vivo is relatively low in 
the sK299 LT cell line (Figure 5.2, F). This is also reflected in the modest in vitro anti-
tumour activity of CAR+ T-cells against the sK299 LT cell line (Figure 4.14). It was 
therefore possible that the low level of target availability was insufficient to sustain 
CAR+ T-cell activation in vivo resulting in T-cell loss and/ or anergy. Since no T-cells 
had been detected at the end of the study or at the time of interim blood sampling, 
phenotyping for anergy markers was not possible.  
 
In order to address the potential impact of low level target expression by sK299 LT 
tumours upon therapeutic activity of CAR+ T-cells, human CSF-1R was over-expressed 
in these tumour cells using retroviral mediated gene transfer (Figure 5.8, A). Ectopic 
CSF-1R expression had no effect on the in vitro growth kinetics but induced slower 
tumour progression in vivo (Figure 5.8, B and Figure 5.9, A). As expected, the high 
level of CSF-1R expression rendered the K299 FMS LT cell line more susceptible to 
killing by CSF-1R-re-targeted T-cells in vitro (Figure 5.8, C). Target cell lysis was 
accompanied by CSF-1R-re-targeted T-cell activation, indicated by IFN- and IL-2 




Despite the fact that ectopic CSF-1R expression induced slower in vivo growth kinetics, 
it did not affect the tumour dissemination pattern observed previously with the parental 
cell line. As evident in Figure 5.9 C, solid tumours formed exclusively in the lymph 
nodes with no tumour detected in the heart, liver, lungs, spleen or peripheral blood 
(Figure 5.9, C and D). High cell surface expression of CSF-1R was also maintained in 
vivo in tumour-bearing mice (Figure 5.9, E). However, the observed in vivo anti-tumour 
effect of CSF-1R re-targeted CAR T-cells against the K299 FMS LT model was inferior 
to that seen in mice engrafted with parental sK299 LT cells (Figure 5.11, B and E). This 
discrepancy may in part have resulted from the different dose of CAR+ T-cells 
administered in the two in vivo studies – while sK299 LT-xenograft-bearing mice were 
treated with 20 x 106 CAR+ T-cells, mice engrafted with K299 FMS LT cells were 
administered only 10 x 106 CAR+ T-cells (Figure 5.5, A and Figure 5.11, A). However, 
functional and phenotypic attributes of cells used in both studies were broadly similar. 
In both cases, T-cells had predominantly effector memory phenotype (CD45RO+CCR7-
), with roughly half of the cells expressing the CD8 co-receptor, In addition, there were 
no significant differences observed in the expression of markers of anergy/ T-cell 
exhaustion (Figure 5.3, E, F and G; Figure 5.4, E, F and G; Figure 5.10, E, F and G). 
Furthermore, T-cell transduction efficiency for all four CAR constructs was comparable 
across both in vivo studies (Figure 5.3, A and B; Figure 5.4, A and B; Figure 5.10, A 
and B). Cytotoxic potential was also maintained in both cases during T-cell preparation 
procedures for infusion (Figure 5.3, C and D; Figure 5.4, C and D; Figure 5.10, C and 
D). Consequently, it was concluded that the poor in vivo anti-tumour activity against 
K299 FMS LT xenografts-bearing mice couldn’t be attributed to the qualities of the T-
cell product itself. This finding also suggests that expression of the CSF-1R target was 
not a limiting factor to the efficacy of these CAR T-cells in vivo.  
 
At post-mortem analysis, CSF-1R expression was detected in all treatment groups 
(Figure 5.12) and levels of expression were similar to those observed in the pilot study 
undertaken to investigate K299 FMS LT growth in vivo (Figure 5.9, E). Interestingly, 
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C4B+ and C34B+ T-cell treated mice showed a considerable, yet not statistically 
significant decrease in cell surface target expression when compared to mice treated 
with UT T-cells (Figure 5.12). This observation correlates with initial treatment 
response observed in 2 mice in the C4B+ T-cell treated group and one mouse in the 
C34B+ T-cell group (Figure 5.11, E). It is therefore likely, that during the initial anti-
tumour activity down-regulation of the target antigen has occurred at least in some 
tumour cells in those 2 groups. Indeed, target antigen modulation under selective 
pressure is one of the most important tumour escape strategies associated with 
treatment failure or with subsequent relapse, following the administration of a 
monospecific product [210, 415], including CAR T-cells [210]. Nevertheless, even 
though antigen loss probably played a role in the initial anti-tumour activity in the C4B+ 
and C34B+ T-cell treated groups, it is unlikely to be responsible for the observed poor 
anti-tumour activity against K299 FMS LT xenografts-bearing mice, as at the end of the 
study target antigen expression was much higher in all groups when compared to the 
sK299 FMS xenograft model (Figure 5.7 and Figure 5.12).  
 
Taken together these results suggest that the high level of target expression, achieved 
by ectopic CSF-1R expression, is of secondary importance to the treatment response 
in this model. Apart from the partial antigen loss that may have occurred in two of the 
treatment groups, this could be attributed to the fast recycling of the receptor from the 
cell surface upon ligand binding.  
 
An alternative possibility is that the T-cells may have undergone activation-induced cell 
death (AICD) due to being overwhelmed by the antigen [416]. Chronic stimulation of T-
cells leads to the up-regulation of both Fas and Fas ligand, which are the principal 
mediators of AICD, leading to subsequent loss of anti-tumour activity [417]. However, 
no T-cells were recovered at the end of the study, which precluded further investigation 




In conclusion, the greater anti-tumour activity observed in mice with sK299 LT 
compared to sK299 FMS tumours can most probably be attributed to the larger dose of 
CAR+ T-cells administered in this study. The overall treatment response in the K299 
FMS LT xenograft bearing mice, even though modest when compared to the previous 
study with the sK299 LT model, was best in the double targeting CAR+ T-cell treated 
groups, consistent with my previous observations (Figure 5.11, B). The most likely 
explanation for the better double targeting CAR+ T-cell control over tumour growth 
when compared to third generation CAR+ T-cells is their better survival following 
adoptive transfer. Although investigations into CAR+ T-cell in vivo persistence (using T-
cell imaging) were not undertaken, collected in vitro data suggest that double targeting 
CAR+ T-cells, and not 3rd generation CAR+ T-cells, retain their ability to produce IL-2 
through recursive antigen re-stimulation, thereby supporting their proliferation and 
survival for longer (Figure 4.9, 4.10 and 4.11). Indeed, lack of sustainable T-cell 
persistence following adoptive transfer has been postulated as a major contributing 
factor to the poor responses so far seen in clinical trials [169-171, 221]. Furthermore, 
beneficial outcomes have been strongly correlated with more pronounced in vivo 
longevity following adoptive transfer in both animal models and patients [180, 418].  
 
Overall, these data have shown that T-cells expressing double targeting CARs but not 
3rd generation CARs retain their anti-tumour activity following adoptive transfer in vivo. 
In the case of C34B+ T-cell treated mice, this response results in a significant delay in 
tumour growth in the sK299 LT xenograft model when compared to mice treated with 
UT T-cells or PBS. A major obstacle to achieving more profound in vivo anti-tumour 
activity of CAR+ T-cells has been the aggressive nature of the lymphoma model, while 
at the same time, T-cell persistence post adoptive transfer has been poor. 
Consequently, strategies aimed at increasing the survival of CAR+ T-cells may need to 
be considered for future efficacy studies in an attempt to ensure complete tumour 
regression and a sustained anti-tumour effect. One such strategy involves the use of 
more severely immune-compromised mice models. Most such models described in the 
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literature rely on NOD/SCID mouse strains, which contain additional mutations in the 
common gamma chain of the IL-2 receptor gene. This mutation can either be a 
truncation in the case of so-called NOG mice or a null mutation in NSG mice [419, 
420]. Both strains are characterised by a similar phenotype lacking T-cells, B-cells and 
NK cells, while macrophages and dendritic cells are defective, thereby providing a 
better setting for CAR+ T-cell engraftment and persistence post in vivo administration 
[421]. Another strategy, would be employing the 4 expansion system in vivo, in 
particular since IL-4 has been administered to patients with diverse malignancies, 





Chapter 6  General Discussion 
The overall aim of this PhD was to investigate whether primary human T-cells could be 
genetically re-targeted against CSF-1R and whether this approach could represent a 
novel therapy for the treatment of cHL and ALCL. 
 
The emerging picture of the CSF-1/CSF-1R axis in cHL and ALCL reveals its central 
role in tumour progression [34, 35]. The oncogenic potential of this cytokine receptor 
pair arises from autocrine and/or paracrine signalling, which promotes tumour cell 
proliferation and survival [294]. Additionally, CSF-1-secreting tumours are known to 
stimulate local macrophage recruitment and monocyte education to TAMs, which in 
turn mediate immune suppression and confer resistance to cytotoxic therapies [294]. 
Thus, blockade of this axis might be expected not only to directly target CSF-1R-
expressing neoplastic cells, but also to abrogate the tumour permissive and 
immunosuppressive microenvironment.  
 
Over the past decade, there has been an exponential increase in the number of clinical 
studies undertaken to evaluate the safety and efficacy of CAR T-cell based 
immunotherapy in patients with diverse malignant disorders. Of these, most successful 
trials have been directed against haematological malignancies of B-cell origin while 
achievements against solid cancers have been more modest. Among the major 
obstacles to effective CAR-based immunotherapy of cancer are poor in vivo longevity 
of the genetically modified T-cells and their sub-optimal effector function within the 
tumour microenvironment. Both limitations may be attributed at least in part to 
inefficient CAR+ T-cell co-stimulation in the often hostile tumour microenvironment. 
Physiological co-stimulation of T-cells is a dynamic process that relies upon a large 
number of co-stimulatory molecules that display great diversity in their expression and 
structure and whose functions are largely context dependent [424]. However, the 
genetic engineering of T-cells imposes restrictions on the number of co-stimulatory 
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molecules that can be employed. Consequently, in an attempt to fine-tune CAR-
mediated T-cell co-stimulation, a panel of eight CARs targeting CSF-1R have been 
designed and cloned. Two targeting moieties with distinct target affinities have been 
utilised to assess the impact of the rate of target engagement and target dissociation 
on CAR activation. Furthermore, classical second and third generation CARs have 
been compared to novel double targeting CARs, providing co-stimulation in trans.    
 
A key starting point in the in vitro characterisation of the panel of CARs was the 
demonstration that they can all be routinely and stably expressed at the surface of 
primary human T-cells. This was confirmed by flow cytometry on a number of 
occasions, including following antigen-mediated activation, indicating successful 
integration of the receptor cDNA into the recipient T-cell genome. This is an important 
observation, as stable CAR expression is central to achieving a sustained anti-tumour 
response.  
 
The targeting strategy employed in this thesis was first validated against the breast 
cancer cell line T47D FMS, which has been shown to express high levels of the target 
CSF-1R in a stable manner. Successful genetic re-targeting of T-cells was confirmed 
by complete target cell destruction within 24h of co-culture. Furthermore, cancer cell 
lysis was accompanied by CAR T-cell activation, which occurred only in the presence 
of the antigen (T47D FMS cells), but not in its absence (T47D cells) or in the absence 
of monolayer, confirming specificity of the CAR T-cell activation. A crucial observation 
made during these in vitro studies was the poorer activation of IL-34-based CARs in 
comparison to CSF-1-based CARs. These findings can most probably be attributed to 
the higher affinity of IL-34 interaction with the target, which can prove an impediment to 
serial target engagement and disengagement by CAR T-cells, thereby causing lower 
biological activity of IL-34-based CAR-grafted T-cells [385-390, 425]. An additional 
crucial observation was that provision of CAR-derived dual co-stimulation in trans, by 
co-expression of a pair of synergistic CARs, elicits more robust and sustained anti-
242 
 
tumour activity in vitro. Whilst all signalling-competent CSF-1R-targeting CAR 
constructs showed identical cytolytic capacity upon encountering the target for the first 
time, successive rounds of antigen stimulations revealed that the C34B CAR 
repeatedly outperformed matched second and third generation CARs. The observed 
poor second and third generation CAR T-cell expansion and accumulation is not 
uncommon when weekly repeated antigen stimulations are performed in the absence 
of exogenous cytokine support [391]. A third crucial observation was that superior 
antigen-specific proliferation, cytokine secretion (IL-2 and IFN-) and cytotoxicity upon 
consecutive rounds of antigen stimulation were observed only with C34B-grafted T-
cells and not in the 34CB+ T-cell group. These results suggest that while providing co-
stimulation in trans results in favourable spatial and temporal differences in the 
recruitment, kinetics and regulation of co-stimulation, fine-tuning of co-stimulation 
through the CAR affinities is necessary to achieve optimal potency of the constructs.   
 
The ability of all signalling-competent CAR-grafted T-cells to be successfully redirected 
against cHL and ALCL was confirmed by their activation when co-cultivated with 6/6 
lymphoma cell lines. All six lymphoma cell lines produced at least one of the natural 
ligands for CSF-1R. Autocrine stimulation of CSF-1R in this manner is known to induce 
receptor down-regulation by internalization of the receptor-ligand complex [335], which 
would be expected to compromise targeting of CSF-1R+ lymphoma cells by CAR T-
cells that have been directed against this target. Nonetheless, significant target cell 
lysis of all lymphoma cell lines was reproducibly observed. In an additional step, 
dexamethasone priming of the panel of lymphoma cell lines was tested as a device to 
up-regulate the expression of CSF-1R by lymphoma cells. However, this approach 
failed to induce significant cell surface up-regulation of the target, precluding its further 
use. A crucial future step in determining the translational feasibility of this approach will 
be to determine whether anti-tumour activity is maintained when re-directed autologous 




A final intention of these studies was to characterize the therapeutic impact of CSF-1R-
re-targeted T-lymphocytes on in vivo tumour growth. A crucial observation in the 
preclinical evaluation of these T-cells was that double targeting CAR-grafted T-cells but 
not 3rd generation CAR+ T-cells retain their anti-tumour activity in vivo. Specifically, in 
the case of C34B+ T-cell treated mice, this response resulted in significant delay in 
tumour growth and 33% long-term survival in the sK299 LT xenograft model. The 
observed superior tumour growth control by double targeting CAR T-cells in 
comparison to 3rd generation CAR T-cells may be attributable to their enhanced 
survival in vivo following adoptive transfer. In support of this, double targeted CAR T-
cells exhibited a more durable ability to undergo re-stimulation in vitro upon co-culture 
with CSF-1R-expressing lymphoma cells. In future studies, imaging of CAR re-targeted 
T-cells could provide valuable information on their in vivo longevity and bio-distribution, 
providing further information on this question.   
 
Safety of CAR T-cell immunotherapy has remained problematic to date. On-target 
toxicity has been linked to frequent occurrence of CRS, which has been lethal on 
occasions [195]. All currently available CSF-1R targeted therapies have shown 
acceptable level of toxicity in phase 1 clinical trials [408, 409]. Grade 3/4 adverse 
events (asthenia, peripheral edema and pyrexia) have been reported in only 18% of 
patients (21/114) upon treatment with a humanised anti-CSF-1R monoclonal antibody 
termed RG7155. Reported toxicities include significant reduction of surrogate skin 
tissue resident macrophages and rapid elimination of CD14+CD16+ peripheral 
monocytes, while classical CD14+CD16- monocytes did not show a sustained 
alteration.  
 
Assessing the potential toxicities of any targeted therapy is extremely difficult in the 
preclinical setting owing to the need for cross-reactivity with the murine analogue of the 
target. However, human CSF-1 is capable of interacting with the murine as well as the 
human CSF-1R [426, 427], while human IL-34 interacts very inefficiently with murine 
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CSF-1R [426, 428]. Initial efficacy studies have revealed that CAR+ T-cell treatment 
was very well tolerated, causing temporary loss of <5% body weight without any other 
side effects attributed to the treatment despite the observed anti-tumour activity. 
Another approach for investigating potential toxicity prior to further in vivo testing 
involves the co-culture of CAR-grafted T-cells with isolated primary monocytes and 
human monocyte-derived macrophages in vitro. Alternatively, depletion of tissue 
resident macrophages and/or circulating monocytes can be assessed following 
adoptive transfer of CAR-grafted T-cells in tumour-free murine models. Taken together, 
data presented in this thesis establish the principle that CSF-1R-targeted CAR+ T-cells 
can exert anti-tumour activity against ALCL cells with acceptable safety in a mouse 
model in which cytokine storm can be elicited [240].   
 
Despite encouraging results in selected haematological malignancies, a variety of 
discrete immune checkpoints can restrict the full potential of CAR T-cell therapy. Use of 
checkpoint inhibitors targeting CTLA-4 and PD-1/ PD-L1 have yielded impressive 
results in a select range of solid tumours, providing exciting opportunities for 
combinational therapy with CAR T-cells. Furthermore, the striking response to PD1 
blockade as a single agent in cHL (74% overall response and 17% complete response) 
suggests that investigation into the potential for a combination therapy with CAR T-cells 
is merited [60].  
 
Overall, the data presented within this thesis show that CAR-grafted T-cells have been 
successfully re-targeted against a panel of cHL and ALCL tumour cell lines in vitro and 
that this anti-tumour activity is maintained in vivo. An innovative approach has been 
developed and optimised in which the 4 chimeric cytokine receptor is co-expressed 
with a pair of synergistic CARs targeted against CSF-1R. Data outlined in this thesis 
suggest that provision of CAR-derived dual co-stimulation in trans elicits more robust 
and sustained anti-tumour activity both in vitro and in vivo. This is accompanied by 
superior antigen-specific proliferation, cytokine secretion (IL-2 and IFN-) and 
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cytotoxicity upon consecutive rounds of antigen stimulation in comparison to second 
and third generation CARs. These encouraging findings warrant further investigations 
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Supplementary Figure S1 Phenotyping of human monocyte-derived macrophages for 
M1/M2 polarisation. MACS-separated CD14+ human monocytes were differentiated into M1 or 
M2 macrophages by cultivation for 7 days in GM-CSF or CSF-1 respectively. (A) Macrophages 
were probed for the cell surface expression of CSF-1R using a monoclonal rat anti-human CSF-
1R antibody followed by a goat anti-rat FITC secondary antibody (red histograms). Cells were 
also stained using the secondary antibody only (blue histograms) to show the specificity of 
staining. (B and C) Macrophages were stained for expression of CD80 (pink histogram, B.) and 
MHC class II (pink histogram, C.) using a monoclonal anti-human CD80-APC and monoclonal 
anti-human HLA-DR-FITC respectively. Blue histograms represent staining with matched 





































































































































Supplementary Figure S2 Cytotoxicity of CSF-1R-retargeted T-cells 
against the K299 cell line in vitro in the presence or absence of 1uM 
dexamethasone. The ALCL cell line K299 was pre-treated with 1uM 
dexamethasone or medium alone for 48h, then washed and co-cultured with a 
panel of CAR-grafted T-cells at a 1:1 ratio for the indicated period of time. The 
level of target cell viability co-culture was monitored using a luciferase assay. 
The data was normalised against the maximal luminescence, as shown by 
tumour cells grown in the absence of T-cells. Normalisation was achieved 
using the following equation: Tumour cell viability = (Sample luminescence 
value / Average No T-cell luminescence value)*100 
Data are presented as mean ± SD from two independent experiments. **** = 
p<0.0001; *** = p<0.001; ** = p<0.01; * = p<0.05 relative to UT T-cells at any 












Supplementary Figure S3 DEL cell line destruction upon co-culture with C4+ T-cells. 
The lymphoma cell line DEL was CFSE-labelled and co-cultured in 1:1 ratio with UT, C4+ and 
CT4+ T-cells. Cancer cell destruction was assessed by clearance of CFSE-labelled cells as 
determined by flow cytometry. Co-cultures were probed at 0h (A.), 24h, 48h, 72h and 96h (B.). 






































































Supplementary Figure S4 Fas and FasL expression on CAR+ T-cells before and after 
antigen stimulation. CAR+ T-cells were probed for the cell surface expression of Fas and 
FasL prior and post antigen stimulation on T47D FMS monolayers using anti-human CD95-







































Supplementary Figure S5 T-cell viability after successive rounds of antigen-stimulation 
CAR+ T-cells were subjected to successive rounds of antigen stimulation by co-culturing on 
T47D FMS monolayers at 1:1 ratio. T-cells were assessed for cell viability after each round of 



































































Supplementary Figure S6 PD1 expression on C34B+ T-cells after successive rounds of 
antigen-stimulation. C34B+ T-cells were subjected to successive rounds of antigen 
stimulation by co-culturing on T47D FMS monolayers at 1:1 ratio. T-cells were stained for the 
cell surface expression of PD1, CD4 and CD8 using anti-human PD1-APC-Cy7, CD8-PE-Cy7 





































































Supplementary Figure S7 TIM3 expression on C34B+ T-cells after successive rounds of 
antigen-stimulation C34B+ T-cells were subjected to successive rounds of antigen stimulation 
by co-culturing on T47D FMS monolayers at 1:1 ratio. T-cells were probed for the cell surface 





































































Supplementary Figure S8 LAG3 expression on C34B+ T-cells after successive rounds of 
antigen-stimulation C34B+ T-cells were subjected to successive rounds of antigen stimulation 
by co-culturing on T47D FMS monolayers at 1:1 ratio. T-cells were probed for the cell surface 



































































Supplementary Figure S9 2B4 expression on C34B+ T-cells after successive rounds of 
antigen-stimulation C34B+ T-cells were subjected to successive rounds of antigen stimulation 
by co-culturing on T47D FMS monolayers at 1:1 ratio. T-cells were probed for the cell surface 
















































































































Supplementary Figure S10 CAR+ T-cells were co-cultured with the panel of lymphoma cell 
lines for 72 hours, before cancer cell viability was quantified using a luciferase assay. This was 
subsequently plotted against the percent CSF-1R expression on each lymphoma cell line, 
which had been measured using flow cytometry. The data presented has been gained from a 
minimum of five independent experiments and each dot represents an individual sample 
measured for lymphoma cell viability. 
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Supplementary Table S1 – statistical significance of cancer cell viability post 
treatment with different CAR+ T-cell populations as determined by two-way ANOVA, 
followed by a Bonferroni post-hoc test.  
 
A. C4+ vs. 43428ζ+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns **** ns ns ns 
48h ns ns **** **** ns ns 
72h ns ** * **** ns ns 
96h ** ns ns **** * ns 
120h * ns ns ** ns ns 
144h * ns ns **** ns ns 
 
B. C4B+ vs. 43428Bζ+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns ns ns ns ns 
48h ns ns ns ns ns ns 
72h ns ns ns ns ns ns 
96h ns ns * ns ns ns 
120h ns ns ns ns ns ns 










C. C34B+ vs. 34CB+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns **** **** ns ns 
48h ns ns **** **** ns ns 
72h ns ns **** **** ** ns 
96h ns ns ns **** ** ** 
120h ns ns ns **** ns ** 
144h ns ns ns **** ns *** 
 
D. C4+ vs. C4B+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns ns ns ns ns 
48h ns ns ns ns ns ns 
72h ns ns ns ns ns ns 
96h ns ns ns ns ns ns 
120h ns ns ns ns ns ns 
144h ns ns ns ns ns ns 
 
E. 43428ζ+ vs. 43428Bζ+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns ns ns ns ns 
48h ns ns ns ns ns ns 
72h ns ns ns ns ns ns 
96h ns ns ns ns ns ns 
120h ns ns ns ns ns ns 




F. C4B+ vs. C34B+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns ns ns ns ns 
48h ns ns ns ns ns ns 
72h ns ns ns ns ns ns 
96h ns ns ns ns ** * 
120h ns ns ns ns ns * 
144h ns ns ns ns ns ns 
 
G. 43428Bζ+ vs. C34B+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns * ** ns ns 
48h ns ns ns **** ns ns 
72h ns ns ns *** ns ns 
96h ns ns ** **** * ns 
120h ns ns * ns ns ns 
144h ns ns ns * ns ns 
 
H. C4B+ vs. 34CB+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns **** ** ns ns 
48h ns ns **** **** ns ns 
72h ns ns *** **** ns ns 
96h ns ns ns **** ns ns 
120h ns ns ns ** ns ns 




I. 43428Bζ+ vs. 34CB+ T-cells 
 KM-H2 K299 DEL FE-PD JB6 L540 
24h ns ns ns ns ns ns 
48h ns ns ns ns ns ns 
72h ns ns ns ns ns ns 
96h ns ns ns ns ns ns 
120h ns ns ns ns ns ns 





Supplementary Table S2 – statistical significance of cytokine release by different 
CAR+ T-cell populations upon co-culture with the panel of lymphoma cell lines as 
determined by two-way ANOVA, followed by a Bonferroni post-hoc test.  
 
A. IFN- release 
 KM-H2 K299 DEL FE-PD JB6 L540 
C4 vs. 43428ζ ns ns ns ns ns ns 
C4B vs. 43428Bζ ns ns ns ns ns ns 
C34B vs. 34CB ns ns * ns ns ns 
C4 vs. C4B ns ns ns ns ns ns 
43428ζ vs. 43428Bζ ns ns ns ns ns ns 
C4B vs. C34B ns ns ns ns ns ns 
43428Bζ vs. C34B ns ns * ns ns ns 
C4B vs. 34CB ns ns ns ns ns ns 
















B. IL-2 release 
 KM-H2 K299 DEL FE-PD JB6 L540 
C4 vs. 43428ζ ns ns ns ns ns ns 
C4B vs. 43428Bζ ns ns ns ns ns ns 
C34B vs. 34CB ns ns ns ns ns ns 
C4 vs. C4B ns ns ns ns ns ns 
43428ζ vs. 43428Bζ ns ns ns ns ns ns 
C4B vs. C34B ns ns ns ns ns ns 
43428Bζ vs. C34B ns ns ns ns ns ns 
C4B vs. 34CB ns ns ns ns ns ns 
43428Bζ vs. 34CB ns ns ns ns ns ns 
 
  
317 
 
Sequences 
 
C4 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
318 
 
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGGCTCTCCCAGTGACTGCCCTAC
TGCTTCCCCTAGCGCTTCTCCTGCATGCAGAGGAGGTGTCGGAGTACTGTAGCCA
CATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG
GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCC
AGTGTGCTACCTTAAGAAGGCATTTCTCCTGGTACAATACATAATGGAGGACACCA
TGCGCTTCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACT
CTCTTTGAGGCTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCC
TGCGTCCGAACTTTCTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATG
TCTTTAATGAAACAAAGAATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAAC
TGCAACAACAGCTTTGCTGAATGCTCCAGCCAAGGCCATGAGAGGCAGTCCGAG
GGAGCGGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGA
GCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTT
CCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTT
GCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGG
AGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCC
ACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCT
CCAGAGTGAAGTTCAGCAGGAGCGCAGAGCCCCCCGCGTACCAGCAGGGCCAG
AACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGG
ACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAAC
CCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTAC
AGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCT
TTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAG
GCCCTGCCCCCTCGCTAACAGCCACTCGAG 
 
319 
 
C4B 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
320 
 
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGGCTCTCCCAGTGACTGCCCTAC
TGCTTCCCCTAGCGCTTCTCCTGCATGCAGAGGAGGTGTCGGAGTACTGTAGCCA
CATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG
GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCC
AGTGTGCTACCTTAAGAAGGCATTTCTCCTGGTACAATACATAATGGAGGACACCA
TGCGCTTCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACT
CTCTTTGAGGCTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCC
TGCGTCCGAACTTTCTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATG
TCTTTAATGAAACAAAGAATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAAC
TGCAACAACAGCTTTGCTGAATGCTCCAGCCAAGGCCATGAGAGGCAGTCCGAG
GGAGCGGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGA
GCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTT
CCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTT
GCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGG
AGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCC
ACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCT
CCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGCGGC
CCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCCGGTTTCCCGAGGAG
GAGGAGGGCGGCTGCGAGCTGAGAGTGAAGTTCAGCAGGAGCGCAGAGCCCCC
CGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAG
AGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGG
AAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGAT
AAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGG
CAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTA
CGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAATAACAGCCACTCGAG 
 
321 
 
C34B 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
322 
 
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGGCTCTCCCAGTGACTGCCCTAC
TGCTTCCCCTAGCGCTTCTCCTGCATGCAGAGGAGGTGTCGGAGTACTGTAGCCA
CATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG
GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCC
AGTGTGCTACCTTAAGAAGGCATTTCTCCTGGTACAATACATAATGGAGGACACCA
TGCGCTTCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACT
CTCTTTGAGGCTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCC
TGCGTCCGAACTTTCTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATG
TCTTTAATGAAACAAAGAATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAAC
TGCAACAACAGCTTTGCTGAATGCTCCAGCCAAGGCCATGAGAGGCAGTCCGAG
GGAGCGGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGA
GCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTT
CCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTT
GCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGG
AGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCC
ACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCT
CCAGAGTGAAGTTCAGCAGGAGCGCAGAGCCCCCCGCGTACCAGCAGGGCCAG
AACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGG
ACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAAC
CCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTAC
AGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCT
TTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAG
GCCCTGCCCCCTCGCAGGAGGAAGAGAAGTGGATCCGGGGAGGGCAGGGGCTC
TCTCCTGACATGTGGAGATGTGGAAGAGAACCCCGGGCCCATGCCTAGAGGCTT
CACATGGCTGAGGTATCTGGGCATCTTCCTGGGCGTGGCTCTGGGAAACGAACC
TCTGGAAATGTGGCCACTGACACAGAATGAAGAGTGCACCGTTACAGGCTTCCTG
323 
 
CGGGACAAGCTGCAGTACAGGTCTAGGTTGCAGTACATGAAACACTATTTCCCTA
TTAACTACAAGATCTCCGTGCCTTACGAGGGAGTGTTCAGGATCGCCAACGTGAC
ACGGCTGCAGAGGGCTCAGGTCAGCGAGCGGGAGCTGCGGTATCTGTGGGTGC
TGGTGAGCCTGAGCGCCACCGAGAGCGTGCAAGACGTCCTGCTGGAAGGCCATC
CTAGCTGGAAGTACCTGCAGGAGGTGGAGACCCTGCTGCTGAACGTGCAGCAAG
GCTTGACCGACGTCGAGGTGAGCCCAAAGGTGGAGAGCGTGCTCAGCCTGCTGA
ACGCTCCTGGACCAAACCTGAAGCTGGTGAGGCCTAAGGCCCTGCTGGACAACT
GCTTCAGAGTGATGGAGCTGCTGTACTGCAGCTGCTGTAAGCAGAGCAGCGTGC
TGAACTGGCAAGACTGCGAAGTGCCTAGTCCTCAGAGCTGCAGCCCTGAGCCCA
GCCTGCAGTACGCTGCAACCCAGCTGTACCCTCCTCCACCTTGGAGCCCTAGCA
GCCCTCCTCACAGCACCGGAAGCGTGAGGCCTGTGAGAGCCCAAGGCGAGGGA
CTGCTGCCTGCGGCCGCACCCACCACGACGCCAGCGCCGCGACCACCAACCCC
GGCGCCCACGATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGGC
CAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATATC
TACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTTA
TCACCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGC
GGCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCCGGTTTCCCGAG
GAGGAGGAGGGCGGCTGCGAGCTGTAATAACAGCCACTCGAG 
 
CT4 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
324 
 
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGGCTCTCCCAGTGACTGCCCTAC
TGCTTCCCCTAGCGCTTCTCCTGCATGCAGAGGAGGTGTCGGAGTACTGTAGCCA
CATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACAGTCAGATG
GAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTTGAAAGATCC
AGTGTGCTACCTTAAGAAGGCATTTCTCCTGGTACAATACATAATGGAGGACACCA
TGCGCTTCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCTGCAGGAACT
CTCTTTGAGGCTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCATGACAAGGCC
325 
 
TGCGTCCGAACTTTCTATGAGACACCTCTCCAGTTGCTGGAGAAGGTCAAGAATG
TCTTTAATGAAACAAAGAATCTCCTTGACAAGGACTGGAATATTTTCAGCAAGAAC
TGCAACAACAGCTTTGCTGAATGCTCCAGCCAAGGCCATGAGAGGCAGTCCGAG
GGAGCGGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGA
GCAATGGAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTT
CCCGGACCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTT
GCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAA 
 
43428ζ 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
326 
 
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGCCTAGAGGCTTCACATGGCTGA
GGTATCTGGGCATCTTCCTGGGCGTGGCTCTGGGAAACGAACCTCTGGAAATGT
GGCCACTGACACAGAATGAAGAGTGCACCGTTACAGGCTTCCTGCGGGACAAGC
TGCAGTACAGGTCTAGGTTGCAGTACATGAAACACTATTTCCCTATTAACTACAAG
ATCTCCGTGCCTTACGAGGGAGTGTTCAGGATCGCCAACGTGACACGGCTGCAG
AGGGCTCAGGTCAGCGAGCGGGAGCTGCGGTATCTGTGGGTGCTGGTGAGCCT
GAGCGCCACCGAGAGCGTGCAAGACGTCCTGCTGGAAGGCCATCCTAGCTGGAA
GTACCTGCAGGAGGTGGAGACCCTGCTGCTGAACGTGCAGCAAGGCTTGACCGA
CGTCGAGGTGAGCCCAAAGGTGGAGAGCGTGCTCAGCCTGCTGAACGCTCCTGG
ACCAAACCTGAAGCTGGTGAGGCCTAAGGCCCTGCTGGACAACTGCTTCAGAGT
GATGGAGCTGCTGTACTGCAGCTGCTGTAAGCAGAGCAGCGTGCTGAACTGGCA
AGACTGCGAAGTGCCTAGTCCTCAGAGCTGCAGCCCTGAGCCCAGCCTGCAGTA
CGCTGCAACCCAGCTGTACCCTCCTCCACCTTGGAGCCCTAGCAGCCCTCCTCAC
AGCACCGGAAGCGTGAGGCCTGTGAGAGCCCAAGGCGAGGGACTGCTGCCTGC
GGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCAATG
GAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGA
CCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATA
GCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAG
327 
 
GCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCG
CAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCAGA
GTGAAGTTCAGCAGGAGCGCAGAGCCCCCCGCGTACCAGCAGGGCCAGAACCA
GCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAG
AGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCA
GGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGA
GATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACC
AGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCC
TGCCCCCTCGCTAACAGCCACTCGAG 
 
43428Bζ 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
328 
 
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGCCTAGAGGCTTCACATGGCTGA
GGTATCTGGGCATCTTCCTGGGCGTGGCTCTGGGAAACGAACCTCTGGAAATGT
GGCCACTGACACAGAATGAAGAGTGCACCGTTACAGGCTTCCTGCGGGACAAGC
TGCAGTACAGGTCTAGGTTGCAGTACATGAAACACTATTTCCCTATTAACTACAAG
ATCTCCGTGCCTTACGAGGGAGTGTTCAGGATCGCCAACGTGACACGGCTGCAG
AGGGCTCAGGTCAGCGAGCGGGAGCTGCGGTATCTGTGGGTGCTGGTGAGCCT
GAGCGCCACCGAGAGCGTGCAAGACGTCCTGCTGGAAGGCCATCCTAGCTGGAA
GTACCTGCAGGAGGTGGAGACCCTGCTGCTGAACGTGCAGCAAGGCTTGACCGA
CGTCGAGGTGAGCCCAAAGGTGGAGAGCGTGCTCAGCCTGCTGAACGCTCCTGG
ACCAAACCTGAAGCTGGTGAGGCCTAAGGCCCTGCTGGACAACTGCTTCAGAGT
GATGGAGCTGCTGTACTGCAGCTGCTGTAAGCAGAGCAGCGTGCTGAACTGGCA
AGACTGCGAAGTGCCTAGTCCTCAGAGCTGCAGCCCTGAGCCCAGCCTGCAGTA
CGCTGCAACCCAGCTGTACCCTCCTCCACCTTGGAGCCCTAGCAGCCCTCCTCAC
AGCACCGGAAGCGTGAGGCCTGTGAGAGCCCAAGGCGAGGGACTGCTGCCTGC
GGCCGCAATCGAGGTGGAGCAGAAGCTGATCAGCGAGGAGGACCTGCTGGACA
ACGAGAAGAGCAACGGCACCATCATCCACGTGAAGGGCAAGCACCTGTGCCCTT
329 
 
CTCCCCTGTTCCCCGGCCCTAGCAAGCCCTTCTGGGTGCTGGTTGTGGTGGGCG
GAGTGCTGGCTTGCTACAGCCTGCTGGTGACCGTGGCCTTCATCATCTTCTGGGT
GCGGAGCAAGCGGAGCCGGCTGCTGCACAGCGACTACATGAACATGACCCCTCG
GAGGCCCGGCCCCACCCGGAAGCACTACCAGCCCTACGCCCCTCCCCGGGACT
TCGCCGCTTACCGGAGCAAGCGGGGCAGGAAGAAGCTGCTGTACATCTTCAAGC
AGCCTTTCATGCGGCCTGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCC
GGTTCCCTGAGGAGGAAGAGGGCGGGTGCGAGCTGAGAGTGAAGTTCAGCAGG
AGCGCAGAGCCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTC
AATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGAC
CCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAAT
GAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGC
GAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGC
CACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAATAA 
 
34CB 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
330 
 
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGCCTAGAGGCTTCACATGGCTGA
GGTATCTGGGCATCTTCCTGGGCGTGGCTCTGGGAAACGAACCTCTGGAAATGT
GGCCACTGACACAGAATGAAGAGTGCACCGTTACAGGCTTCCTGCGGGACAAGC
TGCAGTACAGGTCTAGGTTGCAGTACATGAAACACTATTTCCCTATTAACTACAAG
ATCTCCGTGCCTTACGAGGGAGTGTTCAGGATCGCCAACGTGACACGGCTGCAG
AGGGCTCAGGTCAGCGAGCGGGAGCTGCGGTATCTGTGGGTGCTGGTGAGCCT
GAGCGCCACCGAGAGCGTGCAAGACGTCCTGCTGGAAGGCCATCCTAGCTGGAA
GTACCTGCAGGAGGTGGAGACCCTGCTGCTGAACGTGCAGCAAGGCTTGACCGA
CGTCGAGGTGAGCCCAAAGGTGGAGAGCGTGCTCAGCCTGCTGAACGCTCCTGG
ACCAAACCTGAAGCTGGTGAGGCCTAAGGCCCTGCTGGACAACTGCTTCAGAGT
GATGGAGCTGCTGTACTGCAGCTGCTGTAAGCAGAGCAGCGTGCTGAACTGGCA
AGACTGCGAAGTGCCTAGTCCTCAGAGCTGCAGCCCTGAGCCCAGCCTGCAGTA
331 
 
CGCTGCAACCCAGCTGTACCCTCCTCCACCTTGGAGCCCTAGCAGCCCTCCTCAC
AGCACCGGAAGCGTGAGGCCTGTGAGAGCCCAAGGCGAGGGACTGCTGCCTGC
GGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCAATG
GAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGA
CCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATA
GCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAAGAGGAGCAG
GCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCG
CAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCAGA
GTGAAGTTCAGCAGGAGCGCAGAGCCCCCCGCGTACCAGCAGGGCCAGAACCA
GCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAG
AGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCA
GGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGA
GATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACC
AGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCC
TGCCCCCTCGCAGGAGGAAGAGAAGTGGATCCGGGGAGGGCAGGGGCTCTCTC
CTGACATGTGGAGATGTGGAAGAGAACCCCGGGCCCATGGCTCTCCCAGTGACT
GCCCTACTGCTTCCCCTAGCGCTTCTCCTGCATGCAGAGGAGGTGTCGGAGTACT
GTAGCCACATGATTGGGAGTGGACACCTGCAGTCTCTGCAGCGGCTGATTGACA
GTCAGATGGAGACCTCGTGCCAAATTACATTTGAGTTTGTAGACCAGGAACAGTT
GAAAGATCCAGTGTGCTACCTTAAGAAGGCATTTCTCCTGGTACAATACATAATGG
AGGACACCATGCGCTTCAGAGATAACACCCCCAATGCCATCGCCATTGTGCAGCT
GCAGGAACTCTCTTTGAGGCTGAAGAGCTGCTTCACCAAGGATTATGAAGAGCAT
GACAAGGCCTGCGTCCGAACTTTCTATGAGACACCTCTCCAGTTGCTGGAGAAGG
TCAAGAATGTCTTTAATGAAACAAAGAATCTCCTTGACAAGGACTGGAATATTTTCA
GCAAGAACTGCAACAACAGCTTTGCTGAATGCTCCAGCCAAGGCCATGAGAGGCA
GTCCGAGGGAGCGGCCGCACCCACCACGACGCCAGCGCCGCGACCACCAACCC
CGGCGCCCACGATCGCGTCGCAGCCCCTGTCCCTGCGCCCAGAGGCGTGCCGG
CCAGCGGCGGGGGGCGCAGTGCACACGAGGGGGCTGGACTTCGCCTGTGATAT
CTACATCTGGGCGCCCTTGGCCGGGACTTGTGGGGTCCTTCTCCTGTCACTGGTT
332 
 
ATCACCAAGCGGGGCCGGAAGAAGCTGCTGTACATCTTCAAGCAGCCCTTCATGC
GGCCCGTGCAGACCACCCAGGAGGAGGACGGCTGCAGCTGCCGGTTTCCCGAG
GAGGAGGAGGGCGGCTGCGAGCTGTAATAACAGCCACTCGAG 
 
434Tr 
CCATGGGCTGGCTGTGTTCCGGCCTGCTGTTTCCTGTGTCCTGTCTGGTGCTGCT
GCAGGTGGCCAGCTCCGGGAACATGAAAGTGCTGCAGGAGCCCACATGTGTGTC
CGACTACATGTCCATCTCTACATGTGAGTGGAAGATGAACGGCCCCACAAACTGC
TCTACCGAGCTGCGGCTGCTGTACCAGCTGGTGTTTCTGCTGAGCGAGGCCCAC
ACCTGTATCCCAGAAAATAATGGCGGGGCCGGGTGTGTGTGCCACCTGCTGATG
GATGACGTGGTGTCTGCCGACAATTACACCCTGGACCTGTGGGCCGGACAGCAG
CTGCTGTGGAAGGGGTCCTTCAAACCCTCTGAGCACGTGAAGCCAAGGGCCCCC
GGCAACCTGACAGTGCACACCAACGTGTCTGATACACTGCTGCTGACATGGAGCA
ATCCATACCCTCCTGACAACTACCTGTACAACCACCTGACCTACGCCGTGAATATC
TGGAGCGAAAATGATCCTGCCGACTTTCGGATTTACAATGTGACCTATCTGGAGC
CCTCCCTGAGAATTGCCGCCTCTACCCTGAAATCTGGAATCTCCTACCGCGCCAG
GGTGCGGGCCTGGGCCCAGTGTTACAACACCACCTGGTCTGAGTGGAGCCCAAG
CACCAAGTGGCACAATTCTTATCGGGAGCCTTTTGAGCAGCACCTGATCCCCTGG
CTGGGACACCTGCTGGTGGGGCTGTCTGGCGCCTTTGGCTTCATCATTCTGGTGT
ACCTGCTGATCAACTGTAGGAATACAGGCCCTTGGCTGAAGAAGGTGCTGAAGTG
TAACACCCCCGACCCCTCTAAGTTCTTCAGCCAGCTGTCCTCTGAACACGGGGGA
GATGTGCAGAAGTGGCTGTCCAGCCCTTTCCCATCCAGCTCCTTTAGCCCCGGG
GGCCTGGCCCCTGAGATCTCTCCACTGGAAGTGCTGGAGCGGGACAAGGTGACC
CAGCTGCTGCTGCAGCAGGACAAGGTGCCAGAACCCGCCTCCCTGAGCTCCAAC
CACAGCCTGACATCTTGCTTTACAAATCAGGGATACTTCTTCTTCCACCTGCCCGA
TGCCCTGGAGATCGAGGCCTGCCAGGTGTACTTCACCTACGATCCCTACTCTGAG
GAAGACCCAGATGAGGGCGTGGCCGGGGCCCCAACCGGGTCCAGCCCACAGCC
ACTGCAGCCACTGTCCGGCGAAGATGACGCCTACTGCACATTCCCTTCCAGGGAT
GACCTGCTGCTGTTCAGCCCATCTCTGCTGGGCGGACCCTCTCCTCCAAGCACA
333 
 
GCCCCAGGGGGATCCGGCGCCGGGGAAGAGAGGATGCCCCCTAGCCTGCAGGA
GCGCGTGCCCAGAGACTGGGACCCCCAGCCCCTGGGCCCTCCAACCCCTGGGG
TGCCCGACCTGGTGGACTTCCAGCCTCCACCCGAGCTGGTGCTGAGGGAGGCC
GGCGAAGAGGTGCCCGACGCCGGCCCCCGGGAGGGCGTGTCCTTCCCTTGGTC
CAGACCTCCAGGACAGGGCGAGTTCCGCGCCCTGAACGCCAGGCTGCCTCTGAA
CACCGATGCCTACCTGTCTCTGCAGGAACTGCAGGGCCAGGACCCAACCCACCT
GGTGCGGAGAAAGCGCAGCGGCTCCGGCGAGGGCCGGGGCAGCCTGCTGACCT
GCGGCGACGTGGAAGAGAACCCCGGACCCATGCCTAGAGGCTTCACATGGCTGA
GGTATCTGGGCATCTTCCTGGGCGTGGCTCTGGGAAACGAACCTCTGGAAATGT
GGCCACTGACACAGAATGAAGAGTGCACCGTTACAGGCTTCCTGCGGGACAAGC
TGCAGTACAGGTCTAGGTTGCAGTACATGAAACACTATTTCCCTATTAACTACAAG
ATCTCCGTGCCTTACGAGGGAGTGTTCAGGATCGCCAACGTGACACGGCTGCAG
AGGGCTCAGGTCAGCGAGCGGGAGCTGCGGTATCTGTGGGTGCTGGTGAGCCT
GAGCGCCACCGAGAGCGTGCAAGACGTCCTGCTGGAAGGCCATCCTAGCTGGAA
GTACCTGCAGGAGGTGGAGACCCTGCTGCTGAACGTGCAGCAAGGCTTGACCGA
CGTCGAGGTGAGCCCAAAGGTGGAGAGCGTGCTCAGCCTGCTGAACGCTCCTGG
ACCAAACCTGAAGCTGGTGAGGCCTAAGGCCCTGCTGGACAACTGCTTCAGAGT
GATGGAGCTGCTGTACTGCAGCTGCTGTAAGCAGAGCAGCGTGCTGAACTGGCA
AGACTGCGAAGTGCCTAGTCCTCAGAGCTGCAGCCCTGAGCCCAGCCTGCAGTA
CGCTGCAACCCAGCTGTACCCTCCTCCACCTTGGAGCCCTAGCAGCCCTCCTCAC
AGCACCGGAAGCGTGAGGCCTGTGAGAGCCCAAGGCGAGGGACTGCTGCCTGC
GGCCGCAATTGAAGTTATGTATCCTCCTCCTTACCTAGACAATGAGAAGAGCAATG
GAACCATTATCCATGTGAAAGGGAAACACCTTTGTCCAAGTCCCCTATTTCCCGGA
CCTTCTAAGCCCTTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATA
GCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGAGGAGTAA 
 
